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Zusammenfassung 
Maligne Tumorerkrankungen sind eine der häufigsten Todesursachen der Welt und neue Therapie-
möglichkeiten werden dementsprechend dringend benötigt. Einen vielversprechenden Ansatz stellt 
der adoptive Transfer von Immun-Effektorzellen in Tumorpatienten dar. Die Effizienz dieser 
Therapieform wird jedoch häufig durch eine unzureichende Rekrutierung der transferierten 
Leukozyten in das Tumorgewebe eingeschränkt. Aus diesem Grunde wurden in der vorliegenden 
Studie neuartige Fusionsproteine entwickelt, die spezifisch die Rekrutierung bestimmter Leukozyten 
verstärken sollten. Die Proteine setzten sich zusammen aus einer N-terminalen Chemokindomäne, 
der Muzindomäne des membrangebundenen Chemokins CX3CL1 sowie einem C-terminalen Glykosyl-
phosphatidylinositol (GPI) Membrananker, der die Transmembrandomäne von CX3CL1 ersetzte. Nach 
Injektion in einen Tumor sollten sich die Proteine aufgrund des GPI-Ankers in die Zellmembranen von 
Endothel-, Tumor- und Stromazellen integrieren. Dabei sollte die Chemokindomäne im 
Zusammenspiel mit der Muzindomäne selektiv Leukozyten rekrutieren, die den korrespondierenden 
Chemokinrezeptor exprimieren. Für die Rekrutierung zytotoxischer T-Zellen und NK-Zellen wurde 
zunächst ein Fusionsprotein mit einer CXCL10 Chemokindomäne generiert (CXCL10-mucin-GPI), 
sowie diverse Varianten des Proteins als Kontrollen. Die Fusionsproteine wurden in eukaryotischen 
Zellen exprimiert und konnten anschließend mittels FACS und Immunfluoreszenz-Mikroskopie auf 
der Zellmembran der transfizierten Zellen nachgewiesen werden. Weitere Versuche zeigten, dass die 
CXCL10 Fusionsproteine den korrespondierenden Chemokinrezeptor CXCR3 aktivieren können. Dies 
führte in CXCR3-positiven Zellen zu einer Mobilisation von intrazellulärem Calcium, einer Inter-
nalisierung von CXCR3 sowie zu einer Verstärkung der Adhäsion an Zelloberflächen. Die GPI-
verankerten Fusionsproteine wurden anschließend mittels Affinitätschromatographie aufgereinigt 
und es konnte gezeigt werden, dass sich die gereinigten Proteine aufgrund ihres GPI-Ankers spontan 
in Zellmembranen integrieren. In einem in vitro Modell für Rekrutierungsprozesse in Blutgefäßen 
konnten Endothelzellen nach Behandlung mit CXCL10-mucin-GPI effektiv NK-Zellen in Gegenwart 
physiologischer Scherkräfte rekrutieren. Vergleiche mit entsprechenden Varianten von CXCL10-
mucin-GPI zeigten, dass die Muzindomäne unabdingbar für diesen Effekt war. Im Gegensatz zu NK-
Zellen wurden T-Zellen weniger effizient rekrutiert. In einem in vivo Tumor-Modell zeigte sich, dass 
eine intratumorale Injektion von CXCL10-mucin-GPI zu einer wesentlich stärkeren Rekrutierung von 
NK-Zellen führt als eine Injektion von löslichem CXCL10. Aus den Versuchen der vorliegenden Studie 
kann demnach die Schlussfolgerung gezogen werden, dass Fusionsproteine wie CXCL10-mucin-GPI 
eine vielversprechende Möglichkeit für die gezielte Verstärkung der Rekrutierung von Leukozyten im 
Rahmen zellulärer Immuntherapien darstellen.  
  VI 
Summary 
Cancer is one of the leading causes of death worldwide and novel therapeutic approaches for the 
treatment of this disease are urgently needed. The adoptive transfer of immune effector cells 
represents a promising therapeutic strategy. However, the efficacy of this therapy can be hampered 
by insufficient infiltration of the tumor by the transferred cells. To help address this problem, a novel 
class of reagents was developed to enhance leukocyte recruitment to tumor environments. This class 
of fusion proteins was designed to selectively recruit specific leukocyte subsets based on their 
expression of a given chemokine receptor. The proteins were composed of an N-terminal chemokine 
head and the mucin domain taken from the membrane-anchored chemokine CX3CL1, with a 
C-terminal glycosylphosphatidylinositol (GPI) membrane anchor replacing the normal transmem-
brane domain. When purified and injected into a tumor, these proteins integrate into cell 
membranes of tumor, stromal and endothelial cells by means of their GPI anchor. The mucin domain 
in conjunction with the chemokine head acts to specifically recruit leukocytes that express the 
corresponding chemokine receptor, e.g. adoptively transferred T or NK cells. A fusion protein 
comprising a CXCL10 chemokine head (CXCL10-mucin-GPI) was studied as the proof of concept of 
this approach, with a series of control proteins generated in parallel. The proteins were expressed in 
a mammalian system and it was verified that the GPI anchor signal sequence could correctly target 
them to the cell membrane. The ability of the CXCL10 fusion proteins to trigger the CXCR3 receptor 
was further verified using assays that measured receptor internalization, calcium mobilization and 
enhanced adhesion of T cells to cell monolayers as readouts. Following the identification of a suitable 
detergent for solubilization, the various proteins were isolated from cell extracts using affinity 
chromatography. Purified proteins were found to efficiently integrate into cell membranes in a 
process dependent upon the GPI anchor. In vitro models of leukocyte recruitment showed that 
endothelial cells incubated with CXCL10-mucin-GPI efficiently recruited NK cells under conditions of 
physiologic flow. This process was found to be dependent on the presence of the mucin domain. 
T cells were in contrast not recruited as effectively. When injected into experimental murine tumors 
in vivo, CXCL10-mucin-GPI was more efficient in recruiting NK cells than soluble CXCL10. Thus, fusion 
proteins such as CXCL10-mucin-GPI represent promising candidates for novel adjuvants to be used in 
cellular immunotherapy. 
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1 Introduction 
1.1 Immunotherapy of cancer 
The medical term cancer describes a group of diseases which are all associated with an uncontrolled 
growth of transformed cells. It is one of the leading causes of death, accounting in 2008 worldwide 
for 7.6 million deaths (about 13% of all deaths). Despite many advances in the field of cancer 
therapies, deaths from cancer are projected to rise to 11 millions in 2030 (WHO 2011). Besides 
surgical resection of the tumor mass and radiation therapy, the current medicamentous treatment 
options for cancer patients can be grouped into four major categories: (i) chemotherapy, which 
involves the administration of cytotoxic drugs, (ii) hormonal therapy that interferes with hormone 
receptors on the cancerous cells, (iii) targeted therapy using novel antibodies and small molecules 
that specifically affect proteins involved in growth signaling pathways and (iv) immunotherapy 
(Lesterhuis et al. 2011).  
Immunotherapy builds upon the body´s ability to recognize and destroy transformed cells. Early 
therapeutic approaches were already described more than a century ago. In 1891 William Coley 
treated a sarcoma patient with intratumoral injections of two bacterial strains, which subsequently 
triggered an inflammatory reaction that was followed by a complete disappearance of the tumor 
(Coley 1910). Today, much is known about the immune system and its diverse interactions with a 
growing tumor. An immune cell infiltrate consisting of monocytes, macrophages, neutrophils, 
dendritic cells, natural killer (NK) cells and T cells is found in diverse cancer settings (Becker 1993; Di 
Carlo et al. 2001; Bingle et al. 2002; Pages et al. 2010; Levy et al. 2011; Ruffell et al. 2011). However, 
the immune reaction evoked by the tumor is often not adequate to control tumor growth, as 
evidenced by the outgrowth of the tumor. In some cases, the infiltrating cells have also been shown 
to promote tumor growth by creating a tumor-permissive microenvironment (Figel et al. 2011; 
Meyer et al. 2011). The general aim of cancer immunotherapy is focused on moderating the immune 
response against the tumor so that efficient tumor recognition and destruction is induced. Several 
different approaches have been taken in order to achieve this goal, some examples of which are 
listed in the next section.  
1.1.1 Adjuvants, antibodies and small proteins 
In order to enhance the immune response against the tumor, immune-stimulatory cytokines such as 
interleukin-2 (IL-2) or interferon α (IFNα) have been administered. This was first shown to be 
effective in melanoma patients (Parkinson et al. 1990; Kirkwood et al. 1996). In addition, adjuvants 
like CpG oligonucleotides (Garbi et al. 2004) or bacillus Calmette-Guerin (Sylvester et al. 2010) are 
sometimes used to strengthen the endogenous immune reaction.  
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Secondly, inhibitory pathways that downregulate the immune response can be targeted, as 
exemplified by the antibody Ipilimumab. This reagent blocks the inhibitory receptor cytotoxic T 
lymphocyte associated antigen 4 (CTLA-4) on T cells, thus enhancing their activity. It has recently 
been approved by the food and drug administration (FDA) of the United States for treatment of 
advanced-stage melanoma following a successful phase III clinical trial (Hodi et al. 2010).  
Third, growth factor receptors such as the epidermal growth factor receptor (EGFR) which are 
actively used by some cancer cells can be targeted by blocking antibodies (e.g. the humanized 
antibody Trastuzumab) (Slamon et al. 2001). Antibodies like these mediate their effects not only by 
blocking the respective receptors or altering their signal transduction cascades, but also by inducing 
antibody-dependent cellular toxicity through the activation of Fc-receptor expressing cells, and by 
complement activation. The degree with which each effect contributes to the therapeutic outcome 
varies between the different antibodies (Borghaei et al. 2009).  
Also cell type-specific antigens like CD20, a common B cell marker that is also expressed on many 
non-Hodgkin lymphomas, have successfully been used as antigens for antibody-based 
immunotherapy (McLaughlin et al. 1998).  
An emerging class of antibody-based drugs consists of bispecific antibody reagents. These are 
designed to recognize either two different tumor antigens simultaneously or to recognize one tumor 
antigen with one of their arms and the invariant T cell activating molecule CD3 with the other arm 
[reviewed in (Beck et al. 2010; Müller and Kontermann 2010)]. The latter approach allows redirecting 
the polyclonal T cell pool of the patient towards a specific tumor antigen, irrespective of T cell speci-
ficities. These antibodies are referred to as BiTEs (Bispecific T cell engager) and include 
Catumaxomab, which binds to CD3 and the epithelial cell adhesion molecule (EpCAM) that is often 
overexpressed on tumor cells. Catumaxomab was approved in 2009 by the European medicines 
agency for the treatment of malignant ascites [reviewed in (Linke et al. 2010)]. 
In addition to the approaches detailed above that are generally based on the use of bioactive 
proteins or adjuvants, a major focus of immunotherapy is also directed towards the use of immune 
cells themselves as anti-cancer agents, as discussed below. 
1.1.2 Cell-based immunotherapies 
1.1.2.1 Therapeutic approaches using NK cells 
The central premise of cell-based immunotherapy is focused on harnessing the natural cytotoxic 
potential of immune cells to eliminate their target cells in a highly specific and efficient manner. For 
this purpose, both natural killer (NK) and cytotoxic T cells are under active investigation. NK cells 
recognize their target cells by a combination of (i) missing inhibitory signals like major histo-
compatibility complex I (MHC I) proteins,  (ii) the presence of activating signals such as the stress-
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induced protein MICA binding to the NKG2D receptor, and (iii) activating cytokines. This combined 
stimulation leads to degranulation of the cytotoxic vesicles and ultimately destruction of the target 
cell. In addition, NK cells can also be triggered via their Fc receptors (FCγRIII/ CD16) (Leibson 1997) 
and have therefore been implicated in the mechanism of action of various therapeutic antibodies 
[e.g. for the above mentioned Trastuzumab (Musolino et al. 2008)]. As immunotherapeutic tools, 
they have mostly been studied in the context of hematologic malignancies, e.g. in combination with 
hematopoietic stem cell transplantation. In this setting it has been shown that NK cells can mediate 
graft-versus-leukemia effects, especially when the NK cell inhibitory ligands of donor and recipient 
are mismatched, so that inhibitory molecules on the leukemic cells are ineffective against donor NK 
cells (Ruggeri et al. 2002). Recent studies have also investigated the potential of NK cell therapy in 
the treatment of solid tumors, for example in non-small cell lung cancer, melanoma and renal cell 
cancer patients. Here, first encouraging results were obtained in phase I clinical trials (Arai et al. 
2008; Cho et al. 2010; Iliopoulou et al. 2010). A recent phase II study in patients with ovarian and 
breast cancer has shown a transient donor chimerism after infusion of ex vivo expanded 
haploidentical NK cells, suggesting the need for further investigations to enhance NK cell persistence 
and expansion (Geller et al. 2011). The major focus of cell-based immunotherapy lies, however, on 
cytotoxic CD8+ T cells. 
1.1.2.2 Therapeutic approaches using CD8+ T cells 
In contrast to NK cells, CD8+ T cells recognize specific peptides bound to MHC I on the surface of the 
target cells via their T cell receptor (TCR). The rationale to use CD8+ T cells as anti-tumor agents was 
based on the observation that in some patients, melanoma lesions undergo spontaneous regression 
(Everson 1964; McGovern 1975). Later this regression was associated with a clonal expansion of 
T cells (Ferradini et al. 1993). In addition, the presence of a robust T cell infiltrate within the tumor 
correlated with a favorable prognosis in some cancers including melanoma, colon cancer and ovarian 
cancer (Clark et al. 1989; Clemente et al. 1996; Naito et al. 1998; Sato et al. 2005). Of note, it was 
observed that only the presence of T cells within the tumor had a beneficial effect, whereas T cells 
present at the tumor margin did not alter the probability of survival (Naito et al. 1998). This finding 
suggested that efficient infiltration of the tumor mass is required for the tumoricidal effects of CD8+ 
T cells. This requirement represents a significant hurdle for many current therapeutic strategies as 
will be discussed in more detail later.  
To generate tumor-reactive T cells, two mechanistically distinct approaches have been taken: Either 
T cells are primed in situ by vaccination protocols, or expanded in vitro and subsequently reinfused 
into the patient. The potential of vaccinating tumor patients against their tumors was enhanced by 
the identification of tumor-associated antigens recognized by tumor-infiltrating lymphocytes in the 
early 1990s (van der Bruggen et al. 1991; Kawakami et al. 1994). This has lead to development of 
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cancer vaccines based on different techniques. To date, one of the most successful vaccines is the 
recently FDA approved sipuleucel-T, used for the treatment of metastatic prostate cancer. It consists 
of enriched blood antigen presenting cells cultured in vitro with a fusion protein consisting of 
prostatic acid phosphatase and granulocyte macrophage colony stimulating factor (GM-CSF). In a 
phase III clinical trial, this agent prolonged the median survival by 4.1 months and reduced the risk of 
death by 22% (Kantoff et al. 2010). Another successful example is a peptide vaccine targeting gp100, 
a protein expressed in melanoma cells as well as normal melanocytes. In a recent phase III clinical 
study, metastatic melanoma patients were treated either with high-dose IL-2 alone, or with IL-2 in 
conjunction with the vaccine in incomplete Freud´s adjuvant. The vaccine group displayed a 
6.7 months longer median overall survival than the group receiving only IL-2 (Schwartzentruber et al. 
2011). However, clinical trials generally showed disappointing results, although frequently a tumor-
specific immune response could be generated [reviewed in (Klebanoff et al. 2011; Palucka et al. 
2011)]. Importantly, vaccination protocols rely on the endogenous T cell repertoire, which represents 
a major drawback of this technique as many tumor-associated antigens are self antigens, for which 
the reactive T cells have either been clonally deleted in the thymus or display an anergic or 
regulatory phenotype [reviewed in (Paul et al. 2007)].  
An appealing different approach makes use of adoptive T cell therapy. Here, T cells are isolated 
either from the peripheral blood or from tumor-infiltrating lymphocytes (TILs), expanded in vitro and 
subsequently reinfused into the patient. During the in vitro culture period, the cells can be selected 
for efficient tumor recognition or transduced with a novel receptor to overcome clonal deletion and 
in order to confer a defined tumor-specificity as depicted in Figure 1 [reviewed in (Turtle and Riddell 
2011)].  
The first clinical trial of adoptive T cell therapy was performed in 1985 with IL-2 activated peripheral 
blood lymphocytes (Rosenberg et al. 1985). Complete regression of the tumor in one patient with 
metastatic melanoma was observed. Following the observation that mice could be cured from 
metastatic colon carcinomas by the infusion of IL-2 expanded TILs (Rosenberg et al. 1986), the anti-
tumor effect of TILs was further investigated in the clinic in 20 melanoma patients, of which 11 
displayed tumor regression (Rosenberg et al. 1988). Since then, many trials including randomized 
clinical studies have followed in various cancer settings like gastric cancer, hepatocellular carcinoma, 
renal cell cancer, lung cancer and melanoma. However, many of these trials have not shown a 
statistically significant positive effect of the infused T cells, especially in cancers other than 
melanoma [reviewed in (June 2007)]. 
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Many potential reasons for this lack of reproducible efficiency have been identified. These include a 
general immunosuppressive milieu within the tumor mediated by immunosuppressive cytokines like 
transforming growth factor β (TGF-β), regulatory T cells (Tregs), myeloid suppressor cells and oxygen 
limitation as well as evasion mechanisms by the tumor cells themselves such as MHC I down-
regulation, expression of apoptosis-inducing ligands and others [reviewed in (Quezada et al. 2011) 
and (Leen et al. 2007)]. An additional important factor is a general lack of efficient infiltration of the 
transferred cells into the tumor milieu as detailed below.  
1.1.3 Lack of infiltration as a reason for the failure of cell-based immunotherapies 
Tumor growth is intimately associated with neoangiogenesis, a process in which new blood vessels 
are formed. Angiogenesis is required to provide the growing tumor cells with sufficient nutrients and 
oxygen. In order to stimulate angiogenesis, tumors release pro-angiogenic cytokines like vascular 
endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF) and pro-angiogenic 
chemokines like CXCL8, which in turn induce proliferation and migration of endothelial cells 
[reviewed in (De Luca et al. 2008)]. The degree of angiogenesis in vivo can be correlated with the 
amount of VEGF released by various melanoma cell lines (Danielsen and Rofstad 1998), and 
angiogenesis was shown to be required for the outgrowth of micrometastases in vivo (Gimbrone et 
al. 1972; Holmgren et al. 1995). 
 
Figure 1: Principle of adoptive T cell therapy. Adoptive T cell therapy relies on the ability of T cells to 
specifically recognize and destroy tumor cells. T cells are isolated from a cancer patient either using 
peripheral blood (PBMCs, peripheral blood mononuclear cells) or tumor biopsies (TILs, tumor 
infiltrating lymphocytes). The cells can be selected for tumor reactivity or transduced with a novel 
receptor to confer tumor specificity. Subsequently, the cells are expanded (e.g. using IL-2 in 
combination with activating CD3-specific antibodies) and reinfused into the patient. In order to 
promote expansion and survival of the transferred cells, the patient can be treated with non-
myeloablative lymphodepleting chemotherapy and/or radiation prior to infusion of the cells.  
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Angiogenesis not only keeps the tumor provided with nutrients and oxygen, it also acts as an 
important mechanism of immune escape. Endothelial cells exposed to the pro-angiogenic factors 
released by tumor cells have a markedly reduced expression of adhesion molecules. Intercellular 
adhesion molecule 1 and 2 (ICAM-1 and -2) as well as vascular endothelial cell adhesion molecule 1 
(VCAM-1) have been found to be downregulated on endothelial cells isolated from human solid 
tumors, as well as on endothelial cells treated in vitro with bFGF or VEGF (Griffioen et al. 1996a; 
Griffioen et al. 1996b). Additionally, upregulation of endothelial adhesion molecules in response to 
proinflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα) is 
inhibited in tumor endothelial cells. This phenomenon has been termed endothelial cell anergy in 
analogy to T cells that can no longer react to stimuli via their T cell receptor (Griffioen et al. 1996a). 
This endothelial cell anergy is problematic as the presence and upregulation of ICAM and VCAM are 
centrally important for efficient leukocyte recruitment from the blood stream. These molecules 
moderate the adhesion of leukocytes to the blood vessel wall and foster their subsequent 
extravasation because they act as receptors for integrin molecules on the migrating leukocytes as 
detailed in chapter 1.2 (Springer 1994). Consequently, in many tumor models, a reduced interaction 
of leukocytes with the blood vessel wall has been observed, along with defective infiltration of the 
tumors (Wu et al. 1992; Griffioen et al. 1999; Tromp et al. 2000; Dirkx et al. 2003). Lack of infiltration 
has also been proposed as a potential explanation for the limited success of adoptive T cell therapy in 
some clinical studies (Pockaj et al. 1994; Mukai et al. 1999; Huang et al. 2002), and blockade of VEGF-
mediated angiogenesis by monoclonal antibodies in combination with adoptive T cell therapy has 
been shown to have an additive beneficial effect in a murine melanoma model (Shrimali et al. 2010).  
In addition to the angiogenesis-related phenomenon described above, proteoglycan molecules on 
endothelial cells in tumors undergo dramatic changes on transcriptional and post-translational levels, 
the latter occurring through shedding and enzymatic modifications [reviewed in (Sanderson et al. 
2005)]. During the complex cascade of events that represent leukocyte recruitment, proteoglycans 
are needed for the immobilization and presentation of chemokines at the luminal side of endothelial 
cells. Without properly presented chemokines, leukocytes cannot undergo tight adhesion or 
subsequent diapedesis (Kuschert et al. 1999; Proudfoot et al. 2003). Consequently, elevated levels of 
shed proteoglycans in the serum of myeloma and lung cancer patients have been associated with 
poor prognosis (Seidel et al. 2000; Joensuu et al. 2002). The dysregulated expression of proteoglycan 
molecules in the tumor microenvironment may thus represent an additional barrier for adoptively 
transferred leukocytes to infiltrate the tumor mass because it prevents appropriate chemokine 
signaling. These phenomena suggest the need to find solutions to overcome the deficiency in 
leukocyte recruitment into tumors, especially with regards to the disappointing results generally 
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obtained to date with adoptive T cell therapy. The approach that should be investigated in the 
current study to solve this problem will be outlined below. 
1.2 Leukocyte recruitment and chemokines 
Chemokines (chemotactic cytokines) comprise a family of about 50, mostly small secreted proteins. 
They classically act through binding to G-protein coupled receptors with seven transmembrane 
domains. Chemokines have been grouped into four major subfamilies based on the positioning of the 
first two Cysteine residues near the N-terminus: In chemokines of the CC subfamily, the two 
Cysteines lie directly adjacent to each other, while in the CXC subfamily the residues are separated by 
one amino acid. The majority of the currently known chemokines can be grouped into one of these 
two subfamilies. The C subfamily lacks the second Cysteine residue and contains only two members, 
and CX3CL1 is the only member of the CX3C subfamily, where the first two Cysteines are separated 
by three amino acids (Mantovani et al. 2006). Figure 2 gives an overview of the currently known 
chemokines and the respective subfamilies.  
Chemokines can be produced by many different cell types and orchestrate the migration of virtually 
every cell type in the body, both under homeostatic and pathogenic conditions. In a classical 
inflammatory setting, cytokines such as IL-1β and TNFα are produced, e.g. by cells of the innate 
immune system like macrophages. These cytokines activate endothelial cells of neighboring 
microvascular blood vessels as depicted in Figure 3. The “inflamed” endothelial cells then express 
selectin molecules (usually primarily P-selectin followed by E-selectin) and upregulate the expression 
of ICAM and VCAM molecules as well as proteoglycans (Pober 1987; Klein et al. 1992; Grone et al. 
1999; von Hundelshausen et al. 2001). The selectins induced on the endothelial surface bind to 
sialylated Lewis-X residues on glycoproteins constitutively expressed by leukocytes. This interaction 
leads to a phenomenon called rolling adhesion where the leukocyte is captured from the blood 
stream and subsequently slowly rolls along the vessel wall due to rapid formation and dissociation of 
bonds in the context of continuous blood flow [(Lawrence and Springer 1991), reviewed in (McEver 
and Zhu 2010)]. At the same time, chemokines are released at the infection site, e.g. also by cells of 
the innate immune system, and transcytosed through the endothelial cell layer to the luminal side 
(Middleton et al. 1997). There, the chemokines are immobilized by binding to proteoglycan 
molecules, and once immobilized, they can engage matching chemokine receptors on rolling 
leukocytes. For example, the chemokine CXCL10 is involved in the recruitment of activated T cells 
and NK cells, as it binds to the CXCR3 receptor found on these cell types. 
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Chemokine receptor signaling then results in a conformational change of the leukocyte´s integrin 
molecules that leads to a much increased affinity for their ligands – immunoglobulin superfamily 
molecules like ICAM-1/2 and VCAM-1 on the endothelial cells. This increase in affinity enables the 
leukocyte to tightly adhere to the endothelial cell surfaces (Tanaka et al. 1993; Shamri et al. 2005). 
Once tight adherence is established, the leukocyte crawls along the endothelium until eventually it 
extravasates into the interstitium, a process termed diapedesis (Ryschich et al. 2006). Intraluminal 
 
Figure 2: The chemokine family of proteins. An overview of the currently known chemokines is given 
in the first and second columns. The single proteins are arranged according to the four subfamilies 
(CXC, CC, C and CX3C subfamily), to which they are assigned based on the composition of a 
conserved sequence motif near the N-terminus. The respective subfamily of each chemokine also 
reflects in its systematic name (e.g. CXCL8 or CCL2). Additionally, the historic names are given 
because they are sometimes still used in the literature. Chemokines classically act by binding to G-
protein coupled receptors with seven transmembrane domains, and the receptors for each 
chemokine are listed in the third column. One chemokine can bind to several receptors and one 
receptor can be triggered by several chemokines, by which a considerable combinatorial complexity 
is generated. On the right side of the figure, various leukocyte types are given and the chemokine 
receptors expressed by each type are indicated by small dots in the respective color. Figure from 
(Mantovani et al. 2006).  
 
Introduction   9 
crawling is thought to be required to find optimal extravasation routes, as diapedesis is delayed if 
crawling is inhibited (Phillipson et al. 2006), and for crawling and diapedesis proteoglycan-presented 
chemokines on the endothelial cells are indispensable (Cinamon et al. 2001; Shulman et al. 2009). 
Following diapedesis, leukocytes can either follow soluble or immobilized chemokine gradients 
towards the inflammation site [reviewed in (Friedl and Weigelin 2008)]. In the latter process termed 
haptotaxis, the locally produced chemokines are immobilized on extracellular matrix proteins like 
collagens and presented to the leukocyte, which moves in an amoeboid manner through the tissue 
(Rot 1993; Proudfoot et al. 2003; Kohrgruber et al. 2004). Figure 3 summarizes the steps involved in 
the classical cascade of leukocyte recruitment. The chemokines CXCL8, CXCL10 and CX3CL1 were 
used in the current study. Each of these chemokines play unique roles in leukocyte trafficking as 
detailed below. 
 
 
 
Figure 3: Leukocyte recruitment from the blood stream. In the course of an inflammatory reaction 
(red asterisk), inflammatory cytokines (not depicted) are produced that activate the endothelium. 
The activated endothelial cells subsequently express selectin molecules on their surface that bind to 
sialylated LewisX (sLeX) residues on glycoproteins on the leukocyte surface, leading to leukocyte 
rolling along the vessel wall. Simultaneously, chemokines that can either be produced at the 
inflammation site and transcytosed through the endothelium or be produced by endothelial cells 
themselves are immobilized on proteoglycan molecules on the endothelial surface. In this state, they 
can trigger matching chemokine receptors on rolling leukocytes leading to an increased affinity of the 
leukocytes´ integrins. This activation enables the leukocyte to tightly adhere to immunoglobulin 
superfamily molecules like ICAM-1 and -2 or VCAM-1 on the vessel wall, which is followed by 
chemokine-guided intraluminal crawling (not depicted) and diapedesis through the endothelium. For 
the subsequent interstitial migration towards the inflammation site, the leukocyte follows an 
immobilized chemokine gradient in a process termed haptotaxis. Figure modified from figure 2-49 in 
(Murphy et al. 2007). 
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1.2.1 The chemokine CXCL10 and its receptor CXCR3 
CXCL10 was originally discovered in 1985 as a gene upregulated by interferon γ (IFNγ) in monocytes, 
fibroblasts and endothelial cells (Luster et al. 1985). It encodes a protein of roughly 10 kDa which was 
first named IFN γ-inducible protein 10 or IP-10. In 2002, the CXCL10 structure was solved by nuclear 
magnetic resonance (NMR) revealing a classical chemokine fold consisting of a flexible N-terminus 
which includes the CXC motif preceding a short three amino acid helix followed by three anti-parallel 
beta-sheets and a C-terminal alpha-helix packed across the beta-sheets (Booth et al. 2002).  
This structure is common to most chemokines including CXCL8, CXCL12, CCL4 and CCL5 (Chung et al. 
1995). Human and murine CXCL0 share the same tertiary structure and have 70% amino acid identity 
(83% homology) (Jabeen et al. 2008). CXCL10 binds to, and activates the receptor CXCR3, which it 
shares with the two other ligands CXCL9 (MIG) and CXCL11 (I-TAC) (Loetscher et al. 1996). CXCR3 is 
expressed on activated T cells expressing the CD45RO isoform of the CD45 antigen (Loetscher et al. 
1998; Qin et al. 1998). Specifically, CXCR3 expression in T cells is associated with a Th1 skewed 
phenotype as it is highly expressed on Th1 polarized CD4+ as well as on CD8+ T cells (Qin et al. 1998; 
Sebastiani et al. 2001). CXCL10 bound to activated endothelial surfaces induces rapid adhesion and 
transmigration of T cells via CXCR3 (Piali et al. 1998; Manes et al. 2006). Consequently, CXCR3 has 
been shown to play a major role in the recruitment of effector cells in various Th1 dependent 
diseases like acute allograft rejection (Hancock et al. 2000; Zhao et al. 2002) and viral infections 
(Dufour et al. 2002), and blockade of CXCR3 with antibodies results in diminished recruitment of Th1 
T cells into sites of inflammation (Xie 2003). Importantly, in a murine tumor model, intratumoral 
expression of CXCL10 was demonstrated to synergize with adoptive T cell therapy, leading to the 
eradication of established tumors and  survival rates of 90% (Huang et al. 2002).  
 
Figure 4: Molecular structure of CXCL10. The structure of CXCL10 was solved in 2002 (Booth et al. 
2002). It consists of a flexible N-terminus followed by three antiparallel beta-sheets (green) and a C-
terminal alpha helix (blue). The figure was generated from the structural data deposited by Booth et 
al. in the Protein Data Bank (http://www.pdb.org) under the accession number 1LV9 using PyMol. 
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In addition to T cells, CXCR3 is also present on virtually all NK cells at varying expression levels, most 
pronounced within one of the two major subsets (CD56bright CD16dim) of these cells [(Campbell et al. 
2001), reviewed in (Cooper et al. 2001)]. A homologous subset exists in the murine system, defined 
as CXCR3+ CD27bright NK cells (Marquardt et al. 2010). CXCL10-stimulated murine NK cells have been 
shown to contribute to tumor rejection, partly by activating T cells (Saudemont et al. 2005). 
Moreover, CXCL10 has been shown to enhance exocytosis of cytotoxic granules in NK cells, a 
property it shares with a variety of other chemokines [(Taub et al. 1995; Taub et al. 1996), reviewed 
in (Robertson 2002)]. CXCR3 has also been reported to be expressed on subsets of plasmacytoid and 
myeloid DCs (Cella et al. 1999; Garcia-Lopez et al. 2001), and eosinophils (Jinquan et al. 2000).  
In addition to leukocytes, CXCL10 also has effects on other cell types, in particular, endothelial cells. 
CXCL10 can inhibit proliferation of endothelial cells in vitro (Luster et al. 1995; Feldman et al. 2006) 
as well as angiogenesis in vivo (Angiolillo et al. 1995; Strieter et al. 1995). It may even cause the 
dissociation of newly-formed blood vessels (Bodnar et al. 2009). Based on these effects, CXCL10 can 
delay wound healing and reduce tumor growth in vivo (Luster and Leder 1993; Luster et al. 1998). 
There is some controversy about how CXCL10 may mediate these effects, especially because CXCR3 
is mostly absent on microvascular endothelial cells, or is only expressed during specific stages of the 
cell cycle (Romagnani et al. 2001). In 2004, an alternative variant of CXCR3 named CXCR3-B was 
described that is generated by alternative splicing (Lasagni et al. 2003). This receptor carries 48 
additional amino acids at the N-terminus and, importantly, was demonstrated to be expressed on 
primary endothelial cells as opposed to the classical receptor CXCR3-A. Overexpression of CXCR3-B in 
an endothelial cell line resulted in CXCL10 inhibiting proliferation, whereas the proliferation of cells 
overexpressing CXCR3-A was stimulated by CXCL10 (Lasagni et al. 2003). However, Campanella et al. 
showed that CXCR3-B cannot exist in the murine system because of an in-frame stop codon and that 
the proliferation of endothelial cells isolated from CXCR3(-A) deficient mice is still inhibited by 
CXCL10 (Campanella et al. 2010). These findings suggest that there must be additional ways of 
signaling for CXCL10 beyond chemokine receptor triggering that have not yet been identified.  
A third variant of the CXCR3 receptor named CXCR3-alt was described in peripheral blood 
mononuclear cells (Ehlert et al. 2004). CXCR3-alt is generated by exon-skipping and displays a much 
shorter C-terminus lacking one or two entire transmembrane domains. To date the only functional 
ligand known for CXCR3-alt is CXCL11. However, the exact cell type expressing this receptor variant 
remained elusive and the functionality of the receptor was only verified in transfected cells. 
1.2.2 The chemokine CXCL8 and its receptors CXCR1 and CXCR2 
CXCL8 or interleukin-8 (IL-8) was originally identified as a neutrophil-activating cytokine (Walz et al. 
1987; Baggiolini et al. 1989). It is produced upon stimulation with inflammatory cytokines or 
lipopolysaccharide (LPS) by a variety of cells including fibroblasts, epithelial and endothelial cells, 
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hepatocytes, mononuclear phagocytes and others (Walz et al. 1987; Yoshimura et al. 1987; Strieter 
et al. 1988). CXCL8 is a small protein of about 8 kDa which is secreted primarily as a 79 amino acid 
(aa) protein. The amino terminus can be further processed by proteolytic cleavage yielding various 
forms ranging from 69 to 79 aa with the 72 aa form being the predominant one in vivo [reviewed in 
(Baggiolini and Clark-Lewis 1992)]. Structurally, CXCL8 displays the classical chemokine fold as 
detailed for CXCL10 in 1.2.1 with a flexible N-terminus, three antiparallel beta-sheets and a C-
terminal alpha-helix (Baldwin et al. 1991). The two known receptors for CXCL8, CXCR1 and CXCR2, 
are expressed primarily on neutrophils. CXCL8 not only induces migration in these cells, but can also 
trigger granule exocytosis and respiratory burst [reviewed in (Baggiolini and Clark-Lewis 1992)]. In 
2002, Hess and colleagues described a subset of CD8+ T cells as an additional target for CXCL8 (Hess 
et al. 2004). This subset was enriched in perforin, granzyme B and IFNγ and thus had a high cytotoxic 
potential. The ability to target this highly cytotoxic subset of T cells makes CXCL8 a potential 
candidate for use in cancer immunotherapy. Additionally, neutrophils, co-recruited by CXCL8, have 
been proposed as anti-cancer effector cells due to their ability to release cytotoxic mediators as well 
as chemokines and cytokines (Di Carlo et al. 2001), which can in turn recruit other effector cells. 
Finally, CXCL8 also acts on endothelial cells, where it stimulates proliferation, migration and 
angiogenesis (Li et al. 2003). In contrast to CXCL8 and CXCL10, which both represent classical 
chemokines, the chemokine CX3CL1 displays unique structural and mechanistic features. 
1.2.3 The chemokine CX3CL1 and its receptor CX3CR1 
CX3CL1, also termed Fractalkine, was discovered in 1997 by homology searches in expressed-
sequence tags. The gene identified was found to be expressed primarily in endothelial cells 
stimulated with IL-1 or TNF (Bazan et al. 1997). The mature CX3CL1 protein is far bigger than other 
chemokines – it consists of 373 amino acids. In this relatively large protein, the N-terminal 76 aa 
generate a chemokine domain that structurally resembles other chemokines. But unlike most other 
chemokines, the chemokine domain of CX3CL1 is fused to a 241 aa long mucin-like domain that 
connects to a single hydrophobic transmembrane domain and a 37 aa intracellular tail. Thus, CX3CL1 
is a membrane anchored chemokine, a characteristic shared only with CXCL16. In addition to the 
membrane-bound version, CX3CL1 can also be shed from the surface by proteolytic cleavage and 
exist as a soluble molecule (Bazan et al. 1997; Hundhausen et al. 2003).  
The molecular structure of the chemokine domain of CX3CL1 was solved in 1999, confirming the 
prediction that it resembles, in large part, the structure common to other chemokines (see structure 
described for CXCL10 in 1.2.1) (Mizoue et al. 1999). The mucin-like domain fused to the chemokine 
head is rich in Serine and Threonine residues that are predicted to be O-glycosylated (Bazan et al. 
1997), and it has been shown that CX3CL1 contains 10-20 kDa of O-linked carbohydrates (Fong et al. 
2000). Electron microscopy has revealed that the mucin domain forms an extended stalk that 
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protrudes 26 nm away from the cell membrane, displaying the 3 nm chemokine domain at its end 
(Fong et al. 2000). Figure 5 schematically summarizes the structure of CX3CL1. 
This exceptional architecture is also responsible for another unique characteristic of CX3CL1: In the 
first paper describing the CX3CL1 receptor, CX3CR1, it was noted that the CX3CL1 protein can not 
only mediate chemotactic migration as seen with other chemokines, but it can also induce the 
adhesion of CX3CR1-epressing cells in vitro (Imai et al. 1997). This is in strong contrast to other 
chemokines that can only induce adhesion in rolling leukocytes by upregulating integrin affinity, not 
by acting as an adhesion molecule themselves. Notably, while the migration induced by soluble 
CX3CL1 required G-protein signaling, the induction of adhesion by surface-bound protein did not 
(Imai et al. 1997; Haskell et al. 1999). Leukocyte capture by CX3CL1 also occurred efficiently under 
conditions of physiologic flow (Fong et al. 1998), and CX3CL1-mediated tight adhesion was found to 
take place in the absence of other adhesion molecules such as ICAM-1 or VCAM-1. Moreover, 
activation of CX3CR1 did not lead to an upregulation of integrin affinity, which suggests that the 
adhesion molecules classically involved in leukocyte recruitment are dispensable for CX3CL1-
mediated recruitment (Haskell et al. 1999). Figure 6 summarizes the classical cascade of leukocyte 
recruitment in comparison with leukocyte recruitment as mediated by CX3CL1. 
 
Figure 5: Architecture of the membrane-bound chemokine CX3CL1. A schematic representation is 
shown. CX3CL1 consists of an N-terminal chemokine domain (3 nm in diameter) that is connected to 
a 26 nm long mucin-like stalk, which is O-glycosylated at various positions (grey hexagons). The 
mucin domain is tethered to the cell membrane via a single hydrophobic transmembrane domain 
that is followed by a 37 amino acid intracellular tail.  
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The molecular basis for this feature of CX3CL1 has been a subject of debate. The elevation of the 
chemokine domain by the mucin domain is thought to be a critical parameter for CX3CL1-mediated 
leukocyte capture as this activity is retained if the mucin domain is replaced with six short consensus 
repeat segments from E-selectin that also build a 26 nm extended structure (but lack adhesive 
capacity themselves). In contrast, the activity is dramatically reduced if the mucin domain is deleted. 
The mucin domain alone, without a chemokine head, does not appear to induce adhesion (Fong et al. 
2000).  
As stated above, CX3CL1 is primarily expressed on endothelial cells as a reaction to proinflammatory 
cytokines like IL-1β or TNFα, whereas it is rarely found to be expressed in leukocytes (Bazan et al. 
1997; Foussat et al. 2000). The CX3CR1 receptor however is expressed in several human leukocyte 
types including monocytes (also microglial cells in the central nervous system), CD56dim CD16bright 
NK cells, B cells, and plasmacytoid as well as myeloid DCs (Jung et al. 2000; Campbell et al. 2001; 
 
Figure 6: Classical scheme of leukocyte recruitment in comparison with recruitment by CX3CL1.  
A: The classical cascade of leukocyte recruitment relies on selectins expressed by activated 
endothelial cells to induce rolling adhesion. At the same time chemokines are immobilized on glycos-
aminoglycan molecules also expressed by endothelial cells. In this immobilized state, the chemokines 
can trigger matching receptors on the rolling leukocyte which leads to an upregulation of integrin 
affinity towards immunoglobulin superfamily molecules (not depicted) on the endothelial cells. The 
increased affinity enables the leukocyte to tightly adhere to the endothelium. Subsequently, 
diapedesis through the endothelium is initiated, a process which also requires chemokine signaling. 
B: CX3CL1 is able to mediate all steps of leukocyte recruitment including the initiation of rolling 
adhesion, tight adhesion and diapedesis. Figure modified from (Umehara et al. 2004). 
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Corcione et al. 2009). It is also found on both activated (CD45RO+) and resting (CD45RO-) CD8+ and 
activated CD45RO+ CD4+ human T cells (Foussat et al. 2000). In mice, however, CX3CR1 expression in 
T cells is controversial. Some studies reported that CXCR3 is absent on T lymphocytes (Jung et al. 
2000; Haskell et al. 2001), whereas others reported it to be expressed on a small percentage of T 
cells (Harcourt et al. 2006).  
CX3CL1 has also been implicated in the activation of NK cells. Here it has been shown that CX3CL1 
can activate CX3CR1-positive NK cells leading to higher efficiencies of cell-mediated lysis. (Zhang et 
al. 2006; Zhang et al. 2007).  
An observation important for the current study was made by the Yoshie group. They assessed the 
ability of CX3CL1 to capture leukocytes transfected with various chemokine receptors. As expected, 
they found that CX3CL1 could only recruit cells that were transfected with CX3CR1. However, they 
also generated proteins where they exchanged the chemokine head of CX3CL1 by the chemokine 
CCL17 (also named TARC), leaving the mucin domain unchanged. This novel CCL17-mucin fusion 
protein displayed a redirected specifity - it captured cells expressing CCR4, the receptor for CCL17 
and no longer CX3CR1-transfected cells. Both the mucin domain alone as well as the two chemokine 
domains alone were unable to capture significant amounts of cells, irrespective of the receptor that 
these cells expressed. Furthermore, the efficiency of recruitment was similar for wildtype CX3CL1 in 
combination with CX3CR1+ cells and for CCL17-mucin in combination with CCR4+ cells (Imai et al. 
1997). Another study showed that CXCL8 fused to the mucin domain of CX3CL1 can induce rolling 
adhesion of cells expressing the CXCL8-receptor CXCR1 under conditions of physiologic flow. The 
same was true for a CCL2-mucin fusion protein in combination with CCR2+ cells, although the 
efficiency of recruitment was reported to lack behind that of wildtype CX3CL1 (Haskell et al. 2000). 
Thus, the specificity of CX3CL1 can be redirected by exchanging the chemokine domain by another, 
unrelated chemokine. This possibility was exploited in the current study by fusing different 
chemokine heads to the mucin domain of CX3CL1 as will be detailed in chapter 1.4. Furthermore, we 
combined that approach with the technique of cell painting which will be introduced in the next 
section. 
1.3 GPI-anchored proteins and cell painting 
Glycosylphosphatidylinositol- (GPI-) anchors are membrane anchors that tether proteins to the outer 
leaflet of the cell membrane. Numerous membrane-associated proteins in eukaryotes are known to 
be GPI-anchored, such as alkaline phosphatase, decay accelerating factor (DAF), heparan sulfate 
proteoglycans or the adhesion molecule lymphocyte function antigen 3 (LFA-3) [reviewed in (Brown 
and Waneck 1992)]. The anchor itself consists of a phosphatidylinositol group that is linked via a 
carbohydrate core to the C-terminus of the respective protein. This core structure contains a 
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glucosamine residue that is linked to the phosphatidylinositol lipid group and connects α1,4 
glycosidically to three mannose residues. The last mannose rest is connected via a phosphoryl group 
to ethanolamine that is in turn directly attached to the protein´s C-terminus (Homans et al. 1988). 
The mannose residues as well as the inositol ring of the phosphatidylinositol moiety can be 
substituted with various rests depending on the species as well the respective protein, but the above 
described backbone is relatively conserved (Brown and Waneck 1992). Figure 7 schematically depicts 
the composition of a GPI anchor.  
GPI-anchored proteins are expressed with two signal peptides in their primary structure. The first 
one is an N-terminal signal peptide directs the synthesis of the proteins into the endoplasmatic 
reticulum and is subsequently cleaved from the protein, analogous to what is observed for secreted 
proteins and type I transmembrane proteins. For GPI-anchored proteins however, a second signal 
sequence is present at the C-terminus. It contains a stretch of 15-30 hydrophobic amino acids 
(Gerber et al. 1992). Once synthesis of the nascent protein has reached this sequence, the protein is 
cleaved from the signal sequence and transferred via a transamidase complex onto a preformed GPI 
anchor (Hiroi et al. 2000). There is considerable variance among the C-terminal signal peptides of 
different GPI-anchored proteins and the various sequences have been shown to differ in their 
efficiency of mediating GPI attachment (Chen et al. 2001).  
 
Figure 7: Schematic representation of the composition of a GPI anchor. The protein is linked via its 
C-terminus to ethanolamine, the latter being connected through a phosphatidyl residue to three 
mannose rests. A glucosamine moiety connects the mannose rests to phosphatidylinositol, the fatty 
acids of which anchor the protein to the outer cell membrane leaflet. The mannose rests as well as 
the inositol ring of phosphatidylinositol can be substituted at various positions, depending on the 
respective species and GPI-anchored protein. 
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It has been shown that purified GPI-anchored proteins possess the ability to integrate spontaneously 
into the cell membranes of virtually any other cell. Following this incorporation, they can still exert 
their natural activity. This technique has been referred to as “cell painting” because the proteins are 
“painted” directly onto the surface of the cell without any transfection process needed (Medof et al. 
1984; Medof et al. 1996; Hoessli and Robinson 1998). Almost any protein can be expressed in a GPI-
anchored version by fusing the gene sequence to appropriate signal sequences (Legler et al. 2005). 
Thus, the activity of any given protein can be transferred to any cell surface.  
Cell painting represents a powerful alternative to conventional gene transfer for several reasons. 
First, it can be used with cells that are hard to transfect. Second, the surface modification occurs 
directly, without the need for cultivation or incubation, and the amount of protein that is transferred 
can be precisely controlled. Third, it avoids the safety concerns associated with gene transfer such as 
random integration and potential carcinogenic side effects by oncogene activation, which is 
especially important with regards to in vivo applications (Medof et al. 1996). For these reasons, cell 
painting is an attractive tool to be used for the development of novel treatment options, and it was 
also used in the current study, the rationale of which will be outlined below. 
1.4 Rationale of this study 
As outlined above, the recruitment of effector cells represents a crucial step and major hurdle for the 
efficient immunological treatment of tumors. We sought to overcome this problem by generating a 
novel, flexible class of reagents that could be used for the targeted modification of tissue 
micromilieus. The reagents described in this study were designed to selectively enhance recruitment 
and activation of specific leukocyte subsets in tumors, although the general applicability of the 
underlying concept also extends to other settings. They consisted of three different protein domains 
that were combined into novel fusion proteins as detailed below: 
 The N-terminus of the proteins comprised a chemokine head (e.g. CXCL10 or CXCL8) that would 
direct the specificity of the fusion proteins towards cells expressing the respective chemokine 
receptor.  
 The mucin domain of CX3CL1 fused to the chemokine head would assist in the recruitment 
process by lowering the requirement for additional adhesion molecules. In a tumor setting, this 
could also help overcome endothelial cell anergy, and lead to a larger number of leukocytes 
extravasating into the tumor tissue. 
 The addition of a GPI anchor at the C-terminus would allow the recombinant proteins to directly 
integrate into virtually every cell membrane when added exogenously into a tissue.  
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The composition of the envisioned recombinant fusion proteins is exemplarily shown in Figure 8. The 
scheme depicts CXCL10-mucin-GPI, a fusion protein containing a CXCL10 chemokine head. 
According to our hypothesis, recombinant fusion proteins such as CXCL10-mucin-GPI would, if 
injected into a solid tumor, incorporate into the cell membranes of tumor, stromal and endothelial 
cells. Thereby, they would generate a stable, immobilized chemokine gradient to help facilitate 
leukocyte migration into the tumor. When present on tumor endothelial cells, the proteins would 
help overcome endothelial cell anergy by specifically recruiting leukocytes that express the matching 
chemokine receptor with limited requirement for other adhesion molecules.  
The major part of the current study related to CXCL10-mucin-GPI. This protein would be specific for 
CXCR3+ cells such as cytotoxic T cells or NK cells. Treatment with CXCL10-mucin-GPI could therefore 
be especially useful in conjunction with adoptive T or NK cell therapy to enhance recruitment of 
 
Figure 8: Composition of CXCL10-mucin-GPI as an example for a novel class of GPI-anchored 
chemokine fusion proteins. For the generation of CXCL10-mucin-GPI, the mucin domain of CX3CL1 
was combined with a GPI anchor and a CXCL10 chemokine head in order to generate a flexible tool 
for the modification of tumor micromilieus capable of selectively stimulating the recruitment of 
CXCR3+ leukocytes. The chemokine head would direct the specificity towards CXCR3+ leukocytes, 
while the mucin domain would assist in the recruitment process and lower the requirement for other 
adhesion molecules. Inclusion of a GPI anchor would allow the fusion protein to integrate into the 
cell membranes of tumor, stromal and endothelial cells when applied exogenously, thus superseding 
the transfer of genetic material into the tumor. 
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transferred cells into the tumor. In a second part of the study, an additional set of fusion proteins 
was generated using the same architecture as described above but with a CXCL8 chemokine head 
instead of CXCL10. Thereby, the applicability of the reagents should be extended to the recruitment 
of other leukocyte subsets.  
1.5 Specific aims and scope 
The scope of the study was directed toward the following specific aims: 
 Cloning of recombinant constructs encoding required fusion proteins. These included a fusion 
protein consisting of a CXCL10 chemokine head, followed by the mucin domain taken from 
CX3CL1 and a GPI anchor signal sequence derived from LFA-3 (CXCL10-mucin-GPI). A variant 
lacking the mucin domain (CXCL10-GPI) would act as a control to assess the biologic effects of the 
mucin domain. Soluble versions of both proteins (CXCL10-mucin-Stop and CXCL10-Stop) served as 
controls for effects mediated by the GPI anchor. Proteins with a CXCL8 chemokine domain instead 
of CXCL10 (CXCL8-mucin-GPI and CXCL8-GPI) should allow assessing broader applicability of the 
underlying concept. A GPI-anchored negative control protein lacking function in leukocyte 
recruitment should additionally be generated. All proteins should contain a c-myc epitope tag to 
facilitate detection and purification.  
 Expression of the recombinant constructs in Chinese hamster ovary cells. Successful expression 
should be validated by FACS, and correct targeting to the cell membrane should be further 
assessed by immunofluorescence microscopy. 
 Verification of the bioactivity of CXCL10-GPI and CXCL10-mucin-GPI. The bioactivity of the proteins 
should be tested to ensure proper expression, folding and processing of the fusion proteins.  
 Development of purification protocols. Protocols for the solubilization and purification of the 
recombinant proteins from overexpressing CHO cells should be established.  
 Analysis of the incorporation process. The capacity of purified GPI-anchored proteins to integrate 
into cell membranes and the dependency of the incorporation process on the GPI anchor should 
be verified. 
 Evaluation of bioactivity in vitro. The bioactivity of CXCL10-mucin-GPI following incorporation into 
the cell membranes of endothelial cells should be evaluated in assays that mimic leukocyte 
recruitment in vitro. The experiments should assess if the incorporated proteins were able to 
facilitate NK or T cell adhesion under conditions of physiologic flow and the potential contribution 
of the mucin domain to this effect.  
 Evaluation of bioactivity in vivo. Finally, an in vivo tumor model should be established to test if 
injection of CXCL10-mucin-GPI could enhance recruitment of NK and T cells. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cell culture 
2.1.1.1 Media and Supplements 
Media:  
CD CHO Invitrogen, Carlsbad 
DMEM Invitrogen, Carlsbad 
HAM-F12 Invitrogen, Carlsbad 
Endothelial cell growth medium, microvascular (ECGM MV) Promocell, Heidelberg 
MEM alpha medium (MEMα) Invitrogen, Carlsbad 
RPMI 1640 Invitrogen, Carlsbad 
RPMI 1640, Phenol red free Invitrogen, Carlsbad 
Serum-free freezing medium Cryo-SFM Promocell, Heidelberg 
 
Supplements:  
2-Mercaptoethanol (2-ME), 55 mM Invitrogen, Carlsbad 
Endothelial cell growth supplement (ECGS), microvascular Promocell, Heidelberg 
Fetal calf serum (FCS) Biochrom AG, Berlin 
Fetal calf serum, dialyzed (dFCS) Biochrom AG, Berlin 
Fetal calf serum, ultra-low IgG (FCS IgGlow) PAN, Aidenbach 
Glucose, 35% Sigma Aldrich, Taufkirchen 
HEPES, 1 M Invitrogen, Carlsbad 
HT-supplement, 50x Invitrogen, Carlsbad 
Human serum Provided by Prof. Noessner, 
Helmholtz Zentrum Munich 
L-Glutamine, 200 mM  Biochrom AG, Berlin 
Na-Pyruvate, 100 mM  Invitrogen, Carlsbad 
Non-essential amino acids (NEAA), 10 mM Invitrogen, Carlsbad 
Penicillin/ Streptomycin (P/S), 100x PAA Laboratories, Pasching 
 
Other reagents:  
Collagen G, 4 mg/ml Biochrom AG, Berlin 
Dimethylsulfoxide (DMSO) Merck, Darmstadt 
Dulbecco´s PBS (without Ca2+ and Mg2+, 1x or 10x) PAA Laboratories, Pasching 
EDTA, 1% in PBS Biochrom AG, Berlin 
Trypan blue Sigma Aldrich, Taufkirchen 
Trypsin-EDTA in PBS, 1x  PAA Laboratories, Pasching 
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2.1.1.2 Cell lines and primary cells 
Cell line / growth Description Source Medium Supplements 
291 cells 
B cell lymphoma 
line from c-myc 
transgenic C57/Bl6 
mice 
Provided by  
R. Mocikat, 
Helmholtz 
Zentrum 
Munich 
RPMI 1640 
+ 5% FCS 
+ 0.1 mM NEAA 
+ 55 µM 2-ME 
+ 1 mM Na-Pyruvate 
9E10  
hybridoma cells, 
suspension 
Hybridoma cells 
expressing anti 
c-myc antibody 
9E10 
Provided by  
W. Uckert,  
MDC Berlin 
RPMI 1640 
+ 10% FCS IgGlow 
+ 3,5 g/l Glucose 
+ 2 mM L-Glutamine 
+ 2,383 g/l HEPES 
+ 110 g/l Na-Pyruvate 
A5.12.14 
hybridoma cells, 
suspension 
Hybridoma cells 
expressing anti 
CXCL8 antibody 
A5.12.14 
LGC Standards, 
Teddington 
50% 
DMEM, 
50%  
HAM-F12 
+ 5% FCS IgGlow 
Chinese hamster 
ovary (CHO) cells, 
adherent 
Ovary cells from 
chinese hamster, 
Dhfr deficient 
ATCC, USA MEMα 
+ 10% dFCS 
+ 1% P/S 
non-transfected cells 
additionally : 
+ 1% HT supplement 
DS4 cells,  
suspension 
Human alloreactive 
CD8+ effector T cell 
clone 
Provided by E. Noessner, Helmholtz Zentrum Munich 
Obtained freshly for each assay 
HDBEC, 
adherent 
Microvascular 
endothelial cells 
from blood vessels 
of fetal foreskin 
Promocell, 
Heidelberg 
ECGM MV + ECGS, microvascular 
HMEC,  
adherent 
Microvascular 
endothelial cells, 
SV40-immortalized 
Provided by H.-
J. Gröne, DKFZ 
Heidelberg 
DMEM + 10% FCS 
Human NK cells, 
suspension 
Human NK cells, 
isolated from 
peripheral blood 
(see 2.2.5.5) 
Isolated in 
house 
AIM-V 
+ 10% human serum 
overnight activation: 
+ 500 U/ml IL-2  
JB4 cells,  
suspension 
Human HLA-A2 
alloreactive CD8+ 
effector T cell clone 
Provided by E. Noessner, Helmholtz Zentrum Munich 
Obtained freshly for each assay 
Murine T cells, 
suspension 
Murine CD19-
specific CD4+ T cell 
clone 
Provided by F. Lehmann, Helmholtz Zentrum Munich 
Obtained freshly for each assay 
Murine NK cells, 
suspension 
Murine NK cells, 
isolated from 
spleens of C57/Bl6 
mice 
Provided by J. Pötzl, Helmholtz Zentrum Munich 
Isolated freshly for each assay 
YT cells, 
suspension 
Human NK cell line 
established from 
acute lympho-
blastic lymphoma 
Provided by C. 
Clayberger, 
Stanford Univ. 
RPMI 1640 + 20% FCS 
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2.1.2 Bacteria 
E. coli DH5alpha; Genotype:   supE44, ΔlacU169 (Ф80 lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 
relA1 
E. coli XL1-blue supercompetent cells for site-directed mutagenesis kit: Fermentas, St. Leon-Rot 
 
2.1.3 Buffers and solutions 
If not stated otherwise, all buffers were prepared in ultra-pure H2O, except all buffers used for 
chromatography (2.1.3.1), which were prepared using injection-grade water (Aqua ad iniectabilia). 
2.1.3.1 Chromatography 
Buffers for anti c-myc column:  
Equilibration buffer  1x PBS + 0.025% Triton X-100h 
Washing buffer  145 mM NaCl 
in 1 x PBS (cell culture grade, Invitrogen) 
Elution buffer  0.01 mg/ml c-myc peptide  
in equilibration buffer 
Regeneration buffer  0.17 M Glycine in H2O, pH 2.3 
Storage buffer  0.1% NaN3 (w/v) 
in 1x PBS (cell culture grade, Invitrogen) 
 
Buffers for Protein A column:  
 
Equilibration buffer  20 mM Na2HPO4/ NaH2PO4, pH 7.4 (4°C) 
Elution buffer  20 mM citrate buffer, pH 3.6 (4°C) 
  
Other buffers:  
Extraction buffer 4 mM n-Dodecyl-β-D-maltoside 
50 mM Tris/HCl, pH 7.5 
100 mM NaCl 
1 protease inhibitor cocktail tablet / 50ml 
Tris/HCl, 1 M, pH 7.5 (4°C) 
 
Commercially available; Invitrogen, Carlsbad 
2.1.3.2 SDS-PAGE and western blot 
Buffers and solutions prepared in house:  
Ammoniumpersulfate (APS) 10% APS (w/v)  
Blocking solution 5% skimmed milk powder (w/v) in TBST  
Coomassie staining solution 0.02% ServaBlue R (w/v) 
0.25% methanol (v/v) 
10% acetic acid (v/v) 
Electrophoresis buffer 
 
 
1.9 M Glycine 
0.25 M Tris 
1% SDS (w/v) 
Laemmli buffer, 3x 150 mM Tris/HCl, pH 6.8 (rt) 
30% Glycerine (v/v) 
6% SDS (w/v) 
0.3% Bromphenol blue (w/v) 
7.5% β-mercaptoethanol (v/v) 
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Sodiumdodecylsulfate (SDS), 10% 10% SDS (w/v)  
Tris, 1 M, pH 6.8 1 M Tris, pH 6.8 (rt) 
Tris, 1.5 M, pH 8.8 1.5 M Tris, pH 8.8 (rt) 
Tris-buffered saline (TBS), 10x 1.5 M NaCl 
100 mM Tris 
10 mM NaN3 
Tris-buffered saline with Tween (TBST) 
 
0.05% Tween20 (v/v) in 1x TBS 
Commercially available buffers and solutions:  
Acrylamide/ Bisacrylamide solution, 30% Roth, Karlsruhe 
ECL-substrate for western blot Pierce, Rockford 
NuPAGE LDS sample buffer, 4x Invitrogen, Carlsbad 
NuPAGE transfer buffer, 50x Invitrogen, Carlsbad 
PageBlue protein staining solution Fermentas, St. Leon Rot 
WesternBreeze® Blocking solution 
 
Invitrogen, Carlsbad 
2.1.3.3 Molecular biology 
Buffers and solutions prepared in house:  
EGTA-Solution 100 mM EGTA, pH 8.0 (rt) 
Loading buffer for agarose gels, 6x 0.25% Bromphenol blue (w/v) 
0.25% Xylen-Cyanol FF  (w/v)  
30% Glycerin (v/v) 
Tris-borate-EDTA (TBE) buffer, 1x 90 mM Tris,  
2 mM boric acid 
0.01 M EDTA  
pH 8.0 (rt) 
  
Commercially available buffers:  
Buffers for DNA restriction enzymes, 10x NEB, Frankfurt 
First strand buffer, 5x Invitrogen, Carlsbad 
SpeedAmp PCR buffer, 10x Analytik Jena, Jena 
ThermoPol buffer for Taq polymerase, 10x 
 
NEB, Frankfurt 
2.1.3.4 Microbiology 
Agar, 2x 3% Agar-Agar (w/v), autoclaved 
Ampicillin solution 50 mg/ml Ampicillin in 70% ethanol (w/v) 
CaCl2 solution  
(for preparation of competent bacteria) 
60 mM CaCl2 
15% Glycerin (v/v) 
10 mM PIPES, pH 7 (rt) 
sterile filtered (0.2 µm) 
Freezing solution for bacteria, 10x 132.3 mM KH2PO4 
21 mM Sodiumcitrate 
3.7 mM MgSO4*7 H2O 
68.1 mM (NH)2SO4 
459.3 mM K2HPO4*3 H2O 
35.2% Glycerin (w/v) 
autoclaved 
LB medium, 2x 2% Bacto Tryptone (w/v) 
342 mM NaCl 
1% yeast extract (w/v) 
pH 7.2-7.3 (rt), autoclaved 
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2.1.3.5 ELISA 
Assay buffer 1% BSA (w/v) in 1x PBS 
OptEIA substrate solution for ELISA Commercially available; BD Biosciences, Bedford 
PBS, 20x 2.74 M NaCl 
129.2 mM Na2HPO4 * 2 H2O 
54 mM KCl 
29.4 mM KH2PO4 
Wash buffer 
 
0.05% Tween20 (v/v) in 1x PBS 
2.1.3.6 Flow assay 
Assay buffer 0.5% BSA (w/v) 
50 mM HEPES 
2 mM CaCl2 + MgCl2 added directly before use  
in HBSS (with Phenol red, w/o Ca2+/Mg2+) 
 
Commercially available buffers: 
 
Bovine serum albumin (BSA), 7.5% solution, cell 
culture grade 
Invitrogen, Carlsbad 
Hank´s buffered salt solution (HBSS),  with 
Phenol red, w/o Ca2+/ Mg2+, cell culture grade 
Sigma-Aldrich, Taufkirchen 
HEPES, 1 M solution, cell culture grade 
 
Invitrogen, Carlsbad 
2.1.3.7 Histology and immunohistology 
Antigen unmasking solution  
for paraffin sections, citric acid based 
Vector laboratories, Burlingame 
Eosin Y solution, alcoholic Sigma Aldrich, Taufkirchen 
Hematoxylin solution, Harris modified Sigma Aldrich, Taufkirchen 
Vectamount mounting medium 
 
Vector laboratories, Burlingame 
2.1.3.8 Other buffers and solutions  
Buffers and solutions prepared in house:  
FACS-buffer 2 mM EDTA 
2% FCS (v/v) 
in 1x PBS (cell culture grade, Invitrogen) 
Fixation solution for immunofluorescence 1% PFA (w/v) 
in 1x PBS (cell culture grade, Invitrogen) 
  
Commercially available solutions:  
Biocoll separating solution (Ficoll) Biochrom AG, Berlin 
Hank´s buffered salt solutions (HBSS):  
   with Phenol red, with Ca2+, Mg2+ Sigma-Aldrich, Taufkirchen 
   without Phenol red, with Ca2+, Mg2+ Invitrogen, Carlsbad 
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2.1.4 Antibodies 
Primary antibodies 
Immuno-
gen 
Target 
species 
Host 
species 
Isotype Application Labeling Source 
CD3 human mouse IgG1 κ FACS FITC 
BD Pharmingen, 
Bedford 
CD3 pan rat IgG1 IHC - 
AbD Serotec, 
Langford 
c-myc unspecified mouse IgG1 κ WB, FACS, IF - 
prepared in house 
 
CX3CL1 
muc. dom. 
human mouse IgG1 κ FACS - Abnova, Taipei 
CXCL8 human mouse IgG2a WB, FACS - 
prepared in house 
 
CXCL10 human mouse IgG2a WB, FACS - 
BD Biosciences, 
Bedford 
CXCR3 human mouse IgG1 κ FACS RPE 
BD Pharmingen, 
Bedford 
CXCR3 human mouse IgG1 FACS RPE 
R&D Systems, 
Minneapolis 
CXCR3 mouse 
Armenian 
hamster 
IgG FACS APC Biolegend, San Diego 
NKp46 mouse goat polyclonal IHC - 
R&D Systems, 
Minneapolis 
(isotype 
control) 
- mouse IgG1 κ FACS - 
Sigma-Aldrich, 
Taufkirchen 
(isotype 
control) 
- mouse IgG2a FACS - 
Sigma-Aldrich, 
Taufkirchen 
(isotype 
control) 
- mouse IgG1 FACS FITC 
Dako, Roskilde 
 
(isotype 
control) 
- 
Armenian 
hamster 
IgG FACS APC Biolegend, San Diego 
(isotype 
control) 
- mouse IgG1 FACS RPE 
BD Pharmingen, 
Bedford 
Secondary antibodies 
IgG mouse rabbit  FACS RPE 
Dako,  
Roskilde 
IgG mouse rabbit  WB HRP 
Dako,  
Roskilde 
IgG mouse rat  IF Biotin 
BD Pharmingen, 
Bedford 
IgG goat horse  IHC Biotin 
Vector Laboratories, 
Burlingame 
IgG  rat rabbit  IHC Biotin 
Vector Laboratories, 
Burlingame 
Abbreviations: IHC = immunohistochemistry; IF = immunofluorescence microscopy; WB = western 
blotting; FACS = fluorescence activated cell scanning; Other abbreviations: see 5.8 (page 114). 
 
 
Materials and Methods   26 
2.1.5 Enzymes 
Alkaline phosphatase Roche, Mannheim 
Phosphatidylinositol-specific phospholipase C (PI-PLC) Invitrogen, Carlsbad 
Phusion DNA polymerase NEB, Frankfurt 
Restriction Enzymes: EcoRI, SalI, XbaI, NheI, MluI, MfeI, NdeI NEB, Frankfurt 
SuperScript II reverse transcriptase Invitrogen, Carlsbad 
T4 DNA ligase NEB, Frankfurt 
Taq DNA polymerase NEB, Frankfurt 
 
2.1.6 Recombinant proteins and peptides 
Protein Species Application Source 
c-myc peptide unspecified Protein purification MBL, Japan 
CXCL10 human In vitro and in vivo assays Peprotech, Hamburg 
CXCL10 mouse In vitro assays Peprotech, Hamburg 
Streptavidin-HRP unspecified ELISA BD Biosciences, Bedford 
Streptavidin-RPE S. avidinii FACS Dako, Roskilde 
 
2.1.7 Size standards for electrophoresis 
1 kb DNA ladder  Invitrogen, Carlsbad 
MagicMarkTM XP western protein standard Invitrogen, Carlsbad 
 
2.1.8 Primers  
Application Primer name Sequence 
Amplification of  
c-myc tag 
p2xMycTag_fw 5´- GTTAAGCTGTGTATCTAGAGAACAGAA-3´ 
p2xMycTag_rv 5´- CTTCATTGCTAGCCAGGTCCTCCTC-3´ 
Amplification of  
CX3CL1 mucin domain 
Fra_fw_080901 5´-GAGAATTCATCTAGAAATGGCGGCACCTTCG-3´ 
Fra_rv_080901 5´-GGATACAGGTTGTGCTAGCCTGCCTC-3´ 
Amplification of  
CXCL8 
IL8_fw_1107 5´-GAAGAAACCAATTGAAGGAACCATCTCACTG-3´ 
IL8_rv_1107 5´-GAGAATGAATTTCTAGATGAATTCTCAGCCCTCTTC-3´ 
Amplification of  
CXCL10 
IP10_fw_long 5´-GAGGAACCTGAATTCCCAGTCTCAGCACC-3´ 
IP10_rv_long 5´-CCCCTCTGGTGCTAGCAGGAGATCTTTTAG 
Amplification of EGFP 
from pEGFP-N1 
EGFP_fw_0408 5´-GATCCACCGACGCGTGCCATGGTGAGC-3´ 
EGFP_rv_0408 5´-GAGTCGCGGCCTCTAGACTTGTACAGCTCGTCC-3´ 
Amplification of GPI 
signal sequence of DAF 
DAFPI_fw 5´-CAAATAAATCTAGAGGAAGTGGAACCACTTC-3´ 
DAFPI_rv 5´-CTTTGGGTCGACCTAAGTCAGCAAG-3´ 
Mut. of pUC-CXCL10-GPI 
to restore NheI site 
IP10_NheI_320_fw 5´-CTAAAAGATCTCCTGCTAGCGAACAGAAGCTGATCAGC-3´ 
IP10_NheI_320_rv 5´-GCTGATCAGCTTCTGTTCGCTAGCAGTAGATCTTTTAG-3´ 
Mut. of TIMP-1 signal 
sequence (MluI site) 
SS_mut_fw 5´-GGCTGATAGCCCCCACGCGTGCCTGCACCTGTGTC-3´ 
SS_mut_rv 5´-GACACAGGTGCAGGCACGCGTGGGGGCTATCAGCC-3´ 
Sequencing of  
inserts in pEF 
pEF_Insert_fw 5´-GATCTTGCTTCATTCTCAAGCC-3´ 
pEF_Insert_rv 5´-ATACCGGAGTACTAGCCGCC-3´ 
 
 
 
Materials and Methods   27 
2.1.9 Plasmids and vectors 
Plasmid Description Source 
Resistance 
gene 
Application 
MP71 gp100 
Rectroviral vector containing 
double c-myc tag sequence 
Provided by 
Prof. W. Uckert, 
MDC Berlin 
Ampicillin 
Template for 
amplification of 
c-myc tag 
pEFdhfr 
Contains multiple cloning site 
and dhfr gene separated by 
internal ribosome binding site 
under the control of a CMV 
promoter 
Provided by  
M. Mack, 
University 
Regensburg 
Ampicillin 
Expression vector 
for stable 
transfection in 
CHO cells 
pEGFP-N1 
Expression vector for EGFP 
expression in eukaryotic cells 
TaKaRa, Kyoto Kanamycin 
Template for 
amplification of 
EGFP gene 
pUC19 Standard cloning vector 
Invitrogen, 
Carlsbad 
Ampicillin 
Cloning and 
mutagenesis 
 
2.1.10 Kits 
Avidin/Biotin blocking kit Vector laboratories, Burlingame 
BCA protein Assay kit Thermo Scientific, Rockford 
Bio-Rad protein assay  Bio-Rad, Hercules 
DuoSet CXCL8 ELISA development kit R&D Systems, Minneapolis 
DuoSet CXCL10 ELISA development kit R&D Systems, Minneapolis 
Dynabeads® untouched human NK cell isolation kit Invitrogen, Carlsbad 
Endofree Plasmid Maxi kit Qiagen, Hilden 
Fluo-4 NW Calcium assay kit Invitrogen, Carlsbad 
Innuprep Plasmid Mini kit Analytik Jena, Jena 
Innuprep Doublepure kit Analytik Jena, Jena 
PureLink RNA Mini kit Invitrogen, Carlsbad 
Quant-itTM DNA Assay kit, broad range Invitrogen, Carlsbad 
Quant-itTM DNA Assay kit, high sensitivity Invitrogen, Carlsbad 
Quant-itTM RNA Assay kit Invitrogen, Carlsbad 
Quickchange Site-directed mutagenesis kit Stratagene, Santa Clara 
RNase-free DNase set Qiagen, Hilden 
Vectastain ABC kit Vector laboratories, Burlingame 
 
2.1.11 Protein chromatography equipment 
Chromatography machine ÄktaFPLC GE Healthcare, Uppsala 
c-myc tagged protein mild purification gel MBL, Japan 
Empty glass column Tricorn 5/50  GE Healthcare, Uppsala 
HiPrep 26/10 Desalting column GE Healthcare, Uppsala 
HiTrap Desalting column GE Healthcare, Uppsala 
Protein A-HP HiTrap column GE Healthcare, Uppsala 
recombinant Protein A FF HiTrap column GE Healthcare, Uppsala 
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2.1.12 Other laboratory equipment 
Automatic tissue processor Thermo Fisher, Waltham 
Developer for autoradiography films Agfa, Mortsel 
E. coli Pulser Bio-Rad, Hercules 
Electroporation device for cell culture Bio-Rad, Hercules 
Fluorescence activated cell scanner FACSCalibur BD Biosciences, San Jose 
Fluorescence Microscope DMRBE Leica, Wetzlar 
Fluorometer Qubit Invitrogen, Carlsbad 
Inverted fluorescence microscope DMIL Leica, Wetzlar 
  Video Camera for Leica DMIL Horn Imaging, Aalen 
  Photo Camera for Leica DMIL Jenoptik, Jena 
  Incubation chamber for Leica DMIL Ibidi, Martinsried 
Microtome HM-340-E Microm, Walldorf 
Multiwell plate reader Genios Plus Tecan, Crailsheim 
Paraffin embedding machine EC-350-1 Microm, Walldorf 
PCR machine SpeedCycler Analytik Jena, Jena 
PCR machine Perkin Elmer Perkin Elmer, Waltham 
Rolling system for cell culture CELLROLL Integra Biosciences, Fernwald 
Scintillation counter TOPcount Canberra Packard, Dreireich 
Spinner flask for cell culture ProCulture Corning, Lowell 
Syringe Pump for laminar flow assays WPI, Sarasota 
 
2.1.13 Chemicals 
BRIJ 35, 30% w/w solution Merck, Darmstadt 
C12E8 detergent Merck, Darmstadt 
Methotrexate Sigma Aldrich, Taufkirchen 
NaCl, 5 M solution, for chromatography buffers Sigma-Aldrich, Taufkirchen 
n-Dodecyl-β-D-maltoside, ULTROL grade Calbiochem/ Merck, Darmstadt 
Nonidet P40 (NP40) detergent, 10% solution Calbiochem/ Merck, Darmstadt 
n-Octyl-β-D-glucopyranoside, ULTROL grade Calbiochem/ Merck, Darmstadt 
Paraformaldehyde (PFA) Merck, Darmstadt 
Protease inhibitor cocktail tablets Complete Roche, Mannheim 
RNAsin RNase inhibitor Promega, Madison 
Sodium Azide (NaN3) Merck, Darmstadt 
Triton X-100, hydrogenated (Triton X-100h) Calbiochem/ Merck, Darmstadt 
Water, injection grade (aqua ad injectabilia) Braun, Melsungen 
 
2.1.14 Disposable and other materials 
96-well microtiter plate, round bottom Greiner, Frickenhausen 
96-well microtiter plate for ELISA Nunc, Roskilde 
96-well microtiter plate, flat bottom, black walls Greiner, Frickenhausen 
Amersham Hyperfilm ECL autoradiography film GE Healthcare, Uppsala 
Cell culture dishes for immunofluorescence µ-dish high Ibidi, Martinsried 
Luer connectors Ibidi, Martinsried 
LumaPlate Scintillant coated 96 well plate Perkin Elmer, Waltham 
Roller bottles for cell culture Greiner, Frickenhausen 
Slides for flow assays µ-slides 0.4 Luer Ibidi, Martinsried 
Ultrafiltration devices Vivaspin 6 GE Healthcare, Uppsla 
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2.1.15 Software 
Name Application Source 
CellQuest Acquisition of FACS data BD Biosciences, Bedford 
FlowJo Evaluation of FACS data TreeStar Inc., Ashland 
IC Capture Video acquisition at the Leica DMIL microscope The Imaging Source, Bremen 
Prism 5 Generation of diagrams GraphPad Software, La Jolla 
ProgRes Capture Image acquisition at the Leica DMIL microscope Jenoptik, Jena 
PyMol Graphic representations of protein structures 
DeLano Scientific, San 
Francisco 
Unicorn Protein chromatography control and evaluation  GE Healthcare, Uppsala 
XFluor Control of ELISA plate reader Tecan, Crailsheim 
 
2.1.16 Mice 
Female C57/Bl6 mice were purchased from Taconic Farms Inc., Hudson, and used for experiments at 
11-21 weeks of age. All mice were housed at the Helmholtz Zentrum Munich under special pathogen 
free conditions.  
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 General cell culture 
The culture of living cells was performed in a laminar flow hood to prevent contaminations. All 
reagents were prewarmed to 37°C in a water bath prior to use, except media for primary endothelial 
cells, which were prewarmed for 30 min in a cell culture incubator set to 37°C and 5% CO2 to allow 
for pH adjustment of the media.  All cells were incubated at 37°C and 5% CO2. 
For subculturing, adherent cells were washed with PBS and subsequently detached using Trypsin-
EDTA solution at rt. The reaction was stopped by adding an equal volume of medium containing 10% 
FCS (or more if the medium contained less FCS) and the cells were pelleted by centrifugation for 
3 min at 220 x g (rt). Subsequently, the cell pellet was resuspended in fresh medium and seeded into 
the respective cell culture vessel. If surface molecules on the respective cells were analyzed using 
FACS, western blot or other methods, or the cells were harvested for protein purification, only 6 mM 
EDTA in PBS at 37°C was used to detach the cells. Suspension cells were resuspended prior to 
subculturing and subsequently a fraction of the culture medium according to the desired split factor 
was transferred into a new cell culture flask, which was then filled up with fresh medium to the 
desired end volume.  
For protein production, transfected CHO cells were grown in six 300cm2 cell culture flasks, detached 
with EDTA in PBS, washed with PBS and combined to one pellet, which was stored at -80°C. If cell 
Materials and Methods   30 
culture supernatant should be generated from CHO cells transfected with secreted proteins, the cells 
were grown in 850 cm2 roller flasks using 30 ml of serum-free MEM alpha medium for each flask. The 
cells were monitored microscopically for viability and as soon as a decrease in viability was observed 
(usually after about 4 days), the supernatant was removed, centrifuged for 5 min at 3000 x g (4°C) to 
remove cell debris, sterile filtered (0.2 µm pore size) and stored at 4°C.  
Two hybridoma cell lines were cultured in the current study. The A5.12.14 hybridoma producing an 
anti CXCL8 antibody was cultured in 150 cm2 cell culture flasks, each of which could be filled with up 
to 100 ml of medium. Exponentially growing cells were seeded at 3 x 104 cells/ml, and after 7 days 
the supernatant was harvested, centrifuged for 5 min at 3000 x g (4°C) to remove cell debris, sterile 
filtered (0.2 µm pore size) and stored at 4°C. The 9E10 hybridoma was cultured in 850 cm2 roller 
flasks which could be filled with up to 1 l of medium. For the quantitative production of supernatant, 
phenol red free RPMI 1640 medium was used and the cells were cultured for 7 days as described for 
the A5.12.14 hybridoma.  
2.2.1.2 Freezing and thawing of cells 
All cells, except primary endothelial cells, were frozen in their respective culture medium + 10% 
DMSO. Primary endothelial cells were frozen in serum free freezing medium (Cryo-SFM). The tubes 
were cooled to -80°C over 24 h in an isopropanol container prior to transferring them into a liquid 
nitrogen container. For thawing, the frozen cell suspensions were rapidly thawed in a 37°C water 
bath and immediately transferred into a cell culture vessel filled with prewarmed medium. The 
medium was exchanged after 18 h to remove DMSO. 
2.2.1.3 Counting cells 
To determine the number of cells/ml, an aliquot of the cell suspension was mixed at a 1+1 ratio with 
Trypan blue solution (0.4%) and pipetted into a Neubauer counting chamber. Dye exclusion was used 
to differentiate viable from dead cells and the number of cells per ml was calculated from the 
average number of cells per square x 104. 
2.2.2 Molecular biology 
2.2.2.1 Freezing and thawing of bacteria 
For long-term storage of E. coli strains, 900 µl of an overnight culture was mixed with 100 µl freezing 
solution for bacteria (10x) and frozen at -80°C. To establish cultures from frozen cells, a small amount 
of frozen bacteria was streaked onto an appropriate agar plate and incubated at 37°C over night. 
Subsequently, a liquid culture was established from a single colony on that plate.  
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2.2.2.2 Preparation of agar plates 
For the preparation of agar plates, 3% Agar was heated in a microwave and mixed with an equal 
volume of 2x LB medium. When required, appropriate antibiotics were added (Ampicillin: 100 µg/ml 
final concentration; Kanamycin: 50 µg/ml final concentration) and the solution was poured into petri 
dishes. Plates were sealed in plastic bags and stored at 4°C.  
2.2.2.3 Restriction digestion of DNA 
DNA was cut using restriction enzymes. 1 unit restriction enzyme was used to cut 1 µg DNA per hour. 
In cases when larger amounts of DNA had to be cut, the amount of enzyme and/or the incubation 
time was increased accordingly. To minimize detrimental effects of glycerol, it was taken care that 
the volume of enzyme solution did not exceed 1/10 of the total volume. All digestions were 
performed in a buffer suitable for the respective enzyme (diluted to 1x) at 37°C.  
2.2.2.4 Separation of DNA fragments by electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments for analytical or preparative 
purposes. The concentration of agarose was chosen according to the expected fragment sizes and 
varied between 0.6% and 2% agarose. Gel solutions were prepared in 0.5x TBE buffer and heated in a 
microwave to dissolve the agarose. Subsequently, ethidium bromide was added to a final 
concentration of 100 ng/ml before pouring the gels into appropriate chambers. For electrophoresis, 
the samples were mixed with loading buffer for agarose gels (6x) to yield a 1x final concentration of 
loading buffer and loaded into the wells. Electrophoresis was performed in 0.5x TBE buffer at 120 V 
and the gels were subsequently photographed under UV light for documentation. In the case of 
preparative gels, the respective bands were cut out of the gel under UV light and DNA was extracted 
from the gel fragments using a commercial kit (Innuprep Doublepure kit) according to the 
manufacturer´s instructions.  
2.2.2.5 Determination of DNA and RNA concentrations 
The concentrations of DNA and RNA in solutions were determined fluorometrically using a special 
fluorometer (Qubit) in combination with commercially available reagents (Quant-itTM). All 
determinations were performed according to the manufacturer´s instructions. 
2.2.2.6 Dephosphorylation of DNA ends 
In order to prevent religation of linearized vectors, their 5´ DNA ends were dephosphorylated. To this 
end, 1 unit of alkaline phosphatase per 50 pmol 5´ ends was added to the sample and the mixture 
was incubated at 37°C for 1 h. The reaction was stopped by the addition of EGTA to a final 
concentration of 20 mM and a subsequent incubation at 65°C for 10 min. Prior to the next cloning 
step, the dephosphorylated DNA was purified using a commercially available kit (Innuprep 
Doublepure kit) according to the manufacturer´s instructions.  
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2.2.2.7 Ligation of DNA fragments 
For ligation of vector and insert DNA, separate reactions were prepared using an insert:vector molar 
ratio of 3:1 and 10:1, respectively. A third reaction containing only vector DNA served as negative 
control. All reactions were performed in a total volume of 20 µl containing 400 U (1 µl) T4 DNA ligase 
and 2 µl 10x T4 DNA ligase buffer for 1 h at room temperature.    
2.2.2.8 Preparation and transformation of competent E. coli DH5α 
In order to prepare chemically competent E. coli, 4 ml of an overnight liquid culture of E. coli DH5α in 
LB medium was diluted 1:100 into fresh LB medium and incubated at 37°C and 250 rpm until an 
OD600nm of 0.375 was reached. Subsequently, the suspended bacteria were aliquoted into 50 ml 
aliquots that were kept on ice for 5 min and afterwards centrifuged for 7 min at 1600 x g (4°C). The 
supernatant was discarded, each aliquot of bacteria was resuspended in 10 ml ice cold CaCl2 solution 
and the centrifugation step repeated as above. After that, the supernatant was discarded again, each 
aliquot of bacteria was resuspended in 10 ml fresh ice cold CaCl2 solution and stored on ice for 
30 min. Following another centrifugation as detailed above, the pelleted bacteria were resuspended 
in 2 ml CaCl2 solution per aliquot, snap frozen in an ethanol/ dry ice bath and stored at -80°C. 
For transformation of competent E. coli DH5α bacteria using ligation reactions, 1/10 of the entire 
reaction was used, corresponding to 10-100 ng DNA. The frozen bacteria were rapidly thawed and 
50 µl of suspension were added to the DNA. Following an initial incubation on ice for 10 min, the 
mixture was heated to 42°C for 45 sec and immediately cooled on ice again. The transformed 
bacteria were suspended in 1 ml LB medium and incubated for 45 min at 37°C and 400 rpm. 
Subsequently, the suspension was plated onto agar plates containing the appropriate antibiotic for 
selection of successfully transformed colonies and incubated over night at 37°C. On the next day, 
single colonies were picked and transferred into liquid cultures in order to prepare plasmid DNA. 
2.2.2.9 Isolation and analysis of plasmid DNA from transformed bacteria 
Plasmid DNA was isolated from transformed bacteria using commercially available kits (Innuprep 
Plasmid Mini kit for liquid cultures up to 1.5 ml; Endofree Plasmid Maxi kit for liquid cultures up to 
100 ml) according to the manufacturers´ instructions. Following plasmid DNA isolation, analytical 
restriction digestions were performed using appropriate restriction enzymes (see 2.2.2.3) and the 
resulting fragments were analyzed by gel electrophoresis (see 2.2.2.4). 
2.2.2.10 Polymerase chain reaction (PCR) 
In the current study, several amplifications of genetic material were performed using PCR. The 
reaction mixtures as well as the cycling parameters for the respective amplifications are summarized 
below. The primers for each PCR are listed in 2.1.8. Abbreviations: TB = Thermopol buffer; SA2 = 
Speedamp buffer No. 2; SA3 = Speedamp buffer No. 3; PE = Perkin Elmer cycler; SC = Speed cycler.  
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 c-myc tag CXCL10 CXCL8 
CX3CL1  
mucin dom. 
DAF signal 
sequence 
dNTP mix 0.2 mM 0.25 mM 0.2 mM 0.25 mM 0.2 mM 
fw-primer 0.4 µM 0.3 µM 0.4 µM 0.3 µM 0.4 µM 
rv-primer 0.4 µM 0.3 µM 0.4 µM 0.3 µM 0.4 µM 
Taq DNA Polymerase 0.04 U/µl 0.04 U/µl 0.04 U/µl 0.04 U/µl 0.04 U/µl 
Buffer T, 1x SA3, 1x T, 1x SA2, 1x T, 1x 
Target DNA 4 ng/µl 6.6 ng/µl 5.7 ng/µl 6.7 ng/µl 12 ng/µl 
H2O ad 25 µl ad 15 µl ad 35 µl ad 15 µl ad 25 µl 
 
 c-myc tag CXCL10 CXCL8 
CX3CL1  
mucin dom. 
DAF signal 
sequence 
Initial denaturation 
94°C 
5 min 
95°C 
2 min 
94°C 
5 min 
95°C 
2 min 
94°C 
5 min 
Denaturation 
94°C 
30 sec 
95°C 
4 sec 
94°C 
30 sec 
95°C 
4 sec 
94°C 
30 sec 
Annealing  
64°C  
30 sec 
57°C 
4 sec 
56.5°C, 
90 sec 
58°C 
4 sec 
58°C 
90 sec 
Elongation  
72°C 
30 sec 
72°C 
20 sec 
72°C 
2.5 min 
72°C 
20 sec 
72°C 
2.5 min 
No. of cycles 35 35 30 35 30 
Final elongation 
72°C 
5 min 
72°C 
50 sec 
72°C 
7 min 
72°C 
50 sec 
72°C 
7 min 
Cycler PE SC PE SC PE 
 
2.2.2.11 Site-directed mutagenesis 
A commercially available kit (Quickchange) was used to perform site-directed mutagenesis on 
plasmids. Primers were designed according to the manufacturer´s instructions and are listed in 2.1.8. 
The PCR reactions as well as the subsequent transformation steps were performed according to the 
manufacturer´s instructions.  
2.2.2.12 Sequencing of DNA 
DNA sequencing was performed by Entelechon, Regensburg or GATC Biotech, Konstanz. The primers 
that were used for the sequencing of inserts in pEFdhfr are listed in 2.1.8, standard primers were used 
for other plasmids. 
2.2.2.13 Isolation of mRNA and reverse transcription 
RNA from cultured cells was isolated using a commercially available kit (PureLink RNA Mini kit) 
according to the manufacturer´s instructions including the optional DNase digestion step. RNA was 
eluted from the columns using 30 µl RNase free water and the RNA concentration was determined 
(see 2.2.2.5). 2 µg of RNA were reversely transcribed using the following reaction mixture: 
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Component Concentration 
RNA 50 ng/µl (total 2 µg) 
First strand buffer (5x) 1x 
DTT 0.5 mM 
RNAsin 0.025 U/µl 
Acrylamide 62.5 ng/ml 
dNTPs 2 mM 
Hexamer nucleotides (10x) 1x 
Superscript II reverse transcriptase 0.1 U/µl 
RNase free water ad 40 µl 
 
As a control for contaminations with genomic DNA, a second reaction was prepared using 0.2 µg RNA 
in which the reverse transcriptase was replaced by RNase free water (RTminus control). The reaction 
mixtures were incubated for 90 min at 42°C and 400 rpm and subsequently stored at -20°C.  
2.2.2.14 Stable transfection of CHOdhfr-/- cells 
Dihydrofolate reductase (Dhfr) deficient CHO cells were used to express the membrane-anchored 
chemokines. This cell line is auxotrophic for hypoxanthine and thymidine, and the deficiency can be 
complemented by the dhfr gene encoded in the pEFdhfr plasmid. Thus, stably transfected clones could 
be selected by withdrawal of hypoxanthine and thymidine from the culture medium, which was 
accomplished by the use of FCS which had been dialyzed against PBS.  
Only endotoxin free DNA preparations were used for transfection purposes and to increase the 
efficiency of genomic integration, all vectors were linearized using NdeI prior to transfection.  
CHOdhfr-/- cells were used in the logarithmic growth phase when 90% confluence was reached. The 
cells were detached using Trypsin/EDTA and washed twice with PBS. Subsequently, 5 x 106 cells were 
resuspended in 400 µl PBS, mixed with 30 µg of linearized DNA and incubated on ice for 10 min. After 
that, electroporation was performed at 960 µF and 260 V, followed by another incubation on ice for 
10 min. The transfected cells were transferred into a 75 cm2 cell culture flask and incubated 
overnight in complete medium including hypoxanthine/ thymidine supplement. On the next day, the 
medium was exchanged to selection medium without supplement to allow for the selection of 
transfected clones. 
After this initial selection, some cell lines were additionally treated with methotrexate, an inhibitor of 
the dihydrofolate reductase, to eliminate cells with a low expression level. The dihydrofolate 
reductase gene is expressed in the pEFdhfr plasmids together with the transgenes in one mRNA 
molecule by means of an internal ribosome binding site. Thus, through inhibition of the dihydrofolate 
reductase by methotrexate, cells with a low expression level of dihydrofolate reductase and 
consequently also the transgene can be eliminated. Methotrexate was dissolved in 250 mM sodium-
bicarbonate buffer, pH 9.4, sterile filtered and stored at 4°C. Initially a concentration of 100 nM was 
used, which was supplemented to the medium for several passages until resistant clones grew out. 
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Subsequently the methotrexate concentration was gradually increased up to 200 nM. The expression 
levels of the recombinant fusion proteins were regularly assessed by FACS staining (see 2.2.5.1.1). 
2.2.3 Cloning strategies 
2.2.3.1 Cloning of the CXCL10 constructs 
2.2.3.1.1 CXCL10-GPI and CXCL10-mucin-GPI 
CXCL10-GPI: 
The GPI anchor signal sequence of LFA-3 (amino acids 203-232 of the mRNA translation of LFA-3 
according to GenBank entry NM_001799.2) had previously been amplified from a human inflamed 
kidney cDNA sample (Notohamiprodjo et al. 2006). The signal sequence was ligated into a pUC19 
plasmid using the XbaI (5´) and SalI (3´) restriction enzyme recognition sequences that had been 
introduced via the PCR primers.  
The cloning of the double c-myc epitope tag was performed in collaboration with Dr. N. Rieth. The 
retroviral vector MP71 containing the double c-myc tag sequence served as template and the c-myc 
sequence was amplified by PCR using the primers listed in 2.1.8 and the conditions detailed in 
2.2.2.10. In this PCR, a 5´ XbaI and a 3´ NheI recognition site were added to the sequence via the 
primers. These recognition sites were used to ligate the amplicon into the above mentioned pUC19 
plasmid which contained the LFA3 GPI anchor signal sequence and had been linearized using XbaI. 
Thus, in the resulting plasmid, the c-myc epitope tag sequence directly preceded the GPI signal 
sequence and the NheI restriction site separating the two sequences was lost.  
The CXCL10-GPI and CXCL10-mucin-GPI constructs were cloned in collaboration with S. Böcker from 
our group. A plasmid containing the gene sequence of human CXCL10 had originally been provided 
by PD Dr. B. Luckow and the gene had previously been subcloned into various plasmids. In the 
current study, a plasmid containing CXCL10 and a GPI signal sequence but no c-myc tag sequence 
was used as template to amplify the CXCL10 gene without stop codon. To this end, the primers listed 
in 2.1.8 were used, which introduced 5´ EcoRI and 3´ NheI restriction sites. These sites were used to 
ligate the gene into the above mentioned pUC19 vector already containing the c-myc epitope tag and 
the GPI signal sequence. In the resulting pUC-CXCL10-GPI plasmid, the CXCL10 gene thus preceded 
the c-myc sequence, which was followed by the GPI signal sequence. Subsequently, the entire 
construct was subcloned into a pEFdhfr vector for expression in CHO cells using the 5´ EcoRI and the 3´ 
SalI restriction sites. 
Additionally, the pUC19-CXCL10-GPI plasmid was mutated by site-directed mutagenesis so that the 
NheI restriction site between the CXCL10 gene and the c-myc tag sequence was restored to have 
greater flexibility for subsequent cloning steps. The primers used for the mutagenesis are listed in 
2.1.8 and the resulting plasmid was termed pUC-CXCL10-GPI2. 
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CXCL10-mucin-GPI: 
The mucin domain of CX3CL1 (amino acids 100-341 of the mRNA translation of CX3CL1 according to 
GeneBank entry BC016164.1) had previously been amplified from a human inflamed kidney cDNA 
sample and subcloned into various vectors. In the current study, a pEFdhfr plasmid containing (in that 
order) the CXCL12 gene, the CX3CL1 mucin domain gene, the c-myc tag sequence and the GPI anchor 
signal sequence from LFA3 was used to generate pEF-CXCL10-mucin-GPI. The CXCL12 gene was cut 
out by digestion with EcoRI and XbaI and replaced by the CXCL10 gene that had been cut out of pUC-
CXCL10-GPI2 using EcoRI and NheI. The generated plasmid could then directly be used to transfect 
CHO cells. 
2.2.3.1.2 CXCL10-DAFPI and CXCL10-mucin-DAFPI 
CXCL10-DAFPI: 
A second set of fusion genes was constructed using the GPI anchor signal sequence taken from DAF 
for comparison purposes. The GPI anchor signal sequence of DAF (referred to as DAFPI; amino acids 
348-381 of the mRNA translation of DAF according to GeneBank entry BC001288.1) was amplified by 
PCR from cDNA of primary human monocytes and umbilical vein endothelial cells (HUVEC) using the 
primers listed in 2.1.8 and the conditions detailed in 2.2.2.10. XbaI (5´) and SalI (3´) restriction sites 
were added via the PCR primers. The amplicon was ligated into a pEF-sEGFP-GPI plasmid (see below) 
from which the GPI signal sequence had been removed using XbaI and SalI to yield pEF-sEGFP-DAFPi. 
The sEGFP gene was subsequently removed by digestion with EcoRI and SalI and replaced by a 
cassette containing the CXCL10 gene and the c-myc tag sequence that had been cut out of a second 
vector using EcoRI and NheI.  
CXCL10-mucin-DAFPI: 
The same strategy was employed for the cloning of CXCL10-mucin-DAFPI: The sEGFP gene was 
removed from pEF-sEGFP-DAFPI by digestion with EcoRI and XbaI and replaced by a cassette 
consisting of the CXCL10 gene, the CX3CL1 mucin domain gene and the c-myc tag sequence that had 
been cut out of pEF-CXCL10-mucin-GPI using EcoRI and NheI.  
2.2.3.1.3 CXCL10-Stop and CXCL10-mucin-Stop 
CXCL10-Stop: 
To generate the gene sequence for the secreted protein CXCL10-Stop, the CXCL10 gene was ligated 
using the EcoRI and NheI restriction sites into a pEFdhfr plasmid containing the c-myc tag sequence 
and a stop codon to yield pEF-CXCL10-Stop. 
CXCL10-mucin-Stop: 
The CXCL10-mucin-Stop contruct was generated by first removing the c-myc tag and GPI anchor 
signal sequences from pUC-CXCL10-GPI2 (see 2.2.3.1.1) by digestion with NheI and SalI. 
Subsequently, a cassette consisting of the CX3CL1 mucin domain gene and the c-myc tag sequence 
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followed by a stop codon was cut out of pEF-CXCL8-mucin-Stop (see 2.2.3.3.2) using XbaI and SalI 
and ligated into the above mentioned plasmid. The resulting CXCL10-mucin-Stop gene was then 
subcloned into a pEFdhfr vector using EcoRI and SalI.  
2.2.3.2 Cloning of the sEGFP constructs 
2.2.3.2.1 sEGFP-GPI 
The sEGFP-GPI construct was generated as a GPI-anchored negative control protein. Since EGFP is an 
intracellular protein, an N-terminal (5´) secretion signal sequence as well as a C-terminal (3´) GPI 
anchor signal sequence had to be added to the EGFP gene. The secretion signal sequence was taken 
from human tissue inhibitor of matrix metalloproteases 1 (TIMP-1; amino acids 1-23 of the mRNA 
translation of TIMP-1 according to GenBank entry NM_003254.2), and the GPI signal sequence from 
LFA-3 or DAF as in the other constructs.  
As first cloning step, a MluI restriction site was introduced by site-directed mutagenesis at the 3´ end 
of the secretion signal sequence of TIMP-1 in pUC-TIMP1-GPI (provided by Dr. N. Rieth). The primers 
that were used are listed in 2.1.8. The plasmid already contained the GPI anchor signal sequence of 
LFA-3 at the 5´ end of TIMP-1 and the TIMP-1 gene except the two signal sequences was removed by 
digestion with MluI and XbaI. In a second step, the EGFP gene was amplified without the stop codon 
using a pEGFP-N1 plasmid as template. Concomitantly, a MluI restriction site was introduced at the 
5´ end of the gene and an XbaI site at the 3´ end that were used to ligate the amplicon into the 
pUC19 plasmid with the signal sequences (primers are listed in 2.1.8). In order to introduce the c-myc 
epitope tag sequence, the cassette consisting of the TIMP-1 secretion signal sequence and EGFP was 
subcloned via EcoRI and XbaI into a pUC plasmid containing the c-myc epitope tag sequence followed 
by the GPI signal sequence from LFA-3. The resulting construct was termed sEGFP-GPI (s for secretion 
signal sequence) and subcloned for expression in CHO cells into a pEFdhfr vector using EcoRI and SalI. 
2.2.3.2.2 sEGFP-DAFPI 
The sEGFP-DAFPI construct containing the GPI anchor signal sequence of DAF instead of the one of 
LFA-3 was constructed by amplifying the DAF signal sequence from cDNA samples and subsequently 
ligating it into the pEF-sEGFP-GPI vector, the GPI signal sequence of which had been removed 
beforehand as detailed above.  
2.2.3.3 Cloning of the CXCL8 constructs 
2.2.3.3.1 CXCL8-GPI and CXCL8-mucin-GPI 
To generate the DNA constructs for the GPI-anchored CXCL8 fusion proteins, the CXCL8 gene without 
stop codon was amplified from cDNA of HUVEC cells that had been activated over night with 
10 ng/ml IL-1β. 5´ MfeI and 3´ XbaI restriction sites were added via the primers (see 2.1.8) and used 
to ligate the amplicon into a pEFdhfr vector already containing the LFA3 GPI signal sequence. 
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Subsequently, the GPI anchor signal sequence was replaced by a cassette containing the c-myc 
sequence followed by the LFA3 GPI signal sequence using the XbaI and SalI restriction sites. The 
resulting pEF-CXCL8-GPI plasmid could be transfected into CHO cells.  
The CXCL8-mucin-GPI construct was generated by first linearizing pEF-CXCL10-GPI with XbaI. 
Subsequently, the CXC3CL1 mucin domain was amplified using another plasmid containing the mucin 
domain as template. The corresponding primers are listed in 2.1.8 and introduced a 3´ XbaI and a 5´ 
NheI site into the amplicon, which were used to ligate the mucin domain gene into the linearized 
vector.  
2.2.3.3.2 CXCL8-Stop and CXCL8-mucin-Stop 
The soluble versions of the CXCL8 constructs were created in the same manner as the GPI-anchored 
versions. CXCL8 was amplified by PCR as described above and ligated into a pEFdhfr vector containing 
the c-myc tag sequence followed by a stop codon. For CXCL8-mucin-stop, the mucin domain was 
subsequently inserted as described above for CXCL8-mucin-GPI. 
2.2.4 Protein-biochemical methods 
2.2.4.1 Protein purification 
All protein purifications were performed using an ÄktaFPLC fast protein liquid chromatography 
device. The corresponding Unicorn software was used to control and evaluate chromatography runs. 
All buffers were prepared using pyrogen free components and only pyrogen free disposable 
materials were used in order to prevent contaminations with pyrogens.  
2.2.4.1.1 Purification of the anti c-myc antibody 9E10 
The c-myc specific antibody produced by the hybridoma clone 9E10 was used for various purposes in 
this study. A Protein A (ProtA) Sepharose high performance column (2 x 1 ml columns connected in 
series, 2 ml total bed volume) was used to purify the antibodies. Conditioned medium was obtained 
as described in 2.2.1.1. The column was equilibrated using equilibration buffer (see 2.1.3.1) for 5 CV 
and subsequently the supernatant was loaded with 1 ml/min flow rate. Following a washing step 
with equilibration buffer for 6 CV, the bound antibodies were eluted from the column using elution 
buffer and the elution fractions were immediately neutralized using 1 M Tris, pH 8.0. Aliquots of the 
respective fractions were assayed by reducing SDS-PAGE for the presence of bands corresponding to 
the heavy and light chains of IgG (about 50 kDa and 25 kDa, respectively). PageBlue protein staining 
solution was used to stain the gels according to the manufacturer´s instructions. Positively identified 
fractions were pooled and the buffer was exchanged for PBS using HiTrap desalting columns. The 
protein concentration was determined using the Bradford assay (see 2.2.4.3.3) and aliquots were 
stored at -20°C. 
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2.2.4.1.2 Purification of the anti CXCL8 antibody A5.12.14 
CXCL8-specific antibodies were isolated from the A5.12.14 hybridoma using a recombinant Protein A 
Fast Flow column (rProtA FF; 5 ml bed volume). Conditioned medium was obtained as described in 
2.2.1.1 and the proteins were transferred into equilibration buffer using a HiPrep desalting column. 
Protein-containing fractions were pooled and loaded onto an equilibrated rProtA FF column with 
2 ml/min flow rate. The column was washed with equilibration buffer for 6 CV and the bound 
proteins were eluted using elution buffer. The subsequent steps were performed as detailed above 
for the 9E10 antibody. Typically about 14 mg antibody could be isolated from 1 l of conditioned 
medium.  
2.2.4.1.3 Purification of the GPI-anchored fusion proteins 
General considerations: 
The GPI-anchored fusion proteins (CXCL10-GPI, CXCL10-mucin-GPI, CXCL10-DAFPI, CXCL10-mucin-
DAFPI, CXCL8-GPI, CXCL8-mucin-GPI, sEGFP-GPI and sEGFP-DAFPI) were purified using the double 
c-myc epitope tag that had been integrated into all the constructs preceding the respective GPI 
anchor signal sequence. This epitope tag enabled affinity-chromatographic isolation of the proteins 
using a commercially available resin (c-myc tagged protein mild purification gel). The resin contained 
a specially developed antibody directed against the c-myc tag, the affinity of which was designed in a 
way that allows for efficient binding but also efficient release of the bound proteins using 
competitive elution with c-myc peptides. Thus, with this resin the fusion proteins could be isolated in 
a very gentle way avoiding high or low pH elution steps and other denaturing conditions. 
Methodology of the c-myc affinity chromatography: 
The affinity resins were generally used in Tricorn 5/50 glass columns. Each column was only used for 
one fusion protein to avoid cross-contaminations and the columns were stored in 0.1% NaN3 solution 
to prevent microbial growth. The resins could be reused up to 10 times. All buffers used during the 
purification contained hydrogenated Triton X-100 detergent in order to prevent aggregation of the 
lipophilic fatty acids in the GPI anchors and possibly precipitation of the fusion proteins.  
1.5 x 108 transfected CHO cells (equivalent to twelve 300cm2 flasks) were rapidly thawed and 
resuspended in 10 ml extraction buffer. The extraction buffer contained n-Dodecyl-β-D-maltoside, 
which had been identified as the most efficient detergent for solubilizing the fusion proteins from the 
cell membranes (see 2.2.4.3.2). The cell suspensions were rotated for 1 h at 4°C and subsequently 
centrifuged at 16,000 x g for 20 min (4°C) to remove cell debris and non-solubilized proteins. The 
supernatant was filtered through at 0.2 µm filter prior to chromatography.  
The respective c-myc affinity column was washed with PBS and equilibrated in equilibration buffer 
for 5 CV. Afterwards, the cell extract was applied to the column with 0.01 ml/min flow rate, followed 
by a washing step for 2 CV with equilibration buffer at 0.1 ml/min. In order to elute non-specifically 
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bound proteins, 3 CV of high-salt washing buffer which contained 280 mM NaCl were perfused 
through the column at 0.1 ml/min. Following another washing step with equilibration buffer to 
normalize the salt concentration, the proteins were eluted by injecting 5 ml of elution buffer 
containing 0.01 mg/ml c-myc peptide. The column was subsequently regenerated using regeneration 
buffer, immediately flushed with PBS and stored in storage buffer. 
Analysis of the chromatography fractions: 
All fractions collected over the course of the chromatography were assayed for their content of the 
respective fusion proteins by western blotting. In the case of the sEGFP fusion proteins, the 
fluorescence (485 nm excitation, 535 nm emission) in the respective fractions was measured instead 
of western blotting. Elution fractions containing the highest amount of fusion protein were pooled 
and the elution pool was concentrated using ultrafiltration devices with a molecular size cutoff of 
5 kDa to obtain higher concentrations of fusion protein. The specific concentrations of the 
chemokine fusion proteins were determined using commercially available CXCL8 or CXCL10 ELISA kits 
according to the manufacturer´s instructions. Protein purity was assessed using SDS-PAGE and silver 
staining as well as a comparison between the specific protein content (ELISA) and the total protein 
content (BCA Assay). 
2.2.4.1.4 Purification of the soluble chemokine fusion proteins 
The soluble chemokine fusion proteins were purified from conditioned media that were obtained as 
described in 2.2.1.1 and could be applied directly to the affinity column. Chromatography was 
performed as described above for the membrane-anchored proteins with the only differences being 
that loading was performed at 0.05 ml/min and all buffers were prepared without Triton X-100h.  
2.2.4.2 SDS-PAGE, western blot and silver staining 
2.2.4.2.1 SDS-PAGE 
Preparation of SDS gels: 
SDS PAGE was performed as described by Laemmli (Laemmli 1970). The percentage of 
Acrylamide/Bis-Acrylamide in the gels was chosen according to the expected size of the proteins of 
interest. Separation gels with a final volume of 20 ml were prepared as summarized below: 
 
Percentage 
Acrylamide/Bis-
Acrylamide mix, 30% (ml) 
H2O 
(ml) 
Other components  
(for all gel percentages) 
8% 5.3 9.3 5 ml 1.5 M Tris, pH 8.0 
200 µl 10% SDS 
200 µl 10% Ammoniumpersulfate (APS) 
20 µl Tetramethylethylendiamine (TEMED) 
10% 6.7 7.9 
15% 10.0 4.6 
16% 10.6 4.0 
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 Following polymerization, a 5% stacking gel was poured on top of the separation gels, composed of 
1.7 ml Acrylamide/ Bisacrylamide mix, 1.25 ml Tris (1 M, pH 6.8), 6.8 ml H2O, 100 µl 10% SDS, 100 µl 
10% APS and 10 µl TEMED. Gels were stored in humidified atmosphere at 4°C for no longer than one 
week.  
Electrophoresis: 
For electrophoresis, the protein samples were mixed with the respective sample buffer (either 
Laemmli buffer for reducing or LDS sample buffer for non-reducing chromatography; see below for 
each antibody) to yield a 1 x sample buffer concentration. Afterwards, the samples were incubated at 
95°C for 5 min, centrifuged shortly and loaded onto a gel. 0.5-1.5 µl MagicMark size standard were 
loaded in a separate well for molecular weight estimation. All gels were run in electrophoresis buffer 
first at 80 V until the samples had entered the stacking gel and subsequently at 120 V. 
2.2.4.2.2 Western blotting 
Western blotting was performed analogous to (Towbin et al. 1979). Proteins were transferred from 
the gels onto polyvinylidene fluoride (PVDF) membranes electrophoretically using the wet blot 
technique in NuPage transfer buffer at 30 V for 1 h. Subsequently, the membranes were blocked in 
blocking solution for 1-3 h at room temperature or over night at 4°C, washed twice with water, and 
incubated with the respective primary antibody for 1-3 h at room temperature or over night at 4°C. 
The diluents and conditions for each primary antibody are summarized below.  
 
Antibody SDS-PAGE type Diluent Concentration 
anti c-myc 9E10 reducing blocking buffer 1 µg/ml 
anti CXCL10 non-reducing WesternBreeze blocking solution 0.75 µg/ml 
anti CXCL8 A5.12.14 non-reducing WesternBreeze blocking solution 2 µg/ml 
 
Following incubation with the primary antibody, the membranes were washed 4 times with TBST and 
incubated for 1 h at room temperature with the secondary antibody anti mouse IgG which was 
coupled to horse radish peroxidase (HRP) and diluted in blocking buffer to a concentration of 
0.26 µg/ml. The washing steps were repeated as after incubation with the primary antibody with two 
additional washing steps in TBS for 5 min and the membrane was immersed in 4 ml ECL substrate 
solution for 1 min. Excess substrate was dabbed off and an autoradiography film (Amersham 
Hyperfilm ECL) was exposed to the membrane. The film was subsequently developed using a 
developing machine.  
2.2.4.2.3 Coomassie staining 
To stain protein bands in SDS gels, Coomassie was performed using PageBlue protein staining 
solution according to the manufacturer´s instructions.  
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2.2.4.3 Protein quantification methods 
2.2.4.3.1 ELISA for the quantification of CXCL8 and CXCL10 fusion proteins 
The concentrations of the recombinant chemokine fusion proteins were quantified using 
commercially available sandwich ELISA development kits (DuoSet). Samples were diluted in assay 
buffer (see 2.1.3.5) and each measurement was done in duplicates. Additionally, concentrations of at 
least 3 different dilutions of each sample were measured. All other procedures were performed 
according to the manufacturer´s instructions. OptEIA substrate solution was used for the 
chromogenic development. 
2.2.4.3.2 Modified ELISA for determination of solubilization efficiencies 
A modified ELISA was established in order to test the solubilization efficiency of various detergents 
with regards to the recombinant fusion proteins. The protocol was modified from Bumgarner et al. 
(Bumgarner et al. 2005) and essentially was based on the following principle: First, the proteins were 
labeled with specific antibodies on the cell surface of the CHO cells. Then, the labeled cells were 
incubated with various detergents to solubilize the proteins. The extracts were divided into one 
sample that was centrifuged to remove non-solubilized proteins and one sample that was left 
uncentrifuged. The specific signal strengths in the centrifuge supernatant and the uncentrifuged 
sample were subsequently obtained, compared to each other and expressed as percent 
solubilization.  
A frozen CHO cell pellet was thawed and 106 cells were transferred into each well of a 96 well round 
bottom plate. The plate was centrifuged for 2 min at 755 x g (4°C), the supernatant was discarded 
and the cells were resuspended in 100 µl primary antibody solution per well (10 µg/ml in MEM alpha 
medium; anti CXCL8 for CXCL8 constructs, anti c-myc for CXCL10 constructs). The plate was 
incubated at 4°C for 30 min, centrifuged as above, and the cells were resuspended in 150 µl PBS per 
well. Following another centrifugation, the cells were resuspended in 100 µl secondary antibody 
solution per well (1.3 µg/ml anti mouse IgG, in MEM alpha medium) and incubated at 4°C for 30 min. 
Subsequently, the cells were washed twice with PBS as described above, resuspended in 100 µl of 
the respective lysis buffer per well (duplicates were taken for each lysis buffer) and incubated for 1 h 
at 4°C and 200 rpm shaking. The lysis buffers generally contained 50 mM Tris/HCl, pH 7.5 and the 
respective detergent in different concentrations. Only nonionic detergents were tested and only such 
that were available in very high purity (ULTROL grade or similar). Following solubilization, the 
samples were mixed by pipetting and 10 µl of each sample were transferred into a 96 well flat 
bottom plate (non-centrifuged control = 100% value). The rest of each sample was transferred into 
test tubes and centrifuged at 16.000 x g for 30 min (4°C) to remove non-solubilized proteins and 
debris. 10 µl of the supernatant were transferred into the 96 well flat bottom plate, and 100 µl 
OptEIA ELISA substrate was added to all samples. The reaction was stopped by adding 50 µl 1 M 
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H2SO4 and absorption readings of each well were taken at 450 nm in a microplate reader. The 
percentage of solubilization was subsequently calculated as: 
 
                    
                                    
                                  
      
 
2.2.4.3.3 Bradford and BCA assays 
Total protein concentrations were determined using either the Bradford (Bradford 1976) or the 
bicinchonic acid (BCA) method (Smith et al. 1985). The Bradford assay was used only for samples that 
did not contain detergents as these cause precipitation of the Coomassie dye. Consequently, the BCA 
assay was used for samples containing detergents. The Coomassie assay was performed as follows: A 
standard curve was prepared using serial dilutions of BSA as well as several dilutions of the samples. 
200 µl of each sample were mixed in a 96 well flat bottom plate with 50 µl of Bio-Rad protein assay 
reagent and the absorption at 590 nm was taken using a microplate reader. Subsequently, a standard 
curve was generated, to which the readings of the samples were correlated.  The BCA assay was 
performed with a commercially available kit using the microplate procedure described by the 
manufacturer. 
2.2.4.4 Edman sequencing 
A correct N-terminal amino acid sequence is essential for the function of chemokines. In order to 
verify correct N-terminal processing of the CHO-cell expressed chemokine fusion proteins, Edman 
sequencing was performed (Edman 1949). Sequencing was done using purified protein samples that 
had been prepared as detailed in 2.2.4.1.4. An SDS-PAGE was performed where 1 µl of the sample 
was applied to one lane in order to perform western blotting and 45 µl were applied to another lane 
for Coomassie staining and the actual Edman sequencing. Laemmli buffer was chosen as sample 
buffer in all cases. Following SDS-PAGE, the proteins were transferred onto a PVDF membrane and 
the membrane was cut in half for western blotting (see 2.2.4.2.2) and Coomassie staining. Western 
blotting was carried out using anti c-myc antibodies. For Coomassie staning, the membrane was 
washed with H2O and submerged in Coomassie staining solution (see 2.1.3.2), followed by several 
washes in H2O once the staining was strong enough. The membrane was air-dried, and the respective 
bands were identified by comparison with the western blot and cut out. The Edman sequencing 
reaction as well as data acquisition and analysis were performed by R. Mentele, Max Planck Institute 
for Neurobiology, Martinsried. 
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2.2.5 In vitro experiments 
2.2.5.1 Fluorescence activated cell scanning (FACS) analyses 
2.2.5.1.1 Detection of the recombinant fusion proteins  
FACS was used to detect the recombinant fusion proteins on cell surfaces either after expression in 
CHO cells or after incorporation in various cells. For the analysis of protein expression, the cells were 
detached using EDTA, resuspended in FACS buffer and transferred into a 96 well round bottom plate 
(1 x 106 cells per well). If incorporation of the purified proteins into cell membranes should be 
analyzed, the cells were pretreated with the proteins as detailed in the next section. In both cases, 
the cells were washed with FACS buffer, the plate was centrifuged for 2 min at 755 x g (4°C) and the 
supernatant was discarded. After that, the cells were resuspended in 100 µl FACS buffer per well 
containing the primary antibody (10 µg/ml for antibodies against the c-myc tag, CXCL8 or CXCL10, 
5 µg/ml for antibodies specific for the CX3CL1 mucin domain) or isotype-matched control antibodies 
at the same concentration. Following an incubation for 45 min at 4°C, the cells were washed with 
FACS buffer. To this end, the plate was centrifuged at 755 x g for 2 min (4°C), the supernatant was 
removed and the cells were resuspended in 175 µl of FACS buffer followed by another centrifugation 
at 755 x g for 2 min (4°C) and removal of the supernatant. The cells were resuspended in 100 µl FACS 
buffer per well containing RPE or FITC labeled secondary antibodies at a concentration of 10 µg/ml 
and 4 µg/ml 7-AAD for the identification of dead cells. After 30 min incubation at 4°C, the cells were 
washed again as detailed above and resuspended in 200 µl FACS buffer for analysis.  
Compensation was performed using single-stained samples to ensure that measurements in the 
single fluorescence channels did not interfere with each other and only living cells based on 7-AAD 
exclusion were evaluated.  
2.2.5.1.2 Incorporation of the recombinant fusion proteins 
The ability of the purified recombinant fusion proteins to incorporate into cell membranes was 
assessed by FACS staining. CHO or endothelial cells were detached using Trypsin/EDTA and 
resuspended in prewarmed serum-free medium (the medium that was used for the respective cell 
line without addition of serum or other supplements; compare 2.1.1.1). 1 x 106 CHO cells or 5 x 105 
endothelial cells per well were transferred into a sterile 96 well round bottom plate. The plate was 
centrifuged for 3 min at 220 x g (rt) and the supernatants were removed. Subsequently, the cells 
were resuspended in 100 µl of prewarmed serum-free medium containing defined concentrations of 
purified recombinant fusion proteins or a buffer control. The volume of recombinant fusion proteins 
in chromatography buffer (or the buffer control) was not allowed to exceed 17.5% of the total 
volume and it was taken care that all samples contained the same percentage of buffer. The 
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resuspended cells were incubated at 37°C and 5% CO2 for 1-1.5 h, and the following staining 
procedures were performed as detailed in 2.2.5.1.1. 
2.2.5.1.3 Cleavage of the GPI anchor using PI-PLC 
GPI anchors can be cleaved by phosphatidylinositol-specific phospholipase C (PI-PLC), and this 
property was used to test if the recombinant fusion proteins were GPI-anchored and if the 
incorporation process was dependent on the GPI anchor. 5 x 105 HMEC cells per well were treated 
with the proteins as detailed in 2.2.5.1.2., but following incubation with the proteins, the cells were 
washed with PBS instead of FACS buffer and subsequently resuspended in 100 µl DMEM medium per 
well which contained 0.1 unit of PI-PLC (or DMEM only as control). The cells were incubated at 37°C 
and 5% CO2 for 1 h, washed with PBS again and subsequently stained for the presence of the 
recombinant fusion proteins using anti c-myc antibodies as detailed in 2.2.5.1.1. 
2.2.5.1.4 CXCR3 expression and internalization assays 
CXCR3 expression analysis: 
To determine the expression of CXCR3 in murine 291 lymphoma cells or murine T cells, 1-1.25 x 106 
cells were suspended in 50 µl FACS buffer. APC-labeled, CXCR3-specific antibodies or an identically 
labeled isotype control were added at a final concentration of 20 µg/ml, as well as 5 µl 
Propidiumiodide (PI). All samples were incubated for 45 min at 4°C. Subsequently, the cells were 
washed twice with FACS buffer and suspended in 200 µl FACS buffer for analysis. Approporiate 
compensation was performed, and dead cells were identified in the FL-3 channel and excluded from 
analysis. 
CXCR3 internalization on human cells: 
CXCR3 internalization was used as readout for receptor activation by the recombinant fusion 
proteins. To this end, coincubations of JB4 T cells and transfected CHO cells were performed. CHO 
cells were detached using EDTA, washed using serum free RPMI 1640 medium, and 6 x 105 cells in 
25 µl RPMI 1640 per well were transferred into a 96 well round bottom plate. 25 µl recombinant 
human CXCL10 at concentrations of 1.5 µg/ml or 200 ng/ml in RPMI 1640 was added to other wells 
of the same plate as positive control, and 25 µl RPMI 1640 only as negative control. All samples were 
prepared in duplicates to allow for staining with CXCR3-specific antibodies and an isotype control. 
JB4 cells were washed in RPMI 1640 and 2 x 105 cells in 25 µl RPMI 1640 were subsequently added to 
each well that had been prepared as described above. The plate was incubated at 37°C and 5% CO2 
for 30 min, and after this time, 150 µl ice cold FACS buffer was added to each well. All following steps 
were performed on ice using precooled buffers. The cells were washed using FACS buffer and 
resuspended in 75 µl FACS buffer per well. Subsequently, 7-AAD at a final concentration of 4 µg/ml 
and 4 µl of FITC-labeled CD3-specific antibodies (original concentration not disclosed by the 
manufacturer) were added to all samples. Among each pair of duplicates, one sample additionally 
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received 3 µl of RPE-labeled, CXCR3 specific antibodies (BD Pharmingen¸ original concentration not 
disclosed by the manufacturer), while the other one received the same volume of RPE-labeled 
isotype control. The plate was incubated at 4°C for 45 min, and following another wash with FACS 
buffer, the cells were resuspended in 200 µl FACS buffer and measured. 
Compensation was performed using single-stained samples to ensure that measurements in the 
single fluorescence channels did not interfere with each other and gating was performed as follows: 
First, JB4 cells were roughly identified in a FSC-H/ SSC-H dot plot by their smaller size and lower 
granularity compared to the CHO cells. Among this population, FL-3 positive dead cells were 
excluded. Within that population again, CD3-positive cells were identified in the FL-1 channel and 
subjected to analysis. The strength of CXCR3 signal in the FL-2 channel was determined for each 
sample as the geometric mean of FL-2H. The mean fluorescence intensity (MFI) was determined as 
the difference between the respective isotype-stained sample and the one stained with specific 
antibodies. Subsequently, the MFIs of the sample containing non-transfected CHO cells (for the 
coincubation samples) or the sample containing RPMI 1640 only (for the samples with recombinant 
CXCL10) were defined as 100% expression and the other samples were related to them.   
As additional controls, either the cells were coincubated at 4°C instead of 37°C to slow down cellular 
metabolism, or RPE-labeled CXCR3-specific antibodies from a different supplier (R&D Systems) were 
utilized, of which 10 µl were used. 
CXCR3 internalization on murine cells: 
CXCR3 internalization was also used as readout to assess the cross-reactivity of human CXCL10 with 
murine T cells. This assay was performed essentially as described above for human cells, with the 
following deviations: 3.75 x 105 T cells per well were used, and the assay was performed entirely in 
HBSS (phenol red free, +Mg2+, +Ca2+; Invitrogen) supplemented with 20 mM HEPES. For the staining, 
4 µl of APC-labeled CXCR3-specific antibodies and 4 µl PI were used per 50 µl and comparisons were 
done against cells stained only with PI. Human and murine CXCL10 were tested only at a 
concentration of 660 ng/ml.  
2.2.5.2 Calcium mobilization assays 
2.2.5.2.1 Calcium mobilization assays using recombinant proteins 
Calcium is released from the endoplasmatic reticulum as an essential step in the signaling cascade  
triggered by chemokine receptors. The resulting transient rise in cytoplasmatic calcium concentration 
was used as another readout for receptor activation in order to assess the cross-reactivity of human 
CXCL10 with murine T cells.  
Murine CD4+ T cells were loaded with the calcium-sensitive fluorescent dye Fluo-4 using a 
commercially available kit essentially according to the manufacturer´s instructions. However, the 
following modifications were made to the protocol: Loading was performed in 15 ml tubes, and 
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15 min before the end of the loading time, 7-AAD was added to the cells at a final concentration of 
4 µg/ml. After 15 min, the cells were centrifuged and resuspended in fresh assay buffer to a 
concentration of 1.7 x 106 cells/ml. Using a FACS machine, the development of the fluorescence of 
living (as determined by 7-AAD exclusion) cells in the FL-1 channel was monitored in each sample 
over time. After 30 sec, recombinant chemokines at a final concentration of 1 µg/ml or buffer were 
added to the samples and the fluorescence was monitored for an additional 3 min.  
2.2.5.2.2 Calcium mobilization assays using transfected CHO cells 
Intracellular calcium mobilization was also measured in T cells interacting with transfected CHO cells. 
To this end, cells of the human T cell line DS4 were loaded with Fluo-4 using the same kit as 
mentioned above. Loading was performed according to the manufacturer´s instructions, but 
treatment was performed in 15 ml tubes and after the incubation in loading solution, cells were 
centrifuged and resuspended in fresh assay buffer to yield 5 x 106 cells/ml. 50 µl of this suspension 
were transferred into each well of a special 96 well flat bottom plate with black side walls and ultra-
thin bottom. As a control for CHO cell autofluorescence, the same number of wells as those that now 
contained DS4 cells was filled with 50 µl of assay buffer only. Subsequently, non-transfected CHO 
cells or cells transfected with the recombinant fusion proteins were detached using EDTA, washed 
and resuspended in assay buffer to yield a concentration of 1 x 107 cells/ml. Using a multichannel 
pipette, 50 µl of the CHO cell suspensions were added simultaneously to wells containing labeled DS4 
cells or assay buffer. Immediately after the addition of the CHO cells, measurements were started 
using 485 nm excitation wavelength and 535 nm emission wavelength, and additional measurements 
were taken every 20 sec over a period of 40 min, during which the plate was kept heated to 37°C. All 
samples were run in duplicates. For data evaluation, averages were calculated from the two 
replicates for every sample and time point. To compensate for CHO cell autofluorescence, readings 
that had been taken in the samples in which the respective CHO cells had been “coincubated” with 
assay buffer only were subtracted for each time point from the readings that had been taken in 
samples in which the respective CHO cells had been coincubated with DS4 cells. Finally, to 
compensate for T cells settling to the bottom of the well, thereby steadily increasing the background 
fluorescence, the calculated values with non-transfected CHO cells were subtracted from those 
obtained with transfected cells to obtain Δ fluorescence values against non-transfected CHO. 
As additional positive and negative controls, four wells with labeled DS4 cells were treated with 
1 µg/ml (final concentration) recombinant human CXCL10 or assay buffer only (duplicates each) and 
the resulting fluorescence values were evaluated directly.  
2.2.5.3 Immunofluorescence microscopy of cells 
Immunofluorescent staining was performed to microscopically detect the GPI-anchored proteins on 
cell surfaces and to determine their subcellular localization. Identical experiments were done using 
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either transfected CHO cells or primary microvascular endothelial cells (HDBEC) that had been 
pretreated (“painted”) with the purified proteins. In both cases, the cells were grown in special cell 
culture dishes until they reached 90% confluence. If the cells should be treated with purified 
proteins, they were at this point washed with PBS and incubated for 1.5 h at 37°C and 5% CO2 with 
the respective proteins that had been diluted in serum-free culture medium. In both cases again, the 
cells were washed with PBS and fixed for 20 min using 1% paraformaldehyde in PBS at room 
temperature. All subsequent steps were performed at room temperature and all antibodies as well 
as streptavidin-RPE were diluted in HBSS (with phenol red, with Ca2+, Mg2+). After two washes in PBS, 
the cells were incubated for 50 min in 10 µg/ml anti c-myc antibodies. The cells were washed twice 
with PBS and subsequently incubated for 50 min in 5 µg/ml biotin-conjugated secondary antibodies. 
Following another two washes with PBS, 6 µg/ml streptavidin-RPE was used to stain the cells for 
40 min in the dark. The cells were subjected to two last washing steps in PBS, and covered using 
350 µl PBS and appropriately sized cover slips. Microscopic images were taken with an inverted-stage 
microscope and appropriate fluorescence filters.  
2.2.5.4 Laminar flow assays 
2.2.5.4.1 Background and general considerations 
Laminar flow assays were performed to assess the effect of the recombinant fusion proteins on the 
adherence of leukocytes to endothelial cells or CHO cells. Such assays mimic the conditions found in 
blood vessels in terms of shear stress and are typically performed using channels with rectangular 
geometry. Endothelial cells are grown within the channel, pretreated according to the respective 
experiment, and subsequently leukocytes are perfused through the channel over the endothelial cell 
monolayer and the interactions are monitored by video microscopy. In the current study, flow 
chambers consisting of disposable microscope slides that contained a 5 mm wide, 0.4 mm tall and 
5 cm long channel (µ-slide I 0,4) were used. In these slides, the shear stress at the bottom of the 
channel is constant for any point that is further than 500 µm away from the side walls of the channel 
(“observation area”). In all experiments, HBSS was used in the assay buffer, the viscosity of which has 
been demonstrated to be 0.01 dyn x sec/cm-2 (Donahue et al. 2003). This allowed the direct 
adaptation of the shear stress calculations, which the manufacturer of the flow channels used in the 
current study had made assuming a viscosity of 0.01 dyn x sec/cm-2.  
2.2.5.4.2 Experimental details 
For experiments involving endothelial cells, the cells were grown to 80% confluence in tissue culture 
flasks. 24 hours prior to the experiment, the cells were seeded into the microscope slides. To this 
end, all media and the slides were prewarmed to 37°C in a cell culture incubator to prevent the 
formation of bubbles within the slides. The cells were detached using Trypsin/EDTA (diluted 1:5 in 
PBS), centrifuged and resuspended in culture medium (100 µl/slide) so that the cells were split at an 
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area ratio of 1 : 0.8 into the slides. The slides were precoated with Collagen G for 30 min at 37°C and 
5% CO2 using 100 µl of 12 µg/ml Collagen G in PBS. After washing with PBS, the slides were 
immediately filled with cell suspension and incubated for 24 h. If the endothelial cells should be 
“painted” with purified GPI-anchored proteins, the different slides were treated with the proteins for 
exactly 1 h prior to the analysis of the respective slide. For the treatment, the channel was washed 
with 100 µl purified proteins diluted in serum-free culture medium and the washing medium was 
subsequently replaced with 100 µl fresh protein dilution. Each protein mixture including all buffer 
and recombinant protein controls contained 17.5% v/v chromatography buffer. 
For experiments assessing adhesion to transfected CHO cells, the cells were grown to 90% 
confluence. On the day before the assay, the cells were detached using EDTA and seeded at a ratio of 
1:1 into the slides. All solutions were warmed to 37°C in a cell culture incubator prior to their use, 
and the slides were not precoated.  
The assay buffer was prepared as indicated in 2.1.3.6 excluding CaCl2 and MgCl2 and prewarmed to 
37°C. Directly before use, CaCl2 and MgCl2 were added to a final concentration of 2 mM. Leukocytes 
were counted and stored at 37°C and 5% CO2 in aliquots, each of which contained sufficient cells for 
the analysis of two samples, so that the cell suspension was renewed in every other sample. Before 
the analysis, leukocytes were centrifuged for 5 min at 250 x g (rt) and resuspended in assay buffer to 
yield a concentration of 2 x 105, 2.6 x 105 or 3 x 105 cells/ml for DS4 cells, YT cells and murine NK cells, 
respectively. Subsequently, the cells were transferred into a water bath to keep the cell suspension 
at 37°C throughout the experiment. The respective slide was transferred to an incubation chamber 
which was kept at 37°C and which could be mounted on the stage of an inverted phase contrast 
microscope equipped with a digital video camera. Pyrogen-free perfusion tubing was used to connect 
the flow channel on one side with the cell suspension or assay buffer (using a 3-way stop cock) and 
on the other side with a 50 ml syringe that was operated by a programmable syringe pump, so that 
fluid could be drawn through the slide at a defined flow rate. Each slide was first flushed with assay 
buffer at 1 ml/min for about 1 min until all cell debris had been removed. To allow comparisons 
between the slides, observation areas in all slides were determined to be at least 1 cm away from the 
inlet and outlet of the channel and as close as possible to the diagonal middle of the slide (at least 
0.5 mm away from the channel´s side walls). Subsequently, the medium was switched to cell 
suspension using the 3-way stop cock and the cells were flushed into the slide until it appeared 
homogenously perfused. Afterwards, the flow rate was lowered to the rate that would yield the 
desired shear stress (indicated in each figure) and the interactions were recorded for 5 min. Before 
the next slide was mounted, the system was flushed with assay buffer.    
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2.2.5.4.3 Data evaluation 
The recorded videos were used to determine the number of leukocytes in the respective field of view 
displaying rolling or tight adhesion. The analysis was performed manually by splitting the field of view 
into eight sections and assessing the events in each of the sections. For the analysis, the following 
rules were applied: 
 Tight adhesion was defined as an event where the leukocyte did not move further than one cell 
diameter within 30 sec.  
 Rolling adhesion was defined as an event where the leukocyte was abruptly stopped from the 
flow, but did not reach tight adhesion or detached again from the substrate. 
 Each cell that passed the entire field of view was counted only once. 
 Each cell was counted either as rollingly or tightly adherent. If the cell displayed both forms of 
adhesion, it was counted as tightly adherent. 
 Only such cells were counted that were stopped from the flow within the observation period, 
not such that were already adherent to the substrate at the beginning of the observation. 
The obtained numbers were subsequently converted into adhesive events per 5 min per mm2. 
2.2.5.4.4 Contributions 
Laminar flow assays involving primary microvascular endothelial cells in combination with YT cells or 
primary murine NK cells were performed in collaboration with R. Djafarzadeh. She performed 
seeding of the endothelial cells into the microscope slides as well as treatment of the endothelial 
cells with the various proteins, while N. Münchmeier performed the adhesion experiments and 
evaluated the data. Primary murine NK cells were provided by J. Pötzl (Helmholtz Zentrum Munich), 
who isolated them freshly for each assay from spleens of C57/Bl6 mice using magnetic beads.  
2.2.5.5 Chromium release assays 
The effect of CXCL10-mucin-GPI on target cell lysis by human NK cells was evaluated using chromium 
release assays. 
2.2.5.5.1 Preparation of target cells: 
Two different target cell lines were tested: RCC26, a human renal cell carcinoma line and K562, an 
erythroleukemia line (both provided freshly for each experiment by Prof. Noessner, Helmholtz 
Zentrum Munich). The target cells were harvested, washed with PBS and resuspended in 100 µl FCS. 
Cells were labeled with 50 µCi Na2
51CrO4 for 1.5 h at 37°C and 5% CO2. Subsequently, the cells were 
washed once with RPMI 1640 medium + 15% FCS and once with RPMI 1640, counted and 
resuspended at 4 x 106 cells/ml in CXCL10-mucin-GPI protein that had been diluted in RPMI 1640 to 
240 pM. As controls, additional aliquots of labeled cells were resuspended in RPMI 1640 medium 
containing either 14 nM recombinant CXCL10 or chromatography buffer only. All mixtures contained 
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25% v/v chromatography buffer to exclude buffer artifacts. The cells were incubated for 1 h at 37°C 
and 5% CO2, washed twice with RPMI 1640 + 15% FCS and counted again. Afterwards, the prepared 
target cells were resuspended in RPMI 1640 + 15% FCS (4 x 104 cells/ml) and 50 µl cell suspension per 
well (2000 cells) were added to the effector cells (see below). To assess the maximal possible signal 
(100% lysis), 50 µl of the differently treated target cells were pipetted directly onto the 96 well 
Scintillant coated plate.  
2.2.5.5.2 Preparation of effector NK cells: 
Human NK cells were isolated from peripheral blood mononuclear cells (PBMCs). Peripheral blood 
(heparinized) was mixed with an equal volume of RPMI 1640 and 15 ml aliquots were layered above 
35 ml Ficoll solution. The mixture was centrifuged for 20 min at 840 x g (rt) and the interphase 
containing mononuclear cells was collected. For washing, the cells were mixed with RPMI 1640 and 
centrifuged for 12 min at 758 x g (rt), and the supernatant was removed. The washing step was 
repeated with a 5 min centrifugation step at 302 x g (rt). To remove thrombocytes, the cells were 
resuspended in isolation buffer from the kit mentioned below, centrifuged for 12 min at 210 x g (4°C) 
and the supernatant was removed. This step was repeated once. NK cells were subsequently isolated 
from the PBMCs using a commercially available kit that allowed untouched isolation of the cells with 
magnetic beads. The kit was used according to the manufacturer´s instructions.  
Experiments were done either with freshly isolated NK cells or NK cells that had been activated over 
night in AIM-V medium containing 10% human serum and 500 U/ml recombinant human IL-2. In both 
cases, the NK cells were resuspended in RPMI 1640 + 15% FCS and 50 µl of the suspension were 
diluted in 1:2 steps in a V-bottom 96 well plate to yield various effector:target ratios (the amount of 
target cells per well was kept constant at 2000 cells/well). Effector:target ratios of 10:1 to 0.3125:1 
were used for K562 and ratios of 40:1 to 1.25:1 for RCC26 target cells. All samples were run in 
duplicates. To assess spontaneous release of 51Cr from the target cells, 2 additional wells for each 
target were prepared that contained only RPMI 1640 + 15% FCS and no effector cells. Afterwards, the 
labeled target cells were added (see above). 
2.2.5.5.3 Killing assay: 
After the target and effector cells had been mixed, the plate was incubated for 4 h at 37°C and 5% 
CO2. Subsequently, 50 µl of the supernatant of each well were pipetted onto a 96 well Scintillant 
coated plate, which was dried in a fume hood over night. The plate was sealed with adhesive foil and 
the radiation in each well was measured in a Scintillation counter. For data evaluation, first the 
counts per minute (cpm) of the wells where the target cells had directly been pipetted into the 
Scintillant coated plate were divided by 2 to allow comparison with the other wells where the target 
cells had always been diluted 1:2 with effector cells. This yielded the value for maximum release 
(100% lysis). The cpm of the wells in which target cells had been mixed with medium only 
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(spontaneous release = 0% lysis) were subtracted from the cpm of every other well to compensate 
for spontaneous release of 51Cr. The percentage of lysis could then be calculated by dividing the 
values of each well by the value for maximum release. The calculation is summarized in the formula 
below: 
 
           
                                                                  
                                        
     
 
2.2.6 In vivo experiments 
In order to test if CXCL10-mucin-GPI is able to recruit leukocytes in a physiologic setting, in vivo 
experiments were performed using subcutaneously implantable tumors in C57/Bl6 mice. These 
experiments were performed in collaboration with the group of Prof. Mocikat, Helmholtz Zentrum 
Munich. Culturing and injection of tumor cells as well as protein injections and resection of tumors 
was performed by L. Bankel from this group. The experiments were conducted in accordance with 
animal protection regulations and approved by the responsible authorities.  
2.2.6.1 The 291 tumor model and protein injection protocols 
2.2.6.1.1 Background 
Because of the relative ease and speed, a subcutaneous tumor model was chosen for proof-of-
concept experiments. Murine 291 cells were used to implant tumors. These B cell lymphoma cells 
had previously been isolated from a C57/Bl6 mouse carrying the c-myc oncogene under the control 
of the Igλ promoter. Such mice spontaneously develop B cell lymphomas (Kovalchuk et al. 2000).  
2.2.6.1.2 Experimental details 
Only female mice at an age between 11 and 21 weeks were used for experiments. The experiment 
presented in 3.7 was performed with 11 weeks old mice. 107 291 cells in 150 µl PBS were injected 
subcutaneously into each flank of the mice, each mouse thus receiving 2 tumor injections. Tumor 
growth was monitored by palpation and the experiments were conducted once the tumors had 
reached a diameter of about 8 mm. Purified GPI-anchored proteins or respective controls diluted in 
PBS + 0.025% Triton X-100h were prepared and 50 µl were injected into the center of each tumor. 
Three separate tumors were treated with each protein or control. It was taken care that the different 
samples were equally distributed over larger and smaller tumors. After 4 h, mice were sacrificed and 
the tumors were removed. For analysis, the tumors were cut in half, and one half was subjected to 
FACS analysis, while the other half was fixed for 24 h in 10% neutral buffered formalin for histology.  
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2.2.6.2 FACS analysis of the tumors 
To analyze infiltrating leukocytes, FACS analysis was performed using CD3, CD4, CD8, NK1.1 and 
CXCR3 specific antibodies. To this end, the tumors were mechanically minced, washed in PBS, filtered 
through a nylon mesh and subjected to FACS analysis, which was performed by L. Bankel.  
2.2.6.3 Histology of tumor sections 
Fixed tumors were dehydrated with an automatic tissue-processor using a series of 70% ethanol for 
5 h, 96% ethanol for 2 h, 100% ethanol for 3.5 h, xylene for 2.5 h and paraffin for 4 h. Paraffin blocks 
were prepared using liquid paraffin. After cooling, 2 µm sections were cut from these blocks using a 
microtome and mounted on glass slides. Deparaffinisation and rehydration was performed by 
incubating the slides 3 x 5 min in xylene, 3 x in 100%, 2 x in 96%, and once in 70% ethanol (3 min 
each). 
2.2.6.3.1 Immunohistochemistry 
Immunohistochemical staining was performed to detect CD3+ and NKp46+ cells in the tumors. Before 
the first and in between all incubation steps, the slides were washed with PBS. Endogenous 
peroxidase activity was blocked by incubating the slides in 3% hydrogen peroxide in methanol for 
20 min in the dark. Antigen retrieval was performed using antigen unmasking solution in an 
autoclave oven for 20 min (CD3 staining) or 50 µg/ml proteinase K for 10 min at room temperature 
(NKp46 staining). 
Endogenous biotin was blocked using a commercially available Avidin/Biotin blocking kit. 
Subsequently, the slides were incubated with CD3-specific antibodies (10 µg/ml, diluted in PBS, for 
1 h at rt), NKp46-specific antibodies (10 µg/ml, diluted in 10% skimmed milk powder in PBS, for 1 h at 
rt) or respective controls. Following incubation with biotinylated secondary antibodies (5 µg/ml in 
PBS) for 30 min, a commercially available kit was used to detect bound antibodies (Vectastain) 
according to the manufacturer´s instructions. 3,3´-Diaminobenzidine (3 mM) was used as substrate 
diluted in Tris/HCl, pH 7.7 in combination with NiCl2 (1.7 mM) and H2O2 (0.075 ‰) resulting in a black 
coloured staining. Slides were counter stained using methyl green and washed using 2 x 96% and 3 x 
100% ethanol followed by xylol. Vectamount mounting medium was used to mount the slides.  
2.2.6.3.2 Hematoxylin/ Eosin Y (H/E) staining 
H/E staining was performed to assess the general morphology of the tumor tissue. Following 
deparaffinisation, the slides were washed using distilled water, stained for 5 min in Harris modified 
hematoxylin solution, washed for 5 min in tab water for bluing, incubated in 70% ethanol for 2 min 
and in eosin Y solution for 30 sec. Subsequently, the slides were washed once in 70%, twice in 96% 
and 3 times in 100% ethanol, followed by xylol and mounted using Vectamount mounting medium.  
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3 Results 
3.1 Cloning and expression of the recombinant fusion proteins 
A novel class of protein reagents designed to modulate tissue micromilieus was developed in this 
study. The work focused primarily on one example as proof of concept: CXCL10-mucin-GPI – a fusion 
protein consisting of a CXCL10 chemokine head, fused to the mucin domain taken from CX3CL1, and 
a C-terminal GPI anchor signal sequence substituting for the transmembrane domain of CX3CL1. 
Based on the biology of CXCL10, this reagent should allow the selective recruitment of cytotoxic 
CXCR3+ leukocytes into solid tumors. In parallel, a series of constructs were generated to act as 
controls: CXCL10-GPI, identical to CXCL10-mucin-GPI but lacking the mucin domain, should serve as a 
control for effects mediated by this domain. A membrane-bound, GPI-anchored EGFP protein was 
constructed to act as a GPI-anchored negative control protein lacking any obvious function in 
leukocyte recruitment. In addition, soluble versions of both CXCL10 fusion proteins (CXCL10-Stop and 
CXCL10-mucin-Stop) were designed as controls for the GPI anchor.  
3.1.1 Cloning of the recombinant fusion genes 
The fusion constructs were cloned as described in 2.2.3 and the respective compositions are 
summarized in Figure 9 A. Briefly, the GPI anchor signal sequence from LFA-3 had been previously 
cloned from a human inflamed kidney cDNA sample and inserted into a pUC19 plasmid 
(Notohamiprodjo et al. 2006). The DNA sequence encoding the double c-myc epitope tag that was 
used to facilitate purification and detection strategies was amplified by PCR from the MP71 gp100 
vector and inserted into the pUC19 plasmid, 5´ of the GPI signal sequence. Subsequently, the coding 
sequence of human CXCL10 was ligated in-frame into the plasmid, 5´ of the double c-myc tag and the 
GPI anchor signal sequence. The resulting construct termed CXCL10-GPI was subcloned into a pEFdhfr 
vector for expression in dihydrofolate reductase deficient Chinese hamster ovary (CHOdhfr-/-) cells.  
The CXCL10 gene was then further subcloned into a pEFdhfr plasmid containing the mucin domain of 
CX3CL1, which had been amplified from a human inflamed kidney cDNA sample, a double c-myc tag 
and the GPI signal sequence from LFA-3. In the resulting construct termed CXCL10-mucin-GPI, the 
CXCL10 gene thus directly preceded the mucin domain sequence, followed by the c-myc tag and the 
GPI anchor signal sequence.  
In addition to the genes for the surface anchored proteins, constructs were generated in which the 
GPI signal sequence was replaced by a stop codon. The resulting CXCL10-Stop and CXCL10-mucin-
Stop proteins were expected to be secreted into the supernatant and should serve as non-anchored 
control proteins.  
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Finally, the sEGFP-GPI construct was created to act as a GPI-anchored control protein. It was 
generated by fusing the secretion signal sequence of human TIMP-1 N-terminally (5´) to the gene 
sequence of EGFP followed by a double c-myc tag and the GPI signal sequence from LFA-3. Figure 9 
shows a schematic overview of the various recombinant genes (A) as well as an electrophoretic 
analysis of the respective plasmids (B). For this analysis, all pEF-plasmids were digested with EcoRI 
and SalI and the resulting fragments were separated in a 1% agarose gel.  
As seen in the electrophoretic analysis, the CXCL10-GPI construct was 500 bp long, 317 of which 
constituted the CXCL10 chemokine domain at the 5´ end. The c-myc tag accounted for the following 
66 bp, and the GPI anchor signal sequence for the last 117 bp. CXCL10-mucin-GPI had a total length 
of 1235 bp with the mucin domain, located between CXCL10 and the c-myc tag, accounting for the 
additional 735 bp (245 amino acids) compared to CXCL10-GPI and thus forming the biggest part of 
the resulting protein. The soluble constructs CXCL10-Stop and CXCL10-mucin-Stop were both 112 bp 
shorter than their GPI-anchored counterparts due to the lack of the GPI-anchor signal sequence 
resulting in total lengths of 388 and 1123 bp, respectively. The sEGFP-GPI gene sequence had a total 
length of 978 bp. The first 75 bp of the gene encoded the secretion signal sequence of TIMP-1, 
followed by the 720 bp long EGFP sequence and again 66 bp for the c-myc tag and 117 bp for the GPI 
anchor sequence. The exact DNA sequences of all constructs can be found in 5.7. 
 
Figure 9: The recombinant CXCL10 and EGFP fusion genes display the anticipated lengths.  
A: Schematic overview of the different recombinant genes that were cloned in the present study. The 
scale indicates a length of 100 bp. Abbreviations: s = secretion signal sequence of TIMP-1; m = double 
c-myc epitope tag. B: Electrophoretic analysis of the various recombinant genes. 200 ng of pEF-
CXCL10-mucin-GPI, pEF-CXCL10-mucin-Stop, pEF-CXCL10-GPI, pEF-sEGFP-GPI or 600 ng of pEF-
CXCL10-Stop were digested with EcoRI and SalI to cut out the entire coding sequences and the 
fragments were separated in a 1% agarose gel. DNA bands were visualized under UV light using 
ethidium bromide staining. An inverted image of the resulting gel is shown to visualize the different 
sizes of the recombinant constructs.  
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3.1.2 Expression and detection of the recombinant fusion proteins  
Chinese hamster ovary (CHO) cells were chosen for the expression of the recombinant proteins for 
two reasons: First, only eukaryotic cells are capable of attaching GPI anchors to proteins, which 
precluded the use of bacterial expression systems. Second, a mammalian cell line was chosen in 
order to keep the glycosylation pattern of the mucin domain similar to that found on human 
proteins. All plasmids were linearized prior to transfection and dihydrofolate reductase (dhfr)-
deficient CHO cells that are auxotrophic for hypoxanthine and thymidine were transfected by 
electroporation as described in 2.2.2.14. The dhfr gene in the pEFdhfr plasmids enabled the selection 
of successfully transfected cells on the basis of its ability to complement the auxotrophy of CHOdhfr-/- 
cells. Dialyzed serum devoid of nucleotides was therefore used in the medium to generate selective 
pressure. The transfected CHO-CXCL10-GPI and CHO-CXCL10-mucin-GPI cells were subsequently 
additionally treated with methotrexate, an inhibitor of the dihydrofolate reductase, to eliminate cells 
with a low expression level as described in 2.2.2.14. By means of this treatment, cells with a low 
expression level of the transgenes could be eliminated, as evidenced by the loss of a moderately 
positive population in FACS staining (data not shown).  
3.1.2.1 Subunits of the GPI-anchored fusion proteins can be detected on transfected CHO cells 
FACS staining was performed to evaluate the expression of the recombinant fusion proteins in 
transfected CHO cells. To this end, the cells were stained with antibodies specific for the c-myc 
epitope tag, the CX3CL1 mucin domain or CXCL10 and subsequently analyzed by flow cytometry as 
described in 2.2.5.1.1. Figure 10 shows the results of a representative FACS staining.   
As shown in the figure, the GPI-anchored CXCL10 fusion proteins could readily be detected on the 
surface of the transfected cells. As expected, both CHO-CXCL10-GPI and CHO-CXCL10-mucin-GPI cells 
stained positively for the c-myc epitope tag and the CXCL10 chemokine head, while only CHO-
CXCL10-mucin-GPI cells stained positively also for the mucin domain. The cells that had been 
transfected with the soluble CXCL10-mucin-Stop construct could not be stained with any of the 
antibodies, indicating that this fusion protein was (due to the lack of a GPI anchor) secreted into the 
medium, where it could also be detected by western blotting (data not shown). The same was found 
for CXCL10-Stop transfected cells, suggesting that fusion proteins lacking a GPI anchor did not bind 
nonspecifically to the CHO cells (data not shown). On CHO-sEGFP-GPI cells, the c-myc epitope tag 
could be detected as well as the fluorescence of the EGFP protein, indicating that the protein 
structure of EGFP was not compromised by the membrane-associated expression. 
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3.1.2.2 The GPI-anchored fusion proteins are targeted to the cell membranes of transfected cells 
The FACS analysis described above demonstrated surface expression of the recombinant fusion 
proteins. As an additional verification of correct targeting of the proteins to the cell membrane, 
immunofluorescence microscopy was performed as detailed in 2.2.5.3, because this approach is able 
to more precisely identify the subcellular localization of the detected proteins. To this end, the cells 
were grown in special dishes developed for fluorescence microscopy, fixed, and subsequently stained 
with c-myc specific antibodies. A combination of biotinylated secondary antibodies and RPE-labeled 
streptavidin was used to detect bound antibodies. Figure 11 shows representative images acquired 
on an inverted fluorescence microscope. 
 
Figure 10: Subunits of the recombinant GPI-anchored proteins can be detected on the surface of 
transfected CHO cells. A: Stably transfected CHO cells were incubated with antibodies against the 
c-myc epitope tag, the mucin domain, the CXCL10 chemokine head or matching isotype controls. 
Bound antibodies were detected by staining with FITC-conjugated secondary antibodies and the 
fluorescence intensity was measured by FACS (FL-1H). Black lines indicate staining with the isotype 
controls, blue lines indicate staining with the specific antibodies. B: In the case of sEGFP-GPI 
transfected CHO cells, RPE-conjugated secondary antibodies were used to detect the c-myc epitope 
tag (anti c-myc antibodies: blue line, isotype control: black line) while the fluorescence by the EGFP-
protein was measured in the FL-1 channel (FL1-H; green line) and compared to non-transfected CHO 
cells (grey line). All histograms are gated on viable cells identified by 7-AAD exclusion. 
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For all cells transfected with GPI-anchored fusion proteins, a strong staining by the c-myc specific 
antibodies was observed. The signal was most pronounced at the periphery of each cell, indicating 
that the fusion proteins were expressed in a membrane-associated manner. In contrast, the cells 
transfected with the soluble CXCL10-mucin-Stop construct did not stain positively. This finding was 
expected as the lack of a GPI anchor in CXCL10-mucin-Stop lead to secretion of the expressed protein 
into the medium. An absence of surface staining was also found for non-transfected cells, showing 
that the signal obtained with the anti c-myc antibodies was specific. In the case of sEGFP-GPI 
transfected cells, the fluorescence by EGFP was additionally detected at the cell surface. In summary, 
these results showed that the GPI-anchored proteins had successfully been targeted to the cell 
membrane by the addition of a GPI anchor signal sequence. 
3.1.2.3 The N-termini of the CXCL10 fusion proteins are correctly processed 
The N-terminus of chemokines is vitally important for their function. Changes in the amino acid 
composition of the N-terminus can lead to dramatic changes in the physiologic activity of the 
respective chemokine. For that reason, the N-terminal amino acid sequence of one of the CHO-cell-
expressed CXCL10 fusion proteins was exemplarily determined using Edman sequencing. CXCL10-
mucin-Stop was analyzed because for the soluble protein it was possible to obtain protein amounts 
sufficient for Edman sequencing from cell culture supernatants. The analyses were conducted in 
collaboration with R. Mentele from the Max-Planck Institute for Biochemistry in Martinsried. CXCL10-
 
Figure 11: The recombinant GPI-anchored proteins are expressed in a membrane-associated 
manner. The indicated stably transfected CHO cell lines or non-transfected CHO cells (CHO) were 
grown in special fluorescence microscopy dishes, fixed and subsequently stained with anti c-myc 
primary and biotin-conjugated secondary antibodies followed by RPE-labeled streptavidin. In the 
case of CHO-sEGFP-GPI, the fluorescence of the EGFP protein was additionally detected using 
appropriate filters. All images within each horizontal row were acquired using the same exposure 
time. The bars in each image indicate a length of 50 µm. 
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mucin-Stop protein purified from cell culture supernatants as detailed in 2.2.4.1.4 was subjected to 
SDS-PAGE and subsequently transferred onto a PVDF membrane. As control, commercially available 
recombinant CXCL10 that had been demonstrated to be bioactive by the manufacturer and also in 
our own assays (see below) was identically treated. The membrane was stained and protein bands 
displaying the expected sizes were cut out and subjected to the sequencing procedure.  
The results showed that both recombinant conventional CXCL10 and CXCL10-mucin-Stop comprised 
a mixture of proteins with either the sequence V-P-L or P-L-S at the N-terminus. The V-P-L sequence 
corresponds to the mature N-terminus of the well-documented, naturally occurring 77 amino acid 
form of CXCL10, while P-L-S would correspond to a 76 amino acid form. The latter form could have 
originated either from imprecise cleavage of the signal sequence during the secretion process, or 
from post-translational proteolytic modification which might also occur during the electrophoretic 
procedure. Because the mixture occurred in both protein samples, with the commercial protein 
having been demonstrated to be bioactive, the N-terminus of CXCL10-mucin-Stop was considered to 
be correctly processed by the CHO cells. As all CXCL10 fusion proteins were expressed in the same 
cell type from the same vector and the same CXCL10 gene sequence, it was assumed that the signal 
sequence was also correctly cleaved in the other fusion proteins. This consideration was 
complemented by several bioactivity experiments that were performed later on with the GPI-
anchored proteins (see 3.2, 3.6 and 3.7).  
3.2 Verification of the bioactivity of the fusion proteins 
The fusion of different proteins can lead to changes in their respective secondary and tertiary 
structures. In the case of the CXCL10 fusion proteins, such changes might alter the structure of the 
CXCL10 chemokine head, leading to diminished binding to CXCR3 or even to an antagonistic effect 
where the receptor is occupied but no intracellular signal in the target cell is elicited. To exclude 
these possibilities, three different tests were performed to verify CXCR3-stimulatory activity.  
3.2.1 The GPI-anchored CXCL10 fusion proteins stimulate CXCR3 internalization  
Following activation by a chemokine ligand, the CXCR3 receptor is rapidly internalized, degraded and 
later on replenished on the cell surface by de novo synthesis (Meiser et al. 2008). Receptor 
internalization also occurs with other chemokine receptors [reviewed in (Borroni et al. 2010)] and is 
an established assay to verify bioactivity of chemokines (Proudfoot et al. 2001; Colvin et al. 2004). To 
assess if the CXCL10 fusion proteins could still induce CXCR3 internalization in a surface-bound 
context, the CXCR3+ human T cell line JB4 was incubated for 30 min with stably transfected CHO cells 
or soluble CXCL10 as positive control. The CXCR3 surface signal on the T cells was then determined by 
FACS analysis and the degree of internalization was calculated. The signal intensities found after 
coincubation with non-transfected CHO cells or medium were set as 100%, and the levels found in 
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the other samples related to them. Figure 12 depicts the relative intensities of the CXCR3 signal in 
the various samples. 
A significant decrease of CXCR3 surface staining was found on the T cells after coincubation with 
CHO-CXCL10-GPI or CHO-CXCL10-mucin-GPI cells as seen in panel A. The signal was reduced to about 
50% of the values found after coincubation with non-transfected CHO cells. A similar degree of 
internalization was observed when the T cells were incubated with 750 ng/ml (86 nM) commercially 
available soluble CXCL10. This finding indicated that the surface-bound GPI-anchored CXCL10 fusion 
proteins could induce internalization of CXCR3. To exclude the possibility that the decrease in signal 
intensity was due to occupation of CXCR3 by CXCL10 leading to decreased accessibility of the epitope 
for the detection antibody, additional experiments were performed as depicted in panel B. First, the 
coincubation was performed at 4°C instead of 37°C in order to slow down cellular activity. This lead 
to a much attenuated CXCR3 internalization, consistent with the observation that receptor interna-
lization is an active process that is slowed with decreasing temperature. Second, different antibodies 
were used for the detection of CXCR3, which yielded the same results as the first antibodies. 
 
Figure 12: CXCR3 on human T cells is internalized after coincubation with cells expressing CXCL10-
GPI or CXCL10-mucin-GPI. A: Human JB4 T cells were incubated for 30 min at 37°C with stably 
transfected CHO cells at threefold excess or commercially available soluble CXCL10 (rhCXCL10) at the 
indicated concentrations. The CXCR3 signal on the T cells was subsequently determined by FACS and 
related to the CXCR3 signal on T cells incubated with non-transfected CHO cells or medium without 
chemokine, respectively. Bars represent averages of two (CHO-CXCL10-GPI and 100 ng/ml rhCXCL10) 
or three (all other conditions) independent experiments +/- standard deviations. Statistical signi-
ficance was calculated using the Kruskal-Wallis test (P = 0.0167), followed by Dunn´s post test; 
* = P<0.05. 100 ng/ml rhCXCL10 = 11 nM; 750 ng/ml rhCXCL10 = 86 nM. B: As additional controls, 
either the coincubation was performed at 4°C (black bars) in order to slow down cellular metabolism 
or different CXCR3-specific antibodies from a second supplier (R&D Systems; grey bars) were used for 
the CXCR3 detection. Control experiments were performed once.  
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Interestingly, pertussis toxin, a bacterial toxin that is often used to inhibit the signaling of G-protein 
coupled receptors, was not able to inhibit the internalization process (data not shown) – a finding 
that has also been reported in other studies (Sauty et al. 2001) and will be discussed in 4.2 in more 
detail. 
Taken together, the experiments demonstrated that the GPI-anchored CXCL10 fusion proteins were 
able to induce internalization of the CXCR3 receptor, which served as the first indication that the 
proteins are bioactive.  
3.2.2 The GPI-anchored CXCL10 fusion proteins induce calcium mobilization  
The signaling cascade triggered by activated chemokine receptors also includes the release of 
calcium from the endoplasmatic reticulum (ER) as a reaction to the second messenger inositol 1,4,5-
trisphosphate (IP3). A transient rise in the cytoplasmic calcium concentration is frequently used to 
monitor chemokine receptor activation and the initiation of downstream signaling (Proudfoot et al. 
2001). To test if the GPI-anchored CXCL10 fusion proteins could trigger calcium mobilization in 
CXCR3+ cells, additional coincubation experiments were performed. Cells of the human T cell line JB4 
were loaded with Fluo-4, a dye that exhibits a strongly increased fluorescence in the calcium-bound 
state as compared to the unbound state. The “loaded” cells were then incubated with a twofold 
excess of stably transfected CHO cells at 37°C in a multiwell plate and fluorescence readings were 
taken at regular intervals. For normalization against the background fluorescence, readings obtained 
from coincubation with non-transfected CHO cells were subtracted from the readings obtained with 
the transfected cells. Commercially available soluble CXCL10 was used in separate wells as positive 
control for the loading procedure and the function of the Fluo-4 dye (data not shown). Before the 
experiment, the transfected CHO cells were assayed for the expression levels of the recombinant 
fusion proteins by FACS analysis and found to express the proteins at similar levels (data not shown). 
Figure 13 shows a representative example of the development of the normalized fluorescence 
intensities over time.  
During the coincubation time of 40 min, a transient increase of the fluorescence intensities could be 
observed. This increase was presumably due to calcium being released from the ER in the T cells as a 
result of chemokine receptor triggering. The relatively long period of 40 min, over the course of 
which the increased fluorescence was observed, may have resulted from single contacts between 
T cells and CHO cells - each resulting in short-lived calcium mobilizations - until eventually all T cells 
had been desensitized for CXCL10. Interestingly, CHO cells transfected with CXCL10-mucin-GPI 
induced a much faster and stronger calcium response than cells transfected with CXCL10-GPI. It is 
possible that the mucin domain facilitated the interaction of the chemokine head with CXCR3 on T 
cells by presenting the chemokine domain away from the cell surface. This facilitated interaction may 
then have lead to a faster and stronger response in the cell population as will be discussed in 4.2.  
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In summary the data showed that the GPI-anchored CXCL10 fusion proteins were able to induce 
calcium mobilization in CXCR3+ T cells, supporting the conclusion that the proteins were bioactive.   
3.2.3 The GPI-anchored CXCL10 fusion proteins stimulate T cell adhesion 
One of the central functions of chemokines is the regulation of leukocyte adhesion in the process of 
recruitment. Here, chemokines bound to glycosaminoglycan molecules are presented to leukocytes 
rolling along the vessel wall. Recognition of those chemokines via chemokine receptors leads to a so 
called inside-out signaling cascade which results in activation of the leukocyte´s integrin molecules. 
This leads to an enhanced ability of the respective leukocyte to adhere to its substrate, e.g. the 
endothelium of a blood vessel. This type of adhesion can be monitored and quantified in vitro by 
laminar flow assays that allow the application of precisely defined shear stresses on the adhering 
leukocytes (see 2.2.5.4 and 3.6 for more details). In this study, assessing the effect of the 
recombinant GPI-anchored CXCL10 fusion proteins on the ability of CXCR3+ T cells to adhere to a cell 
monolayer should serve as a third indicator of bioactivity. Transfected CHO cells were grown to 
confluence in channels with defined geometry. Subsequently, cells of the CXCR3+ human T cell line 
DS4 were drawn into the channel and left to adhere for 5 min under static conditions. Afterwards, 
the cells were subjected to a physiologic shear stress (1 dyn/cm2). The detachment of the T cells was 
monitored by video microscopy and cells that were still adherent after 2 min of flow were counted. 
Figure 14 shows the averaged results of three independent experiments.  
 
Figure 13: Coincubation with CHO cells expressing CXCL10-GPI or CXCL10-mucin-GPI leads to 
calcium mobilization in CXCR3+ T cells. JB4 T cells were loaded with the cytoplasmic calcium-
sensitive fluorescent dye Fluo-4, which displays a much increased fluorescence in the calcium-bound 
state. Subsequently, the cells were coincubated with a twofold excess of transfected CHO cells at 
37°C and the fluorescence was measured. The curves show the fluorescence (arbitrary units) in the 
samples incubated with the indicated CHO cell lines, each normalized against the fluorescence values 
obtained from coincubation with non-transfected CHO cells. Data represent averages of duplicates.  
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Significantly more T cells adhered in a shear-resistant manner to CHO cells expressing CXCL10-mucin-
GPI (on average 69 cells/mm2) than to CHO-sEGFP-GPI cells that were used as negative control (on 
average 37 cells/mm2). Thus, the recombinant CXCL10-mucin-GPI protein expressed on the CHO cells 
enabled the T cells to more efficiently adhere to the CHO cell monolayer. On average 56 cells/mm2 
remained adherent to CHO cells expressing CXCL10-GPI. This observation indicated a positive trend 
also for the protein lacking the mucin domain, which was however not statistically significant.  
The mucin domain of CX3CL1 has been demonstrated to mediate capture of leukocytes under flow 
conditions. Thus, it was hypothesized that CXCL10-mucin-GPI could, in contrast to CXCL10-GPI, be 
able to bind freely flowing T cells under conditions of continuous flow. To test for this hypothesis, 
DS4 T cells were continuously drawn over the CHO cell monolayer at a subphysiologic shear stress 
(0.5 dyn/cm2) and the number of cells that adhered tightly was quantified using video microscopy. 
Figure 15 summarizes the averaged results of three independent experiments. The results indicated a 
trend towards the CHO cells carrying CXCL10-mucin-GPI on their surface being able to recruit more 
T cells (on average 13 cells/cm2) under flow conditions than the CHO cells expressing either CXCL10-
GPI or sEGFP-GPI (on average 8 cells/mm2 for both proteins). 
 
Figure 14: Adhesion of CXCR3+ T cells is stimulated by contact with the GPI-anchored CXCL10 fusion 
proteins. CHO cells transfected with CXCL10-GPI, CXCL10-mucin-GPI or sEGFP-GPI as control were 
grown to confluence in channels with defined geometry. On the day of the assay, DS4 T cells were 
drawn into the channel, left to adhere for 5 min under static conditions and subsequently subjected 
to a shear stress of 1 dyn/cm2. T cells that were still adherent after 2 min of flow were counted and 
the results were expressed as cells/mm2. The bars represent averages from three independent 
experiments +/- standard deviations. Statistical significance was calculated using the Kruskal-Wallis-
test (P = 0.039) followed by Dunn´s post test; * = P<0.05.  
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These results contrast those of the assay depicted in Figure 14 where the T cells were allowed to 
adhere under static conditions, and in which also CXCL10-GPI showed a positive trend. This discre-
pancy might indicate an important role for the mucin domain in mediating adhesion under conditions 
of flow. However, the differences observed in this experiment were not statistically significant, and 
the cell numbers were generally relatively low, therefore not allowing definitive interpretations. On 
the other hand, the transfer of these results to the context of leukocyte recruitment in a blood vessel 
is very difficult as the experiments were performed using CHO cells. The extracellular composition of 
these cells including integrin ligands is presumably profoundly different from endothelial cells, with 
the latter cell type being designed to allow efficient recruitment of leukocytes from the blood 
stream.  
Taken together, the conclusion that could be drawn from the experiments detailed above was that 
the recombinant GPI-anchored CXCL10 fusion proteins were able to activate CXCR3+ T cells leading to 
enhanced adhesion to cell monolayers. This again indicated that the proteins were bioactive. Thus, 
having demonstrated bioactivity, a purification protocol for the recombinant proteins had to be 
established in order to be able to test their bioactivity in the intended setting of “painted” primary 
endothelial cells, which will be detailed below. 
 
 
Figure 15: CXCL10-mucin-GPI expressed on CHO cells shows a trend towards being able to bind 
CXCR3+ T cells under flow. CHO cells were grown in channels with defined geometry as detailed in 
the legend of Figure 14. Subsequently, DS4 T cells were perfused over the CHO cell monolayer at 
0.5 dyn/cm2 and the interactions were monitored by video microscopy over the course of 5 min. Only 
such T cells were counted that tightly adhered to the CHO cell monolayer for at least 30 sec. The bars 
represent averages from three independent experiments +/- standard deviations. Differences 
between the mean ranks of different samples were not statistically significant as assessed by the 
Kruskal-Wallis test. 
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3.3 Dodecyl-maltoside can efficiently solubilize the GPI-anchored fusion proteins 
Prior to their purification, the recombinant GPI-anchored proteins had to be solubilized from the cell 
membranes of transfected CHO cells. In the process of solubilization, the cell membrane lipids are 
replaced with detergent molecules resulting in the membrane proteins being embedded with their 
hydrophobic parts in detergent micelles. These micelle-bound proteins can then be purified using 
conventional methods. The choice of detergent plays an important role in the purification process as 
a too strong detergent may disrupt the protein´s secondary or tertiary structure, while using too 
weak a detergent could result in incomplete solubilization and thereby loss of protein.  
A panel of different detergents was established based on two characteristics: The detergents had to 
be available in ultra-pure form to avoid contaminations, e.g. with pyrogens, and only nonionic 
detergents known to be “gentle”, i.e. to solubilize proteins in their native state, were included. To 
test the different detergents, a modified ELISA protocol was established [based on (Bumgarner et al. 
2005)] as described in 2.2.4.3.2. Briefly, the proteins were labeled with anti c-myc primary and horse 
radish peroxidase (HRP)-conjugated secondary antibodies prior to solubilization. Subsequently, the 
cells were treated with lysis buffers containing the various detergents. An aliquot of each cell lysate 
was centrifuged to remove debris and non-solubilized proteins. The HRP signal in the supernatant 
was then related to the signal in the uncentrifuged sample and expressed as percent solubilization. 
Figure 16 shows the averaged results of at least two independent experiments for CXCL10-GPI and 
CXCL10-mucin-GPI.  
The experiments showed that n-Dodecyl-β-D-maltoside (DDM) was most potent at solubilizing the 
CXCL10 fusion proteins. With this detergent, solubilization rates of over 90% at the given cell 
concentration of 107 cells/ml could be reached. The efficiency of DDM ranged between 86% and 
(calculatively) 101% solubilization for CXCL10-GPI and between 92% and 104% for CXCL10-mucin-GPI, 
depending on the respective detergent concentration. A related detergent, n-Octyl-β-D-
glucopyranoside, was found to be the second best at solubilizing the proteins with maximum 
efficiencies of 84% for CXCL10-GPI and 91% for CXCL10-mucin-GPI. The efficiencies of all other 
detergents under study ranged below 75% solubilization. Of note, DDM was efficient over a relatively 
wide range of concentrations. This was in contrast to n-Octyl-β-D-glucopyranoside, the efficiency of 
which dropped drastically already at 15 mM to 36% for CXCL10-GPI and 51% for CXCL10-mucin-GPI. 
Thus, DDM appeared to be a robust reagent for the intended purpose.  
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Similar experiments were performed for the sEGFP-GPI protein by measuring the EGFP fluorescence 
in cell extracts and comparing the values to the fluorescence in uncentrifuged samples (data not 
shown). These experiments lead to virtually the same results with solubilization rates of up to 95% 
using DDM. This detergent was therefore found to be best suited for the solubilization of the GPI-
anchored fusion proteins and was consequently used in the following experiments.  
3.4 Purification of the recombinant fusion proteins by affinity chromatography 
Once solubilized, the GPI-anchored proteins had to be purified in order to test their efficiency of 
insertion into cell membranes. Attempts to isolate the proteins by cation exchange, anion exchange, 
size exclusion or heparin affinity chromatography yielded unsatisfactory results as discussed in 4.3. 
To help address this problem, the double c-myc epitope tag was included into all constructs directly 
adjacent to the GPI anchor. This tag allowed isolation of the fusion proteins from cell extracts by 
 
Figure 16: N-Dodecyl-β-D-maltoside is most efficient for the solubilization of the GPI-anchored 
CXCL10 fusion proteins. A modified ELISA variant was used to determine solubilization efficiencies of 
various detergents. CHO-CXCL10-GPI (A) or CHO-CXCL10-mucin-GPI (B) cells were labeled with anti 
c-myc primary and HRP-conjugated secondary antibodies and treated with different detergents at 
the indicated concentrations for 1 h. An aliquot of each extract was centrifuged to remove unsolu-
bilized proteins and debris and the HRP signal in the supernatants was related to the signal in 
uncentrifuged samples. Bars represent the average values of three (CXCL10-GPI) or two (CXCL10-
mucin-GPI) independent experiments +/- standard deviations. Abbreviations: Dodecyl-maltoside = 
n-Dodecyl-β-D-maltoside; Octyl-glucoside = n-Octyl-β-D-glucopyranoside; NP40 = Nonidet P40; 
C12E8 = octaethylene glycol monododecyl ether; BRIJ35 = tricosaethylene glycol ether; Triton X-100h 
= Triton X-100, hydrogenated. 
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affinity chromatography using a commercially available resin that contained a specially designed 
antibody directed against the c-myc tag.  
The GPI-anchored proteins CXCL10-GPI, CXCL10-mucin-GPI or sEGFP-GPI were solubilized (see 
above), and non-solubilized proteins and debris were removed by centrifugation. The samples were 
sterile filtered and applied to the c-myc affinity resin. In cases when soluble proteins were isolated 
from cell culture supernatants, the supernatants were directly applied to the affinity resin. A slow 
flow rate was used to allow quantitative binding of the proteins. After a washing step with PBS + 
145 mM NaCl to remove nonspecifically bound contaminants, the proteins were eluted using c-myc 
peptides in equilibration buffer. Following chromatography, all fractions were assayed for their 
specific protein content by western blotting and the fractions containing the highest amounts of 
protein were pooled. Figure 17 shows exemplary chromatograms and matching western blots for the 
isolation of CXCL10-GPI and CXCL10-mucin-GPI. Similar chromatograms were obtained from 
purifications of sEGFP-GPI.  
In the western blot analysis, CXCL10-GPI appeared as a prominent band at about 10-15 kDa (see 
Figure 17 A). The observed band matches the molecular weight of CXCL10 plus the c-myc tag as 
derived from the amino acid sequence (11.6 kDa). Predicting the contribution of the GPI anchor to 
the apparent molecular weight is difficult as the GPI anchor structure interacts with SDS in a way 
much different from protein structures. (Azzouz and Capdeville 1992; Walmsley et al. 2001; O'Connor 
et al. 2005). Sometimes an additional band at around 20 kDa was seen for CXCL10-GPI, suggesting 
dimerization of the protein. Also additional bands at 30 to 40 kDa were occasionally observed (as 
seen in the cell extract and the flow through), which presumably contained protein oligomers. 
Oligomers that do not break up in SDS-PAGE are a phenomenon frequently found for chemokines in 
general and in particular for CXCL10 (Luster et al. 1995).  
CXCL10-mucin-GPI appeared in western blots predominantly as a band at around 45-50 kDa (see 
Figure 17 B). The molecular weight of the CXCL10 part plus the mucin domain and the c-myc tag 
predicted from the amino acid sequence is 36.8 kDa. The difference between the predicted and the 
observed size was due to glycosylations in the mucin domain, as this domain has been demonstrated 
to contain around 10-20 kDa of glycosylations (Fong et al. 2000). It was therefore assumed that the 
45-50 kDa band contained monomeric glycosylated CXCL10-mucin-GPI protein. A second band was 
often observed at around 90 kDa, which most likely contained protein dimers.  
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Figure 17: Solubilized CXCL10-GPI and CXCL10-mucin-GPI proteins can be purified by anti c-myc 
affinity chromatography. Transfected CHO cells were lysed in extraction buffer containing 
n-Dodecyl-β-D-maltoside. Non-solubilized proteins and debris were removed by centrifugation and 
the extract was applied to a commercially available resin containing immobilized anti c-myc 
antibodies. Representative chromatograms and matching western blots for the purifications of 
CXCL10-GPI (A) or CXCL10-mucin-GPI (B) are shown. The UV absorption at 280 nm (blue line) as a 
measure of protein concentration and the conductivity (brown line) as a measure of the salt 
concentration are plotted against the total volume passing through the column. The green line 
indicates the percentage of washing buffer being applied to the column. Following a washing step at 
high salt concentration, proteins were competitively eluted using c-myc peptides. Fractions were 
collected and assayed by western blotting for their specific protein content. 
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Observing the chromatograms for both CXCL10 fusion proteins, it was evident that large amounts of 
proteins passed through the columns without binding (flow through), while the western blots 
showed that the respective fractions contained only minimal amounts of CXCL10 fusion proteins. 
Thus, many contaminating proteins could be removed during this step. The same was true for the 
washing step, where significant amounts of contaminants were eluted, but no CXCL10 fusion 
proteins. In the elution step, a distinct protein peak was generated, the fractions of which contained 
the majority of the CXCL10 fusion proteins.  
A commercially available CXCL10-specific sandwich ELISA was used to determine specific protein 
concentrations. The total protein content was additionally determined and compared to the ELISA 
values. On average, the percentage of the CXCL10 fusion proteins among the total proteins was 
about 45 times higher in the elution fractions than in the cell extracts, indicating that the respective 
proteins had been significantly enriched. For the sEGFP-GPI proteins, the fluorescence in the 
respective fractions (which correlates linearly to the EGFP concentration) was compared to the total 
protein content. The ratio of these values was also much increased in the elution fractions, in the 
same order of magnitude as found for the CXCL10 fusion proteins using the ELISA measurements. 
This degree of specificity and purification efficiency could in our hands not be reached with any other 
purification chemistry. Nevertheless, the GPI-anchored fusion proteins were not purified to 
homogeneity. For that reason, the sEGFP-GPI protein was used as control in functional assays, as it 
contained the same type and amount of contaminants as the CXCL10 fusion proteins, which was also 
verified using silver staining (data not shown).  
In summary, sufficiently pure preparations of the GPI-anchored proteins could be obtained by c-myc 
affinity chromatography, which allowed further experiments assessing the functionality of the 
purified proteins. 
3.5 Purified GPI-anchored fusion proteins incorporate into cell membranes 
The GPI anchor at the C-terminus of the recombinant fusion proteins should enable them to 
integrate into the cell membranes of virtually any cell type when added exogenously. Experiments 
were performed to test this hypothesis and characterize the incorporation process using purified 
proteins which had been prepared as detailed above. 
3.5.1 The GPI-anchored fusion proteins can be detected on the surface of treated cells  
FACS staining was used to determine the presence of incorporated GPI-anchored proteins on the 
surface of cells that had been treated with the purified proteins. Non-transfected CHO cells were 
routinely used as target cells. As detailed in 2.2.5.1.2, the cells were incubated for 1 h with 0.9 nM of 
purified CXCL10-GPI or CXCL10-mucin-GPI or with sEGFP-GPI that had been identically purified and 
diluted in MEMα medium. As control for the GPI anchor, purified CXCL10-mucin-Stop protein was 
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used, which lacked the GPI anchor. It was applied at a higher concentration than the GPI-anchored 
proteins (3.9 nM) to allow potential detection of non-specific binding occuring at low affinity. Two 
additional samples were treated with elution buffer from the chromatographic purification of the 
fusion proteins, or MEM alpha medium as controls. All samples (except the medium control) 
contained the same percentage of chromatography buffer and detergent to exclude buffer artifacts. 
Following treatment, the cells were washed and subsequently stained using c-myc specific primary 
and RPE-labeled secondary antibodies as detailed in 2.2.5.1.1. Dead cells were identified by 7-AAD 
staining and excluded from the analysis. Figure 18 shows the results of a representative FACS 
staining.  
As evident from the histograms, only the CXCL10-GPI, CXCL10-mucin-GPI and sEGFP-GPI proteins 
could successfully be detected on the surface of the treated CHO cells, whereas the soluble CXCL10-
mucin-Stop protein could not be detected. The buffer and medium controls did not result in a 
fluorescence signal demonstrating specificity of the staining protocol. These observations indicated 
 
Figure 18: Purified GPI-anchored proteins incorporate into cell membranes. In order to test the 
capacity of the purified GPI-anchored fusion proteins to incorporate into cell membranes, non-
transfected CHO cells were incubated with the proteins for 1 h at 37°C. As controls, two samples 
were treated either with identically diluted chromatography buffer (buffer) or MEM alpha medium 
(medium). The soluble CXCL10-mucin-Stop protein served as additional control because it lacked the 
GPI anchor and should therefore not be able to integrate into cell membranes. All samples except 
the medium control contained the same percentage of chromatography buffer and detergent. 
Following incubation, the cells were washed and tested for the presence of the proteins on their 
surface by FACS staining using anti c-myc primary and RPE-labeled secondary antibodies. Dead cells 
were identified by 7-AAD staining and the histograms shown are gated on viable cells. The black lines 
indicate staining with isotype-matched control antibodies, blue lines staining with anti c-myc 
antibodies. Mean fluorescence intensities (MFIs; geometric mean of c-myc stained sample – 
geometric mean of isotype control) are given for each sample.  
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that the GPI-anchored proteins incorporated spontaneously into the cell membranes of the target 
cells.  
Similar results were obtained using primary or immortalized microvascular endothelial cells (HDBEC 
or HMEC, respectively; see 3.5.2, 3.5.3 and data not shown) or primary endothelial cells isolated from 
umbilical veins (HUVEC; data not shown). Thus, a variety of different cells could be “painted” with 
the purified proteins, which indicated that the exact extracellular composition of the target cells was 
of minor importance for the incorporation process. The staining intensities were found to correlate 
with the general concentration of recombinant proteins used in the respective experiment (compare 
the MFIs in the experiments described in 3.5.3 and 5.6, which were performed with lower protein 
concentrations and data not shown). The technique of cell painting thus allowed the transfer of 
defined amounts of proteins onto target cell surfaces by varying the protein concentrations used for 
cell painting. Furthermore, this observation also indicated that it might be possible to generate a 
stable gradient of recombinant proteins if they were injected into a tissue. Here, diffusion in 
combination with incorporation of a fraction of the proteins at each point should gradually lower the 
concentration of available proteins, leading to lower degrees of painting with increasing distance 
from the injection site. However, this assumption is largely hypothetical.  
3.5.2 Incorporated GPI-anchored fusion proteins associate with the cell membranes of 
treated cells 
Having shown that the purified GPI-anchored fusion proteins could integrate spontaneously into cell 
membranes, the exact subcellular localization of the incorporated proteins was assessed in more 
detail using immunofluorescence microscopy.  
In order to mimic the situation found in a blood vessel as closely as possible, primary microvascular 
endothelial cells (HDBEC) were used as target cells. Furthermore, the cells were treated with the 
purified proteins in an adherent state to exclude changes to the incorporation process when the cells 
are detached from their substrate for treatment. In this adherent setting, it was expected to find a 
membrane-associated incorporation pattern of the recombinant proteins. Of note, the experimental 
conditions used in this experiment were virtually identical to the painting of endothelial cells for the 
laminar flow assays described in 3.6, allowing conclusions also for these assays.  
Primary microvascular endothelial cells were grown in special culture dishes with high fluorescence 
permeability as described in 2.2.5.3. Subsequently, the cells were washed and incubated for 1.5 h 
with purified CXCL10-GPI (1.8 nM), CXCL10-mucin-GPI (0.8 nM) or a buffer control, all diluted in 
culture medium and all containing the same percentage of buffer to exclude artifacts. Different 
protein concentrations were used in this experiment as a comparison of staining intensities was not 
the primary objective, but rather the maximal available amount of the respective proteins (which 
depended on the yield in the respective protein purification) should be transferred onto the cells to 
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enable precise localization of the incorporated proteins. Following treatment, the cells were washed 
and fixed with paraformaldehyde to exactly preserve the situation found after the incorporation 
process. Incorporated proteins were then detected using anti c-myc primary and biotinylated 
secondary antibodies in combination with RPE-labeled streptavidin. Figure 19 shows representative 
fluorescence images and corresponding bright field images acquired on an inverted fluorescence 
microscope. 
The images showed pronounced fluorescence signals in both samples treated with the GPI-anchored 
CXCL10 fusion proteins, but not in the buffer control, indicating specificity of the staining. The 
strongest signals were found at the periphery of the cells, a staining pattern which is commonly 
associated with membrane-bound targets. For the sample treated with CXCL10-GPI, a stronger 
overall fluorescence was found, which was due to the higher protein concentration used in this 
sample. In summary, it can be stated that the purified GPI-anchored CXCL10 fusion proteins 
incorporated spontaneously into the cell membranes of primary microvascular endothelial cells. 
Furthermore, the incorporated proteins could be detected in a membrane-associated manner, 
indicating correct targeting to the cell membrane.  
 
Figure 19: The GPI-anchored CXCL10 fusion proteins can be detected on the cell membranes of 
primary microvascular endothelial cells following treatment with purified proteins. In order to 
identify the subcellular localization of the incorporated proteins, immunofluorescence microscopy 
was performed. Primary microvascular endothelial cells were treated with 1.8 nM purified CXCL10-
GPI, 0.8 nM CXCL10-mucin-GPI or a buffer control, with all samples containing the same percentage 
of buffer to exclude artifacts. Primary cells were used and the cells were treated in an adherent state 
to mimic the situation found in a blood vessel. Following treatment, the cells were fixed and incor-
porated proteins were detected using anti c-myc primary and biotinylated secondary antibodies 
followed by RPE-labeled streptavidin. Representative fluorescence images and corresponding bright 
field images are shown. All images within each row were acquired using the same exposure time. The 
black bars represent a length of 50 µm.  
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3.5.3 The incorporation process is dependent on the presence of a GPI anchor 
Additional experiments were performed to more directly show that the GPI anchor was responsible 
for anchoring the purified proteins to the cell membranes of target cells after incorporation. To this 
end, microvascular endothelial cells were treated with purified CXCL10-GPI (0.5 nM) or CXCL10-
mucin-GPI (0.6 nM) or a buffer control and then treated with 0.1 U phosphatidylinositol-specific 
phospholipase C (PI-PLC) for 1 h. PI-PLC specifically cleaves GPI anchors, thereby releasing the 
proteins for the cell surface. Thus, if the proteins were anchored via GPI structures, this treatment 
should lead to a reduction in surface staining. Following treatment with PI-PLC, the cells were stained 
with anti c-myc primary and RPE-labeled secondary antibodies and staining intensities were assessed 
by FACS. Figure 20 depicts the results of a representative experiment.  
 
Treatment with PI-PLC lead to a pronounced reduction in surface staining of the GPI-anchored 
protein treated cells (light blue lines). The MFIs of these samples were reduced by about 60% 
compared to the respective medium controls (dark blue lines). This marked reduction in surface 
staining verified that the proteins were anchored to the cell membrane via GPI anchor structures.  
3.6 CXCL10-mucin-GPI can enhance leukocyte recruitment in vitro under 
conditions of physiologic flow 
Based on our initial hypothesis, CXCL10-mucin-GPI should be able to recruit leukocytes in the 
absence of an inflammatory reaction, thereby overcoming endothelial cell anergy within tumor 
 
Figure 20: Phosphatidylinositol-specific phospholipase C (PI-PLC) treatment releases the GPI-
anchored CXCL10 fusion proteins from the cell surface following incorporation. Microvascular 
endothelial cells were treated with 0.5 nM CXCL10-GPI, 0.6 nM CXCL10-mucin-GPI or a buffer control 
with all samples containing the same percentage of chromatography buffer. Subsequently, the 
samples were aliquoted and incubated with 0.1 U PI-PLC or medium as control. FACS staining was 
performed using anti c-myc primary and RPE-labeled secondary antibodies. Chromatograms are 
gated on viable cells identified by 7-AAD exclusion. The light blue lines indicate cells treated with PI-
PLC (matching isotype control: grey lines) while the dark blue lines indicate the medium control 
(matching isotype control: black lines). The MFIs (geometric mean of c-myc stained sample – 
geometric mean of isotype control) are given for every treatment condition. In order to better 
visualize the differences in fluorescence intensity, the histograms are displayed using a relative scale 
on the Y axis (% of max), where the number of events is related for each particular fluorescence 
intensity to the number of events in the largest group of cells with the same fluorescence intensity.  
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tissues. Once anchored into the cell membranes of endothelial cells via the GPI anchor, the mucin 
domain together with the chemokine head should concertedly induce rolling and tight adhesion of 
leukocytes, followed by diapedesis into the tumor tissue. Two major types of leukocytes were 
envisioned as targets of CXCL10-mucin-GPI as both types express the CXCR3 receptor: cytotoxic 
T cells and NK cells. Therefore, the effect of CXCL10-mucin-GPI on the recruitment of these cell types 
was assessed in vitro using laminar flow assays. These assays mimic conditions found in blood vessels 
in terms of shear stress, and are typically performed using channels with rectangular geometry. 
Endothelial cells are grown within these channels, pretreated according to the respective 
experiment, and leukocytes are then perfused through the channel over the endothelial cell 
monolayer. The subsequent interactions between leukocytes and endothelial cells are monitored by 
video microscopy. The rectangular geometry of the channel allows a precise calculation of the shear 
stress occurring between the channel walls (or the endothelial cells) and adhering leukocytes. The 
local flow velocity at any given point within the channel can be calculated from the dimensions of the 
channel, the viscosity of the medium, and the pressure change within the channel, which is 
dependent on the volumetric flow rate (Cornish 1928). The local flow velocity is then used to 
calculate the shear stress at any given point, which is again dependent on the viscosity of the 
medium. Most experiments presented here were performed at a shear stress of 1 dyn/cm2, which 
resembles the shear stress found in postcapillary venules, where leukocyte recruitment 
predominantly occurs (Lawrence et al. 1987; Lawrence and Springer 1991; DiVietro et al. 2001). 
Primary microvascular endothelial cells from blood vessels (HDBEC) were used in the experiments to 
as closely as possible mimic the capillary vasculature (for details see 2.2.5.4). 
3.6.1 CXCL10-mucin-GPI mediates enhanced adhesion of NK cells to primary 
microvascular endothelial cells  
In order to gain initial insights into the function of the GPI-anchored fusion proteins, a series of 
laminar flow assays were performed using the human NK cell line YT. A low expression of CXCR3 was 
detected in these cells by reverse transcriptase real-time PCR (2dCt vs. 16S rRNA = 1.37 x 10-6) as well 
as in FACS analyses (data not shown). The assays were conducted using resting primary micro-
vascular endothelial cells. These cells normally do not support adhesion of leukocytes under 
conditions of physiologic flow due to the absence of selectin molecules, which are only upregulated 
in response to pro-inflammatory stimuli and are not present on resting cells (Haraldsen et al. 1996). 
Also in our hands, E-selectin was not detected on resting endothelial cells by FACS analysis (data not 
shown).  
For the experiments, endothelial cells were grown in microscope slides containing a channel of 
defined geometry. On the day of the assay, the cells were incubated for 1 h in 0.34 nM of purified 
GPI-anchored CXCL10 fusion proteins diluted in endothelial cell growth medium, or with identically 
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purified and diluted sEGFP-GPI protein. As an additional control, parallel slides were incubated with 
commercially available recombinant CXCL10 at 1000 fold higher concentration (340 nM), to allow 
detection of even small effects mediated by conventional CXCL10. All samples contained the same 
percentage of chromatography buffer and detergent to exclude buffer artifacts. Following treatment 
of the endothelial cells, NK cells were suspended in assay buffer and perfused over the endothelial 
cells with a shear rate of 1 dyn/cm2 for 5 min. The interactions were monitored by video microscopy 
and the number of NK cells that accumulated on the endothelial cells within the respective field of 
view was counted and expressed as cells/mm2. Figure 21 summarizes the results of at least three 
independent experiments that were performed using independent protein preparations with each 
symbol representing one independent slide and horizontal bars representing the overall average.  
In these experiments, on average 65 NK cells/mm2 were found to have adhered to endothelial cells 
that had been incubated with CXCL10-mucin-GPI. Despite this large average number of cells, the 
outcomes of single experiments varied considerably, resulting in a large standard error of the mean 
(SEM) of 25 cells/mm2. These variations are thought to reflect the series of variables that underlie 
 
Figure 21: Human NK cells accumulate on primary microvascular endothelial cells treated with 
purified CXCL10-mucin-GPI. Laminar flow assays were performed to test if resting primary 
microvascular endothelial cells that had been treated with the GPI-anchored CXCL10 fusion proteins 
were able to recruit freely flowing NK cells under conditions of physiologic flow. Resting endothelial 
cells were treated with 0.34 nM of GPI-anchored CXCL10 fusion proteins or with identically diluted 
sEGFP-GPI protein for 1 h. Other slides were treated with commercially available CXCL10 at 1000 fold 
higher concentration as additional control (rhCXCL10). All samples contained the same percentage of 
chromatography buffer and detergent. Subsequently, YT cells (a human NK cell line) were perfused 
over the endothelial cells with 1 dyn/cm2 and the number of cells that had accumulated on the 
endothelial cells after 5 min was counted. Data shown here are derived from three (controls) or four 
(CXCL10 fusion proteins) independent experiments that were performed using independent protein 
preparations. Each symbol represents one independent slide, horizontal bars the average. Statistical 
significance was calculated using the Kruskal-Wallis test (P = 0.0084) followed by Dunn´s post test; 
* = P<0.05, ** = P<0.01.  
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laminar flow experiments, although extensive efforts were taken to minimize these variables. 
Nevertheless, on average only 2 cells/mm2 adhered to the samples treated with the GPI-anchored 
negative control protein sEGFP-GPI, and the difference between this protein and CXCL10-mucin-GPI 
was highly significant. This indicated that the incorporation process itself, or the presence of a GPI-
anchored protein on the cell surface, did not activate the endothelial cells and cause the adhesion 
events observed with CXCL10-mucin-GPI.  
CXCL10-GPI lacking the mucin domain failed to recruit significantly more cells than the two controls 
(5 cells/mm2 on average), suggesting that the presence of the mucin domain is a prerequisite for 
efficient function of the fusion proteins in NK cell recruitment.  
A significant difference was also observed between CXCL10-mucin-GPI treated cells and cells treated 
with commercially available CXCL10 (0 cells/mm2 on average), although the latter protein was used 
at 1000 fold higher concentration than the GPI-anchored proteins. This observation made it unlikely 
that the effects seen in the experiments were based upon an interaction of the CXCL10 chemokine 
domain with the endothelial cells. The fact that chemokines alone were insufficient to induce 
leukocyte recruitment on resting endothelial cells has also been demonstrated in other publications 
(Kukreti et al. 1997; Peled et al. 1999; Manes et al. 2006).  
These experiments described the first proof of principle that a fusion protein containing a chemokine 
head, the mucin domain of CX3CL1 and a GPI anchor can incorporate spontaneously into endothelial 
cell membranes, and once incorporated, bind leukocytes that are moving at physiologic flow rates. 
The recruitment occurred in the absence of inflammatory stimulation of the endothelial cells, which 
is an important finding because the upregulation of adhesion molecules by inflammatory cytokines is 
often defective in tumor endothelia (see 1.1.3). Efficient recruitment of NK cells would however 
require not only binding, but also that the cells undergo tight adhesion, which represents an 
important step in the extravasation cascade and was evaluated as described below. 
3.6.2 CXCL10-mucin-GPI induces both rolling and tight adhesion of NK cells  
In the recruitment cascade, rolling adhesion is first initiated by endothelial-expressed selectin 
molecules. Subsequently, tight adhesion is triggered in rolling leukocytes via chemokine receptor 
stimulation leading to activation of the leukocyte´s integrins (Jones et al. 1994; Laudanna and Alon 
2005). This tight adhesion to the endothelium is required for leukocyte extravasation from blood 
vessels into the tissue. To more precisely analyze if CXCL10-mucin-GPI also induced tight adhesion of 
the captured NK cells, the adherent cells in the experiments described above were further 
subgrouped. Cells that displayed tight adhesion, defined as an event in which the respective NK cell 
did not move further than one cell diameter within 30 sec, were differentiated from those that 
displayed rolling adhesion, defined as an event in which the leukocyte was abruptly stopped from the 
flow, but did not reach tight adhesion or detached again. The exact evaluation criteria that were 
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applied can be found in 2.2.5.4.3. Figure 22 shows the results of a representative experiment, each 
bar representing the average of two independent slides. 
The evaluation showed that endothelial cells incubated with 0.34 nM CXCL10-mucin-GPI induced 
both rolling and tight adhesion of the NK cells. On average 52 cells/mm2 displayed rolling adhesion, 
while 46 cells/mm2 adhered tightly to the endothelial cells. CXCL10-GPI lacking the mucin domain 
could only induce 9 events of rolling adhesion and 4 tight adhesions/mm2. Virtually no adhesion was 
seen with endothelial cells incubated with the sEGFP-GPI control protein or commercially available 
CXCL10 (340 nM), again indicating that the incorporation process or the CXCL10 chemokine domain 
alone did not activate the endothelial cells.  
In summary, primary microvascular endothelial cells treated with CXCL10-mucin-GPI acquired the 
ability to recruit NK cells at physiologic flow in the absence of inflammatory stimulation. The 
recruitment process involved the induction of both rolling and tight adhesion, indicating robust 
binding of the leukocytes and thus laying the ground for subsequent extravasation.  
Since following the in vitro proof of concept also in vivo trials should be performed, further 
experiments were carried out to examine the activity of the CXCL10 proteins with murine cells, which 
will be described in the next sections.  
 
 
Figure 22: CXCL10-mucin-GPI induces both rolling and tight adhesion under conditions of 
physiologic flow. Primary microvascular endothelial cells were treated with the GPI-anchored fusion 
proteins or commercially available CXCL10 (rhCXCL10) as described in the legend of Figure 21. 
Subsequently, NK cells of the YT cell line were perfused over the endothelial cells with a shear rate of 
1 dyn/cm2 and interactions were monitored by video microscopy. Tight adhesion was defined as an 
event in which the particular NK cell did not move further than one cell diameter within 30 sec, while 
rolling adhesion was defined as an event in which the cell was abruptly stopped but did not reach 
tight adhesion or detached again. Cells displaying both types of adhesion were counted as tightly 
adherent. Each bar represents averaged values from two independent slides.  
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3.6.3 CXCL10-mucin-GPI can recruit also primary murine NK cells  
The experiments described in the last sections were all performed with human cells and the GPI-
anchored CXCL10 fusion proteins contained a human CXCL10 domain. Human and murine CXCL10 
share the same three-dimensional structure and display 83% amino acid homology (Jabeen et al. 
2008). Nevertheless, with respect to the in vivo experiments that should be performed later on, it 
was tested if the CXCL10 fusion proteins were active with murine cells. Soluble human CXCL10 was 
shown in calcium mobilization and receptor internalization assays to crossreact with murine CXCR3 
using a murine T cell line (see 5.2). Here, murine and human CXCL10 elicited virtually identical 
signals. In the following experiment, the effects of the GPI-anchored proteins on murine NK cells 
were tested in terms of the induction of adhesion under flow.  
Primary murine NK cells were kindly provided by J. Pötzl from the Helmholtz Zentrum Munich and 
isolated freshly on the day of each assay from the spleens of wildtype C57/Bl6 mice. Magnetic beads 
were used for the isolation and the purity of the preparation was routinely assessed by FACS staining. 
In the experiment presented here, the cell population comprised 94% NK cells. High CXCR3 
expression was found on 43% of the murine splenic NK cells (data not shown). Primary human 
microvascular endothelial cells were used in the experiments as primary murine microvascular 
endothelial cells were not commercially available. It was though assumed that the general cell 
surface composition of human endothelial cells was largely compatible with murine leukocytes.  
The experiment was performed as described in 2.2.5.4. Resting endothelial cells grown in microscope 
slides were treated with 0.2 nM of CXCL10-GPI or CXCL10-mucin-GPI or commercially available 
CXCL10 at much higher concentration (115 nM) to allow detection of small effects mediated by the 
soluble protein. All samples were diluted in culture medium and contained the same percentage of 
buffer and detergent. Partly also a medium control with completely untreated endothelial cells was 
included. Subsequently, murine NK cells were perfused over the endothelial cells with a shear rate of 
either 0.4 or 1 dyn/cm2. The subphysiologic shear rate of 0.4 dyn/cm2 was included to allow a more 
precise characterization of the effects of the proteins. The interactions were monitored for 5 min and 
adherent NK cells were counted. Cells with rolling adhesion were differentiated from tightly adherent 
cells as described above and in more detail in 2.2.5.4.3. Figure 23 shows the results of the 
experiment, with panel A summarizing cell counts at 0.4 dyn/cm2 and panel B at 1 dyn/cm2. 
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At the subphysiologic flow rate of 0.4 dyn/cm2, 70 events of rolling adhesion and 37 tightly adhering 
NK cells/mm2 were observed on endothelial cells treated with CXCL10-mucin-GPI. For the CXCL10-
GPI protein, 14 rolling and 18 tight adhesions/mm2 were found, indicating that 20% of the rolling 
adhesions and about half of the tight adhesions seen with CXCL10-mucin-GPI also took place in the 
absence of the mucin domain. While some adherence (up to 8 events/mm2) was seen with soluble 
CXCL10, this was also true for the medium control, indicating that the events observed with soluble 
CXCL10 were based only on the low flow rate. This background adherence was completely abrogated 
when the physiologic shear rate of 1 dyn/cm2 was employed as shown in panel B. At this shear rate 
also the difference between the two CXCL10 fusion proteins was more pronounced. Endothelial cells 
treated with CXCL10-GPI triggered tight adhesion of 3 NK cells/mm2, while endothelial cells 
incubated with CXCL10-mucin-GPI recruited 24 tightly adhering cells/mm2. Thus, 8 x more cells were 
tightly bound by the protein containing the mucin domain, opposed to a twofold difference observed 
at 0.4 dyn/cm2. In addition, also the differences in the induction of rolling adhesion were more 
pronounced at the more physiologic shear rate: No events were observed in the sample with 
CXCL10-GPI, while CXCL10-mucin-GPI was able to induce 30 rolling adhesions/mm2.  
These results showed that CXCL10-mucin-GPI is able to recruit murine NK cells in the same range of 
efficiency as seen with human NK cells and underlined the importance of the mucin domain for 
 
Figure 23: CXCL10-mucin-GPI efficiently recruits murine NK cells and induces both rolling and tight 
adhesion under conditions of physiologic flow. Experiments were performed to assess the 
applicability of the GPI-anchored fusion proteins in the murine system. Primary microvascular 
endothelial cells were incubated for 1 h with 0.2 nM of CXCL10-GPI or CXCL10-mucin-GPI or 
commercially available CXCL10 (rhCXCL10) at much higher concentration (115 nM) to allow detection 
of even minor effects. All samples except the medium control contained the same percentage of 
buffer and detergent. Primary murine NK cells were then perfused over the endothelial cells with 0.4 
(A) or 1 (B) dyn/cm2 and adherent cells were counted. Cells with rolling adhesion were differentiated 
from such that adhered tightly to the endothelium as described in the legend of Figure 22. 
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recruitment at physiologic shear stress. Having demonstrated activity of CXCL10-mucin-GPI on NK 
cells, further experiments were performed to test the efficacy in terms of recruitment also with 
T cells.  
3.6.4 CXCL10-mucin-GPI has no significant effect on T cell recruitment  
In the experiments described above, CXCL10-mucin-GPI was shown to be highly active in recruiting 
NK cells under conditions of physiologic flow. The activity of the recombinant protein in T cell 
recruitment was tested analogous to the assays described above for NK cells. Primary microvascular 
endothelial cells were treated with 0.23 nM CXCL10-mucin-GPI, identically diluted sEGFP-GPI or 
commercially available CXCL10 at either the same concentration as the GPI-anchored CXCL10 protein 
or at a much higher one in order to detect even small effects of the soluble protein. Subsequently, 
cells of the human CD8+ T cell line DS4, which had been demonstrated to be highly CXCR3-positive by 
FACS analysis (see 3.2.1 and data not shown), were perfused over the endothelial cells with the 
physiologic shear rate of 1 dyn/cm2. In these experiments, however, no significant adhesion to the 
endothelial cells could be detected (data not shown). For this reason, the shear rate was lowered to 
0.4 dyn/cm2, as it had been shown earlier (e.g. see 3.6.3) that this subphysiologic shear rate can 
considerably increase the numbers of adhering cells and should therefore allow to detect even small 
effects. Figure 24 summarizes the results of two independent experiments performed at 
0.4 dyn/cm2, with each dot representing one individual sample. 
The figure shows background adhesion of approximately 10 cells/mm2 in all treatment conditions, 
which could be attributed to the subphysiologic flow rate. However, CXCL10-mucin-GPI was not 
superior to the other proteins in the recruitment of T cells. In fact, none of the treatments was able 
to significantly augment cell adhesions. This finding was in contrast to the results presented in 3.2.3, 
where CXCL10-mucin-GPI expressed on CHO cells had shown at least a trend towards being able to 
recruit freely flowing T cells of the same cell line as the one used in the experiment described here. 
The explanation for this divergence may possibly be found in the surface levels of CXCL10-mucin-GPI. 
Clearly the levels of the protein were much lower on “painted” endothelial cells than on CHO cells 
expressing the construct. Thus, the amount of protein present on treated endothelial cells may have 
been too low to induce T cell adhesion, although it was able to efficiently induce NK cell adhesion.  
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The assumption that T cells required relatively high degrees of chemokine stimulation were further 
corroborated by another experiment, where human umbilical vein endothelial cells (HUVEC) were 
used. Manes et al. demonstrated that CXCL10 can induce rapid transendothelial migration (TEM) of 
T cells through a monolayer of TNFα-stimulated HUVEC using a similar system of physiologic flow 
(Manes et al. 2006). Thus, although directed at a different step of leukocyte recruitment, the 
advantage of this assay was that a direct positive control (commercially available CXCL10) was 
available. In this assay, only high concentrations of commercially available CXCL10 (115 nM) were in 
our hands efficient in increasing TEM, while concentrations identical to that of CXCL10-mucin-GPI 
used in the experiments (0.92 nM) were not. The same was true for CXCL10-mucin-GPI itself (data 
not shown). It was therefore concluded that either CXCL10-mucin-GPI was ineffective with regards to 
T cell recruitment or (rather) the amounts of CXCL10-mucin-GPI protein that could be transferred 
onto endothelial cells in vitro using the available purification methods were not sufficient to induce a 
significant effect in T cells. Possible ways to overcome this problem will be discussed in 4.5 and 5.5. 
3.7 CXCL10-mucin-GPI can enhance intratumoral leukocyte recruitment in vivo 
A model based on subcutaneously transplantable tumors was used to study the effects of CXCL10-
mucin-GPI after intratumoral injection in vivo. The experiments were performed in collaboration with 
L. Bankel from the Helmholtz Zentrum Munich. Cells of the 291 B cell lymphoma line were used as a 
 
Figure 24: CXCL10-mucin-GPI fails to recruit T cells under conditions of flow. Primary microvascular 
endothelial cells were incubated with 0.23 nM CXCL10-mucin-GPI or sEGFP-GPI which had been 
identically diluted in culture medium. Additional samples were treated with commercially available 
soluble CXCL10 (rhCXCL10), either at the same or at 250 x higher concentration. All samples 
contained the same percentage of chromatography buffer. Subsequently cells of the human T cell 
line DS4 were perfused over the endothelial cells with a shear rate of 0.4 dyn/cm2 and tightly 
adherent cells were counted. Data are presented from two independent experiments, each dot 
representing one independent slide and horizontal bars the average values.  
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model system, which have been isolated from a transgenic C57/Bl6 mouse carrying the c-myc 
oncogene under the control of the Igλ promoter. The tumor cells were demonstrated to be negative 
for CXCR3 by FACS and reverse transcriptase real-time PCR (data not shown). This was a prerequisite 
for their use as model system for the CXCL10 fusion proteins as binding of the proteins to tumor cell 
chemokine receptors should be avoided. The cells were injected into the flanks of wildtype C57/Bl6 
mice. Wildtype mice were used as recipients to ensure a normal immune response, despite the 
general artificiality of a transplantable tumor model. In pilot experiments, it was found that 107 
tumor cells were required to induce robust tumor growth, allowing to conduct experiments 
approximately 10 days after tumor injection. For a general characterization of the tumor tissue, 
tumors were excised and subjected to hematoxylin/eosin staining (H/E) or immunohistology for CD3 
and NKp46 as described in 2.2.6.3. Representative images are shown in Figure 25. 
 
 
Figure 25: Subcutaneously implanted tumors of the 291 cell line are well vascularized and show a 
pronounced infiltration with T cells. Tumor cells (107 cells) were injected subcutaneously into the 
flanks of wildtype C57/Bl6 mice. Grown tumors were excised, fixed and analyzed by 
hematoxylin/eosin (H/E) staining or immunohistology using antibodies against CD3 or NKp46. The 
respective magnifications are indicated at the top of each image. Panels A and B show the presence 
of numerous blood vessels (arrows) throughout the tumors in H/E staining. Panels D, E and F 
represent serial sections of the same position within a tumor. Various blood vessels are visible in H/E 
staining and the CD3 staining shows infiltration of the tumor with CD3+ cells (dark grey/ black 
staining). Less NKp46+ cells could be detected in the respective staining of the same position (dark 
grey/ black staining; one cell is marked by an arrow). Panel C depicts a cluster of NKp46+ cells, which 
could sometimes be found at the margins of tumors (margin: upper part of the picture). 
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The tumors were mostly well vascularized with a relatively high number of blood vessels visible in 
H/E staining as depicted in panels A and B and usually displayed little signs of necrosis such as loss of 
nuclear staining. Panels D, E and F represent serial sections of a position near the tumor center. 
Various blood vessels could be seen, and CD3 staining showed marked infiltration of the tumor mass 
with T cells in the vicinity of the blood vessels. NKp46 staining of the same position revealed a much 
lower infiltration with NK cells compared to CD3+ cells. This finding was true for all untreated tumors, 
where a much more pronounced infiltration of the tumor with CD3+ than NKp46+ cells was seen. At 
the tumor margins, however, occasionally clusters of NKp46+ cells could be found, as exemplified in 
panel C. These clusters contained only few CD3+ cells (data not shown). In summary, CD3+ cells were 
found relatively equally distributed throughout the tumors, while NKp46+ cells sometimes displayed 
a highly unequal distribution. For this reason, it was chosen to analyze the infiltration of the tumors 
by NK cells with FACS analysis in order to avoid skewing of the results by biased image acquisition in 
histology, while infiltration with CD3+ cells could be assessed by immunohistological staining of 
tumor sections.  
3.7.1 Injection of CXCL10-mucin-GPI moderately increases T cell infiltration 
Protein injections were performed to analyze the effect of CXCL10-mucin-GPI on the infiltration of 
tumors with T cells and NK cells. Once the tumors had grown to a size that technically allowed 
injection of the proteins (about 5 mm in diameter), 0.23 pmol of CXCL10-mucin-GPI or the same 
molar amount of commercially available CXCL10 were injected into the center of the tumors in a 
volume of 50 µl. As controls, equally purified sEGFP-GPI protein or a 500 x higher molar amount of 
commercially available CXCL10 (115 pmol) were injected also in a volume of 50 µl. All proteins were 
diluted in PBS + 0.025% Triton X-100h to exclude buffer artifacts. It was taken care that the various 
treatment conditions were equally distributed over larger and smaller tumors. Four hours after the 
injections, the animals were sacrificed and the tumors excised. This time point was selected as it had 
been found to be the one where injection of commercially available CXCL10 had the most potent 
effect (data not shown). Half of each tumor was subjected to FACS analysis, the results of which will 
be shown in 3.7.2, and the other half was fixed in formalin for immunohistology. All tumors were 
embedded in the same orientation and sections were made perpendicular to the surface where the 
tumors had been bisected, so that center and margin of each tumor could easily be identified. The 
sections were stained immunohistologically to identify CD3+ cells and three low-power images (100 x 
magnification) of each section were taken at the tumor center, the margin and in between these two 
positions. The numbers of CD3+ cells in each image were counted by an observer blinded to the 
experimental conditions and averages were calculated for each tumor. The results are presented in 
Figure 26, with each symbol representing the averaged values of one tumor.  
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The cell counts showed no pronounced differences between the single treatments, which had 
already been anticipated from the in vitro results presented in 3.6.4. Moreover, a high basal level of 
infiltration was found already in completely untreated tumors (on average 183 cells per low power 
field; also compare the high power microscopic image depicted in 3.7), indicating a preexisting strong 
stimulus for T cell infiltration. This pronounced basal infiltration of course made it more difficult to 
assess potential interventional strategies to further enhance T cell infiltration. Nevertheless, tumors 
treated with CXCL10-mucin-GPI showed a small trend towards higher infiltration (on average 301 
cells per low power field), which could not be reached by commercially available CXCL10 even at 
500 x higher molar quantities (on average 237 cells per low power field). The cell counts in tumors 
treated with 0.23 pmol commercially available CXCL10 or sEGFP-GPI (188 and 207 cells per low 
power field, respectively) were similar to the counts in untreated tumors. Of note, the data 
presented here are of preliminary nature and further experiments with larger sample sizes will be 
needed to draw definitive conclusions. 
In many tumor sections secondary lymphoid organs were observed at the tumor margins, which had 
been resected together with the tumors. These organs naturally contain large numbers of CD3+ cells 
and were omitted in the cell counts presented above. However, the presence of these organs 
 
Figure 26: Injection of CXCL10-mucin-GPI tends to moderately increase T cell infiltration of 
subcutaneous tumors. Purified CXCL10-mucin-GPI (0.23 pmol) was injected into subcutaneously 
implanted 291 tumors. As controls, either the same or a 500 x higher molar quantity (115 pmol) of 
commercially available human CXCL10 (rhCXCL10) were injected. Additional controls included 
completely untreated tumors and injection of the same volume of identically purified sEGFP-GPI. All 
injections were done using the same volume and the same buffer. The animals were sacrificed 4 h 
after injection and tumor sections were stained immunohistologically to detect CD3+ cells. The 
numbers of cells in three low power fields per tumor were counted by an observer blinded to the 
experimental conditions and averaged. Each symbol represents averaged values for one tumor.  
 
Results   85 
rendered the analysis of T cell infiltrations generated by FACS uninformative, which is why these 
results are not presented here. In order to assess the influence of this finding on the analysis of NK 
cell infiltrations by FACS, tumor sections containing the described organs were stained for the 
presence of NKp46+ cells. This revealed that only very few NKp46+ cells were present in these 
structures, which should therefore not interfere with FACS analysis (see 5.3).  
3.7.2 Injection of CXCL10-mucin-GPI leads to NK cell accumulation 
In order to analyze infiltration by NK cells, half of each tumor treated as described above was 
analyzed by FACS (performed by L. Bankel, Helmholtz Zentrum Munich). NK cells were defined as 
CD3- NK1.1+ cells and the percentage of NK cells among the total number of cells was used for 
evaluation rather than absolute values in order to compensate for the slightly different sizes of the 
tumors. Figure 27 summarizes the results for the various treatment conditions, with each symbol 
representing one individual tumor and horizontal bars the average values. 
The analysis revealed the presence of NK cells in the tumors at ratios ranging from 0% to 0.55%. The 
Kruskal-Wallis test showed that the mean ranks of all treatment groups did not differ significantly 
from each other (P = 0.19), although Dunn´s post test indicated a significant difference between 
untreated tumors and such treated with CXCL10-mucin-GPI. Nevertheless, clear trends were evident 
despite the lack of statistical significance. Based on the average values, tumors treated with CXCL10-
mucin-GPI harbored higher numbers of NK cells (0.34%) than tumors that had received any of the 
 
Figure 27: Injection of CXCL10-mucin-GPI increases NK cell infiltration of subcutaneous tumors. 
Subcutaneous tumors were implanted and treated as described in the legend of Figure 26. Following 
resection, infiltration of the tumors was assessed by FACS analysis. The figure shows the percentage 
of CD3- NK1.1+ cells among the total cell count with each symbol representing one individual tumor 
and horizontal bars the average values. Statistical significance was calculated using the Kruskal-
Wallis-test (P = 0.19) followed by Dunn´s post test. 
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other treatments. Tumors injected with the same molar amount of commercially available CXCL10 
contained on average only half as many NK cells (0.16%) as CXCL10-mucin-GPI treated tumors. Also 
500 x higher molar amounts of commercially available CXCL10 were on average less efficient (0.24%) 
than CXCL10-mucin-GPI.  
In summary, CXCL10-mucin-GPI was much more efficient in recruiting NK cells into tumors in vivo 
than commercially available CXCL10 or the GPI-anchored negative control protein sEGFP-GPI. The 
differences between the differently treated tumors were also much higher for NK cells than for 
T cells, which might be based on the lower background degree of infiltration by NK cells or on the 
higher chemokine signal strength required for T cell recruitment as detailed in 3.6. In order to 
generate statistically significant conclusions, however, further experiments with higher sample sizes 
will be performed in future studies.  
Taken together, CXCL10-mucin-GPI showed a modest trend towards being able to recruit T cells after 
intratumoral injection, and a much stronger trend with regards to NK cells. The average efficiency of 
CXCL10-mucin-GPI was orders of magnitude higher than the efficiency of the soluble natural CXCL10 
chemokine based on the concentrations required to generate a robust infiltration. Thus, the CXCL10-
mucin-GPI agent developed in this study might be used to strengthen the infiltration of tumors with 
NK cells, potentially also in an adjuvant setting to adoptive NK cell therapy.  
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4 Discussion 
Chemokines are a family of chemotactic cytokines that direct the migration of cells. Since cellular 
migration plays a central role in many human diseases, therapeutic tools to modify chemokine 
signaling networks have been studied by many researchers, mostly with the aim of suppressing 
recruitment of select cell types (Mackay 2008; Proudfoot et al. 2010). In the present study, a novel 
approach to modify tissue micromilieus was developed that in contrast allowed selective recruitment 
of cells carrying specific chemokine receptors. The approach was based on fusion proteins consisting 
of an N-terminal chemokine head, linked to the mucin-like domain taken from CX3CL1, with a 
C-terminal GPI anchor replacing the CX3CL1 transmembrane domain. According to the underlying 
hypothesis, the recombinant proteins should integrate by means of their GPI anchor into virtually 
any cell membrane when injected into a tissue (Medof et al. 1996). On cell membranes of endothelial 
cells, the mucin domain in combination with the chemokine should assist in the recruitment of cells 
carrying the receptor for the respective chemokine from the blood stream. In the tissue itself, the 
proteins would generate a stable haptotactic gradient that could be used by recruited cells to 
migrate towards the injection site. This novel type of reagents has diverse potential applications 
ranging from regenerative medicine, e.g. in the context of myocardial infarction where endothelial 
progenitor cells need to be recruited, to cancer therapy, where tumor infiltration with anti-neoplastic 
effector cells needs to be enhanced.   
In the present study, first examples of fusion proteins were designed and tested in order to 
investigate the feasibility of this approach. The proteins were designed for an application in cancer 
therapy, especially as adjuvants to adoptive cell transfer. This adoptive transfer of immune effector 
cells (T cells or NK cells) has proven efficacy under some circumstances and thus holds promise for 
the development of future cancer therapies [reviewed in (June 2007) and (Levy et al. 2011)]. 
However, one of the major hurdles for a broader application of this treatment modality lies in 
insufficient infiltration of the tumors by the adoptively transferred cells (Pockaj et al. 1994; Griffioen 
et al. 1999; Mukai et al. 1999; Dirkx et al. 2003; Shrimali et al. 2010). The fusion proteins described in 
the present study were designed to help overcome this hurdle through selective modification of the 
tumor micromilieu. To this end, a CXCL10 chemokine head was used in the proteins (the primary 
protein thus being termed CXCL10-mucin-GPI) because this chemokine acts on cytotoxic effector 
cells like CD8+ T cells and NK cells that express the CXCR3 receptor. A second set of proteins 
containing the CXCL8 chemokine, specific for a subset of highly cytotoxic CD8+ T cells and 
neutrophils, was additionally generated and characterized as described in 5.1. Thereby, the 
applicability of the general concept to a broader perspective should be assessed, at least with 
regards to technical issues.  
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4.1 The recombinant fusion proteins can be expressed in eukaryotic cells 
Expression of the recombinant fusion proteins represented an important step because bioactivity, 
especially of the chemokine fusion proteins, could only be assured if the proteins were correctly 
processed. In addition to correct three-dimensional folding of the proteins, necessary processing 
steps involved glycosylation of the mucin domain, cleavage of the N- and C-terminal signal sequences 
at the correct positions, and subsequent transfer of the proteins to a preformed GPI anchor. The 
latter step precluded the use of a prokaryotic expression system and among the many eukaryotic 
expression systems, Chinese hamster ovary (CHO) cells were chosen for several reasons. First, as they 
are derived from a mammalian host, CHO cells display a glycosylation pattern similar to that of 
human cells (Hossler et al. 2009), which might be important for the architecture and stability of the 
mucin domain. Second, CHO cells are already being used for the production of many protein-based 
drugs in large scale, which could facilitate the transfer of the approach described here to clinical 
studies (Wurm 2008).  
Following transfection, the recombinant GPI-anchored fusion proteins were detected on the CHO cell 
surfaces by FACS staining. Monoclonal antibodies against various subunits of the proteins 
(chemokine head, mucin domain and c-myc epitope tag) were used in order to ensure that all parts 
were correctly expressed. For the sEGFP-GPI control protein, the protein´s autofluorescence could 
easily be detected, implicating that the addition of a GPI anchor did not compromise the architecture 
of the protein. The subcellular localization of the expressed proteins was determined by immuno-
fluorescence microscopy and a membrane-associated staining pattern could be observed. These 
findings indicated that the proteins had been correctly targeted to the cell membrane by the addition 
of a GPI anchor signal sequence.  
In addition to proper anchoring of the proteins, another concern was the correct cleavage of the N-
terminal secretion signal sequence. This sequence is normally cleaved from the nascent proteins 
during synthesis in the ER, thereby generating the mature N-terminus of the respective protein. 
Cleavage of the chemokine heads had to occur at precisely the correct site as the N-terminal amino 
acid sequence is vitally important for the physiologic activity of chemokines (Proudfoot et al. 1996). 
Therefore, the N-terminal amino acid sequence of one of the CHO-cell expressed chemokine fusion 
proteins was verified by Edman sequencing. This analysis revealed that the N-terminus was identical 
to that of commercially available CXCL10 which had been proven to be bioactive. This finding was 
complemented by several experiments, which at later stages showed bioactivity of the GPI-anchored 
proteins. Thus, it was assumed that the N-termini of all of the recombinant CXCL10 fusion proteins 
were correctly processed by the CHO cells.  
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4.2 The GPI-anchored CXCL10 fusion proteins are bioactive as they can trigger 
CXCR3 
Prior to their purification, the bioactivity of the expressed proteins was tested as described in 3.2. 
Due to the lack of direct assays assessing the bioactivity of the mucin domain, the activity of this 
domain could only be tested indirectly at later stages of the project by comparisons between the 
protein containing the mucin domain and the one that did not. However, a series of experiments 
were performed to investigate the bioactivity of the chemokine heads of CXCL10-GPI and CXCL10-
mucin-GPI as the three-dimensional arrangement of various parts of the CXCL10 structure is required 
for efficient receptor binding. Interactions of CXCL10 with the CXCR3 receptor are mediated by 
amino acids at or near the N-terminus, in the N-loop preceding the first beta-sheet, in the 30s loop 
between the first and the second beta-sheet and within the second beta-sheet, and all these amino 
acids have to be in the correct three-dimensional arrangement (Booth et al. 2002). In contrast, the 
mucin domain can be completely replaced by non-related protein modules without impairing CX3CL1 
function (Fong et al. 2000). Of note, amino acids at similar positions were found to be involved in 
receptor binding by the similarly structured CX3CL1 chemokine domain, underlining from a molecular 
standpoint the possibility to functionally replace the CX3CL1 chemokine head with a CXCL10 head 
(Mizoue et al. 1999). 
Internalization of the CXCR3 receptor upon chemokine triggering was assessed as a first readout of 
bioactivity. Most chemokine receptors are internalized after triggering (Borroni et al. 2010), and 
subsequently either recycled to the cell membrane as is seen with CCR5 (Signoret et al. 2000), or 
degraded in the lysosomal pathway as it is the case for CXCR3 (Meiser et al. 2008). Because the 
proteins designed here are surface bound, a modified assay was developed to measure potential 
internalization of CXCR3. In this assay, CHO cells expressing the GPI-anchored CXCL10 fusion proteins 
were coincubated with CXCR3-positive human T cells. The presence of CXCR3 on the T cells was 
subsequently tested by FACS, where a pronounced reduction of the CXCR3 surface levels was 
observed. Normal soluble CXCL10, which was used as positive control, lead to identical results, while 
incubation at 4°C instead of 37°C much attenuated internalization, indicating an active process. 
CXCR3 internalization could not be inhibited by pertussis toxin, an inhibitor of signal transduction by 
G protein coupled receptors. The fact that pertussis toxin can inhibit CXCR3-mediated chemotaxis 
and calcium mobilization, but not internalization has been previously published (Sauty et al. 2001). 
Mutagenesis analyses have shown that the amino acids in CXCR3 required for internalization differ 
from the ones required for calcium mobilization and chemotaxis (Colvin et al. 2004). Thus, 
independent signaling pathways are thought to mediate these effects.  
The question arises how CXCR3 could be internalized when it was bound to a construct anchored to 
the cell membrane of a neighboring cell. CXCR3 has however been shown to be internalized after 
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contact with CXCL10 immobilized on glycosaminoglycan (GAG) molecules (Sauty et al. 2001). 
Importantly, the internalization observed in the present study indicated that the physical connection 
between the T cells and the CHO cells could be dissociated. This might be beneficial as in the context 
of facilitated recruitment of leukocytes by the fusion proteins, efficient binding of the leukocytes 
would be as important as their subsequent release, because the latter would allow diapedesis and 
migration of recruited leukocytes.  
Cytoplasmic calcium mobilization in T cells was used as a second means of verification of bioactivity. 
As detailed above, this signaling is thought to be mediated by a second set of signal transduction 
pathways. Here, chemokine receptor triggering leads to activation of phospholipase C-β, which in 
turn generates diacyl glycerol and inositol 1,4,5-trisphosphate. The latter then acts on ligand-gated 
calcium channels in the ER, inducing release of calcium into the cytosol (Wu et al. 2000). To assess 
the activation of this signaling cascade, T cells were loaded with a calcium-sensitive fluorescent dye 
and coincubated with CHO cells expressing the GPI-anchored CXCL10 fusion proteins. The 
fluorescence was continuously measured and normalized against a sample with non-transfected CHO 
cells. A transient rise in the fluorescence signal over the course of 40 min was found.  
The observed curves presumably represent transient activation of single T cells within the total cell 
population, each resulting in a short-lived fluorescence signal until eventually all T cells had been 
desensitized for CXCL10. The cell-cell contact required for this signaling resulted in a time course 
kinetic differing from that seen with soluble proteins. The fluorescence signals occurred earlier and 
slightly stronger when T cells were coincubated with CHO cells expressing CXCL10-mucin-GPI as 
compared to the CXCL10-GPI transfected cells. Thus, the mucin domain appears to have enhanced 
the interaction of the chemokine domain with the CXCR3 receptor. Interestingly, a second, smaller 
fluorescence peak was observed for both CXCL10 fusion proteins from 40 min to about 60 min (data 
not shown). This second peak may represent replenishment of surface CXCR3 in the T cells triggered 
at the beginning of the incubation time.  
Chemokine receptor signaling in leukocytes also leads to the activation of integrin molecules. The 
activated high-affinity integrins then allow the leukocyte to more efficiently adhere to immuno-
globulin superfamily molecules such as ICAM-1 or VCAM-1 [reviewed in (Laudanna and Alon 2005)]. 
In studies by Piali and coworkers, IL-2 activated T cells were left to adhere in the presence of CXCL10 
to immobilized ICAM-1 or VCAM-1 under static conditions and CXCL10 was shown to increase T cell 
adherence, with maximal activation occurring after 3-10 min (Piali et al. 1998). 
Similar experiments were performed as a third assay of bioactivity. T cells were left to adhere under 
static conditions to monolayers of transfected CHO cells. Non-adherent or loosely adherent cells 
were washed away using a physiologic shear rate of 1 dyn/cm2. Significantly more T cells remained 
adherent to CXCL10-mucin-GPI transfected CHO cells than to cells expressing the negative control 
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protein sEGFP-GPI. CXCL10-GPI transfected cells showed a clear positive trend, but were less efficient 
than cells expressing CXCL10-mucin-GPI. The presence of the mucin domain thus played a role in the 
adhesion process, as T cell counts were higher on cells expressing the CXCL10 fusion protein 
containing this domain as compared to cells expressing only membrane-anchored CXCL10. Based on 
the calcium mobilization experiments, it appeared that the CXCR3 receptor was more efficiently 
triggered by the CXCL10 protein presented by the mucin domain. In subsequent laminar flow assays 
however, CXCL10-mucin-GPI was also found to directly enhance leukocyte binding under flow (see 
below). Thus, adherence to CXCL10-mucin-GPI transfected CHO cells may in part have been mediated 
by this effect. In future studies, antibodies able to detect activated integrins or block their activity 
can be used to dissect the effects of leukocyte activation from direct binding to CXCL10-mucin-GPI.  
In summary, the described in vitro experiments showed on multiple levels that the GPI-anchored 
CXCL10 fusion proteins were able to efficiently induce CXCR3 signaling. Thus, the structure of the 
chemokine domain was not compromised by fusing it to the mucin domain of CX3CL1, an important 
prerequisite for the applicability of the proteins. 
4.3 The recombinant fusion proteins can be purified by affinity chromatography 
In the next phase of the study, the recombinant proteins were purified from CHO cell extracts. Since 
the proteins were anchored to the cell membranes via a hydrophobic GPI anchor structure, 
detergents had to be used to allow solubilization of the proteins. An assay was established based on 
works by Bumgarner and colleagues that allowed direct quantification of the relative amounts of 
solubilized and non-solubilized proteins following the application of different detergents (Bumgarner 
et al. 2005). In these experiments, n-Dodecyl-β-D-maltoside (DDM) proved to be most efficient in 
solubilizing all GPI-anchored proteins under study. The fact that other commonly used detergents 
such as Triton X-100 were less efficient is not surprising as GPI-anchored proteins are known to 
associate with cholesterol-rich microdomains within the cell membrane, which may cause resistance 
to solubilization with weak detergents such as Triton X-100 (Cerneus et al. 1993; Schroeder et al. 
1998). In addition, DDM is a gentle detergent commonly used for solubilizing membrane proteins in 
their native state, both for crystallization and functional studies (Wiener 2004; Reisinger and 
Eichacker 2008). Notably, identical results were also obtained with proteins containing a CXCL8 
chemokine head (see 5.1), suggesting that DDM may be generally applied for the solubilization of this 
novel class of reagents. This might facilitate broader application of the technique.  
Considerable efforts were made to develop robust purification protocols for the GPI-anchored 
chemokine fusion proteins without the use of an affinity tag.  As chemokines bind strongly to GAG 
molecules, heparin affinity chromatography was applied, as well as anion and cation exchange 
chromatography. However, no combination of these methods yielded pure enough protein 
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preparations for cell painting. Purification factors were generally too low, and enhanced aggregation 
phenomena were observed that were associated with the changes in salt concentration used during 
the various elution steps. In addition, attempts to generate custom-built affinity resins using 
antibodies against the chemokine domain (e.g. for the CXCL8 fusion proteins) failed because the 
proteins bound too strongly to the antibodies, resulting in extremely poor recovery rates (these 
methods typically require special antibodies with low avidity). Therefore it was decided to integrate 
an affinity tag into the constructs. The choice of a suitable tag was complicated by the GPI anchor at 
the C-terminus and the need for an untouched N-terminus to preserve chemokine activity. 
Therefore, most commonly used protein tags that are attached at either the N- or the C-terminus 
could not be used. Cleavable N-terminal tags would have had to be integrated between the secretion 
signal sequence and the first amino acid of the mature chemokine, which proved technically difficult. 
Most cleavable tags also leave one or two amino acids behind at the N-terminus after cleavage, 
which was not acceptable with regards to chemokine function. For these reasons, the c-myc epitope 
tag was chosen as it could be integrated internally into the proteins preceding the GPI anchor, a 
commercially available affinity resin was available for purification and monoclonal antibodies were 
available for detection purposes. Through use of the commercially available affinity resin, sufficiently 
pure protein preparations were obtained that allowed subsequent functional studies. The proteins 
were not purified to homogeneity, but very pure protein preparations can enhance protein 
degradation and aggregation (Bondos and Bicknell 2003; Cromwell et al. 2006), the latter being a 
tendency which is strongly inherent to both membrane proteins and chemokines (Luster et al. 1995). 
Therefore, some level of impurity was acceptable for the purposes of the present study, also as 
impurities in the protein preparations could effectively be controlled by using the identically purified 
sEGFP-GPI control protein. Importantly, the purification protocol could be applied for the purification 
of all of the CXCL10 fusion proteins, the CXCL8 fusion proteins (compare 5.1) and the sEGFP-GPI 
control protein. Thus, the use of the c-myc epitope tag could greatly facilitate the expansion of the 
basic concept described in the present study to a broader context.  
4.4 Purified GPI-anchored proteins can be used to paint primary endothelial cells 
When untransfected CHO cells or endothelial cells were incubated with purified GPI-anchored fusion 
proteins, the proteins were incorporated into the target cell membranes as determined by surface 
staining using either FACS or immunofluorescence microscopy. Incorporation occurred only with GPI-
anchored proteins and was therefore not due to interactions with cell surface molecules. This is at 
first sight in contrast to the fact that some endothelial cells are able to immobilize chemokines on 
their surface via GAG molecules - an essential prerequisite for leukocyte recruitment. However, the 
required GAG molecules are generally only upregulated as response to inflammatory stimuli (von 
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Hundelshausen et al. 2001). For example, we could detect binding of soluble CXCL10 to primary 
endothelial cells only after their pre-activation using IL-1β or TNF-α. Therefore, in our studies the GPI 
anchor was included to help facilitate the presentation of the chemokine fusion proteins on 
unactivated endothelial cells or tumor endothelial cells. Of note, GAG molecules required for normal 
chemokine presentation are often dysregulated in tumor endothelial cells, underlining the need for a 
GPI anchor for the proteins to function in a tumor setting (Sanderson et al. 2005).  
As a second proof of the GPI anchorage, “painted” endothelial cells were treated with phosphatidyl-
inositol-specific phospholipase C (PI-PLC), an enzyme which cuts the GPI anchor structure, thereby 
releasing the proteins from the cell surface. This treatment markedly reduced the surface signal after 
incorporation, verifying GPI anchorage of the proteins. The fact that the proteins could not be 
entirely removed from the cell surface by PI-PLC treatment may be explained by the relatively low 
enzyme concentration used in the experiments or by oligomerization effects of the incorporated 
proteins leading to retention of the protein complex on the surface.  
4.5 CXCL10-mucin-GPI can recruit leukocytes in vitro 
The central hypothesis of the present study was that CXCL10-mucin-GPI would, when it is injected 
into a tissue, integrate into cell membranes and enhance the recruitment of leukocytes carrying the 
CXCR3 receptor. Laminar flow assays were performed in order to test this hypothesis in a defined in 
vitro system. These assays were based on microscopic channels of rectangular geometry, in which 
the conditions found in the postcapillary microvascular bed could be closely mimicked. Primary 
microvascular endothelial cells were grown in the channels, pretreated with purified proteins and 
leukocytes were then perfused over the endothelial cell monolayer at a defined shear stress. Real-
time video microscopy allowed the identification and categorization of adhesive events occurring 
between the leukocytes and the endothelial cells.  
All assays were performed with non-activated, resting endothelial cells that normally do not support 
leukocyte adhesion, because CXCL10-mucin-GPI was designed to work under conditions where 
leukocyte recruitment is defective due to endothelial cell anergy. This is a phenomenon associated 
with tumor endothelium where upregulation of adhesion molecules on endothelial cells in reaction 
to proinflammatory cytokines fails, allowing the endothelial cells to remain in a resting-like state, and 
forcing interventional strategies to be efficient without endogenously upregulated endothelial 
adhesion molecules (Griffioen et al. 1996a; Griffioen et al. 1996b; Griffioen et al. 1998; Tromp et al. 
2000; Dirkx et al. 2003).  
Flow experiments were performed using NK cells as well as T cells as model leukocytes because both 
cell types have important functions in tumor rejection, and are potential targets of the CXCL10 
chemokine fusion proteins. Studies involving NK cells were mostly performed using the human NK 
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cell line YT. Here it could be shown that endothelial cells treated with less than 1 nM CXCL10-mucin-
GPI acquired the ability to bind freely flowing NK cells under conditions of physiologic flow, leading to 
an accumulation of NK cells on the endothelial cell layer. In contrast, NK cells did not adhere to 
endothelial cells treated with the sEGFP-GPI negative control protein, indicating that potential 
byproducts of the protein purification procedure or the incorporation of a GPI-anchored protein per 
se did not activate the endothelial cells in terms of adhesion molecule induction. Also CXCL10-GPI, a 
fusion protein lacking the mucin domain, could not induce significant amounts of adhesion. The 
presence of the mucin domain thus plays a central role in the recruitment of leukocytes by CXCL10-
mucin-GPI. Treatment of the endothelial cells with soluble CXCL10, even at much higher concen-
trations than the GPI-anchored proteins, did also not induce adhesion of NK cells. This indicated that 
CXCL10 itself did not lead to an activation of the endothelial cells in terms of upregulation of 
adhesion molecules.  
Nevertheless, the GPI-anchored CXCL10 fusion proteins may still have direct effects on endothelial 
cells with regards to proliferation and angiogenesis as CXCL10 is known to efficiently inhibit both 
processes (Angiolillo et al. 1995; Luster et al. 1998; Romagnani et al. 2001; Lasagni et al. 2003; 
Feldman et al. 2006; Campanella et al. 2010). Inhibition of angiogenesis can in turn control tumor 
growth, suggesting a potential additive antitumor effect of CXCL10-mucin-GPI. In mouse models it 
has recently been shown that angiostatic therapy can synergize with adoptive T cell therapy, leading 
to significantly enhanced tumor growth inhibition (Shrimali et al. 2010; Dings et al. 2011). A first 
indication for an antiproliferative activity of the CXCL10 fusion proteins was found in the present 
study when it was attempted to express CXCL10-GPI and CXCL10-mucin-GPI in endothelial cells. The 
expression of both proteins lead to a dramatically reduced proliferation in combination with a high 
rate of apoptosis, suggesting an inhibitory effect of the proteins on endothelial cell growth (data not 
shown). Thus, in CXCL10-mucin-GPI, the angiostatic activity of CXCL10 might synergize with the 
effects on leukocyte recruitment, making this reagent even more attractive for tumor therapy. 
In the present study, no construct was generated that expressed the mucin domain alone without 
any chemokine head. Thus, it cannot be excluded that the observed effects were generated by the 
mucin domain itself rather than by the combination of a chemokine with the mucin domain. 
However, in previous studies it has been shown that the mucin domain alone does not have an effect 
on leukocyte recruitment (Imai et al. 1997; Fong et al. 2000). In addition, the CX3CL1 mucin domain 
can be functionally replaced with unrelated protein modules, as long as the chemokine domain is still 
protruded away from the cell membrane (Fong et al. 2000), making it unlikely that the mucin domain 
itself is responsible for the observed effects.   
It was found that CXCL10-mucin-GPI was able to induce both rolling and tight adhesion of NK cells. 
This was an important finding as tight adhesion is considered to be a prerequisite for diapedesis of 
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leukocytes through the endothelium, which represents the final step of the recruitment cascade 
(Springer 1994). In combination with the results described in 3.2, where it was shown that the 
chemokine domain of the recombinant CXCL10 fusion proteins was able to stimulate the CXCR3 
receptor on leukocytes, it seems possible that the observed tight adhesion to the endothelium was 
mediated in part by activation of the NK cells through the chemokine head leading to increased 
integrin affinity, while the presence of the mucin domain was required to initiate rolling adhesion. 
Of note, this finding is in contrast to observations made with CX3CL1 itself. CX3CL1 directly induces 
tight adhesion in leukocytes, without involving rolling adhesion (Haskell et al. 1999). In addition, 
CX3CL1 does not upregulate integrin affinity, and adhesion between CX3CL1 and CX3CR1 works in 
the presence of pertussis toxin or when CX3CR1 is mutated so that it cannot transmit intracellular 
signals, underlining the independence of this protein pair from other adhesion molecules (Haskell et 
al. 1999). Haskell and colleagues have shown that this complete independence from other adhesion 
molecules does not necessarily hold true for combinations of other chemokines with the CX3CL1 
mucin domain (Haskell et al. 2000). Under flow, such fusion proteins were all less efficient in binding 
leukocytes than the original CX3CL1 protein. However, Haskell et al. performed experiments with 
purified proteins immobilized on glass slides in the absence of other ligands such as ICAM-1. We also 
performed experiments in which the soluble CXCL10-mucin-Stop protein was immobilized on a glass 
surface. These experiments failed to demonstrate significant functionality of CXCL10-mucin-Stop 
alone (data not shown). Considering that in the present study CXCL10-mucin-GPI was found to be 
highly effective in an endothelial cell context, it seems likely that recombinant chemokine/mucin 
domain fusion proteins rely at least in part on the upregulation of integrin affinity by the chemokine 
head and require the presence of some degree of integrin counterparts on the endothelial side to 
convert rolling adhesion induced by the mucin domain into tight adhesion. Closer investigation of the 
differences between the mechanisms of adhesion induced by chemokine/mucin domain fusion 
proteins and the original CX3CL1 chemokine will be performed in future studies.  
Another aspect influencing the efficiency of CXCL10-mucin-GPI is the cell type under study. While the 
protein was highly efficient in recruiting NK cells, no significant in vitro activity could be 
demonstrated when CD8+ T cells were used. At physiologic flow, no adhesion of T cells to endothelial 
cells treated with CXCL10-mucin-GPI could be detected and even when the flow rate was lowered to 
subphysiologic levels, the number of adhesions observed with CXCL10-mucin-GPI did not differ from 
those observed with the control proteins. Of note, in this case the absolute numbers of adherent 
T cells were similar to the numbers of NK cells adhering at the same flow rate to endothelial cells 
treated with the control proteins, indicating that no general adhesion defect was present in the 
T cells. Little is known about the differences between NK cells and T cells regarding chemokine-
mediated recruitment mechanisms at physiologic flow. To our knowledge no studies have been 
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published directly comparing these two cell types in vitro. In principle NK and T cells follow the 
classical scheme of leukocyte recruitment mediated by selectins, chemokines and integrins in 
combination with immunoglobulin superfamily molecules, although much more is known about 
T cells than NK cells (Bianchi et al. 1993; Laudanna and Alon 2005; Grégoire et al. 2007). Given the 
current knowledge about the chemokine system, it is however not surprising that the two cell types 
respond differently to identical stimuli. It has been shown that the same chemokine can differently 
influence the induction of tight adhesion of different lymphocyte subsets. In a study by D´Ambrosio 
and colleagues, CCL17 (a chemokine binding to CCR4) could induce tight adhesion of Th2, but not of 
Th1 CD4+ T cells, although both cell types express the CCR4 receptor. In contrast, CCL22, another 
chemokine binding to the same receptor, could induce tight adhesion of both Th1 and Th2 cells. 
Similar effects have been observed for the CXCR3 ligands CXCL9 and CXCL11, and this mechanism has 
been proposed as an explanation for the question how a plethora of seemingly redundant 
chemokines can mediate specific effects (D’Ambrosio et al. 2002). A greater sensitivity of NK cells 
towards relatively low chemokine concentrations would also make sense from a biologic standpoint 
because NK cells, as part of the innate immune system, are designed to respond early in a developing 
infectious process. T cells, by contrast, are often recruited at later stages of the inflammation, when 
higher chemokine concentrations may be present as compared to the early phases. In experimental 
models of viral infection, it has also been shown that NK cell infiltration precedes infiltration with 
T cells, and that the recruited NK cells produce high levels of IFNγ – a cytokine known to induce 
CXCL10 expression (Hussell and Openshaw 1998). 
The earlier experiments demonstrating that the CX3CL1 chemokine head can be functionally 
replaced with other chemokines were performed using either transfected K562 cells (an 
erythroleukemia line) or unsorted PBMCs, thus not allowing identification of the exact cell types 
recruited (Imai et al. 1997; Fong et al. 2000). Therefore, these experiments cannot provide clues as to 
if the efficiency of this approach varies among different leukocyte types.  
Given the hypothesis that T cells and NK cells are differently sensitive towards recruitment by 
CXCL10-mucin-GPI, higher protein concentrations on the endothelium may be able to generate 
detectable effects of CXCL10-mucin-GPI also for T cells. In order to establish an experimental system 
with very high surface levels of CXCL10-mucin-GPI, we attempted to stably transfect immortalized 
endothelial cells with the recombinant constructs (data not shown). However, transfection with 
CXCL10-GPI or CXCL10-mucin-GPI lead to severely impaired proliferation of the cells in combination 
with a very high rate of apoptosis. Furthermore, the few clones that grew out under selection 
displayed only minimal CXCL10 surface levels (while the sEGFP-GPI protein was expressed at very 
high levels), indicating that cells with high CXCL10 expression levels were negatively selected. This 
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inhibitory effect of CXCL10 on endothelial cells is well documented in the literature and prevented 
use of the transfected cells in laminar flow assays (Angiolillo et al. 1995; Feldman et al. 2006). 
Another means to increase surface levels of CXCL10-mucin-GPI would be to increase protein yields in 
the purification process. It was however not possible to isolate much higher amounts of protein with 
the protocol developed in the current study, mostly due to limitations at the cell culture level. 
Attempts to increase the expression levels of the GPI-anchored proteins by methotrexate treatment 
did not provide sufficient increases in protein levels. Therefore, future protein isolation protocols will 
need to make use of much higher cell numbers. As a first step in this direction, the transfected CHO 
cells were adapted growth in suspension (shortly described in 5.5). Here, 4-5 x more cells could be 
harvested from the same volume of medium compared to adherent culture. Additionally, suspension 
cells could be conveniently grown in spinner flasks, minimizing handling time and allowing the 
generation of much higher cell numbers. These improvements could in the future enable the 
isolation of significantly higher amounts of GPI-anchored proteins. 
In addition to fostering selective leukocyte recruitment, the recombinant chemokines may also have 
other effects. CX3CL1 and CXCL10 have both been shown to activate NK cells leading to higher 
efficiency of target cell lysis (Taub et al. 1995; Saudemont et al. 2005; Zhang et al. 2006). To test if 
tumor treatment with the GPI-anchored proteins could also enhance NK killing, chromium release 
assays were performed, in which the ability of human NK cells to lyse target cells pretreated with 
CXCL10-mucin-GPI was determined (see 5.4). Freshly isolated primary NK cells with and without IL-2 
activation were tested against two different target cell lines (K562 and RCC26). It was found that 
treatment of target cells with CXCL10-mucin-GPI or commercially available CXCL10 had no significant 
effect on lysis efficiencies compared to the buffer control, at least at the concentrations studied. Also 
here, higher amounts of protein might reveal previously undetected effects. 
4.6 CXCL10-mucin-GPI can recruit leukocytes in vivo 
The efficiency of CXCL10-mucin-GPI on leukocyte recruitment was not only assessed using in vitro 
systems, but also in a murine tumor model in vivo. Since the chemokine head in the fusion proteins 
was of human origin, it was first established that human CXCL10 is able to activate murine CXCR3. 
Here, human and murine CXCL10 were found to elicit identical levels of calcium mobilization and 
receptor internalization in CXCR3+ murine T cells (see 5.2). In addition, CXCL10-mucin-GPI was found 
to efficiently induce the adhesion of primary murine NK cells in vitro, suggesting orthogonality of the 
fusion protein.  
A subcutaneously implantable tumor model was used for in vivo experiments. Such a model was the 
most suitable for the present study as the aim was to provide proof of principle for the activity of 
CXCL10-mucin-GPI with regards to recruitment and not for therapeutic efficacy resulting in reduced 
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tumor growth or other endpoints. The cell line used for tumor implantation was derived from a 
spontaneously arising B cell lymphoma in mice expressing the c-myc oncogene under the control of 
the Igλ promoter (Kovalchuk et al. 2000). This would also allow direct verification of the results in the 
spontaneous model (which is currently underway).  
The implanted tumors appeared well vascularized in H/E staining and thus constituted a good model 
system for the analysis of induced recruitment of leukocytes from the blood stream. Moreover, they 
displayed little signs of necrosis that could have interfered with the analyses.  
Immunohistology was performed to detect CD3+ infiltrates in the tumors using previously described 
antibodies (Vielhauer et al. 2009). Here, a pronounced infiltration was observed even in untreated 
tumors. This is in agreement with findings made in the spontaneous variant of the tumor model, 
where a strong infiltration of diseased lymph nodes with T cells was observed (Brenner, 2009; PhD 
thesis LMU). In the present study, it was found that secondary lymphoid structures were often 
resected together with the tumors. These structures contained large numbers of CD3+ cells. 
Immunohistology was thus the only feasible way to analyze T cell infiltrates in the tumors as this 
technique allowed exclusion of these structures from analysis (see 5.3).  
In order to assess tumor infiltration with T cells induced by CXCL10-mucin-GPI, the various proteins 
were injected into grown tumors, and subsequent leukocyte infiltrates were analyzed four hours 
later. Tumors treated with CXCL10-mucin-GPI harbored on average the highest numbers of CD3+ 
cells, while tumors treated with the same molar amount of soluble CXCL10 or sEGFP-GPI on average 
contained about 33% less CD3+ cells. Even 500 x higher molar amounts of soluble CXCL10 were less 
efficient than CXCL10-mucin-GPI. Nevertheless, the differences were not deemed statistically 
significant due to the low numbers of animals, and the large variances between single tumors of the 
same treatment condition. Thus, caution must be taken in interpreting the results. In future studies 
using modified experimental setups, the effects of the different CXCL10 species may prove 
significant. Notably, the low increase in infiltration by CD3+ cells compared to NK cells (see below) 
reflected the results obtained in vitro, where CXCL10-mucin-GPI was efficient for the recruitment of 
NK cells, but not for T cells.  
NK cells were detected immunohistologically with polyclonal antibodies against NKp46. These 
antibodies have been described for the detection of NK cells in situ by immunofluorescent staining of 
frozen sections (Walzer et al. 2007) and the staining was validated in our laboratory on formalin-fixed 
paraffin sections of spleens of C57/Bl6 mice (data not shown), where the same staining pattern was 
found as described by Walzer and colleagues on frozen sections (Grégoire et al. 2007; Walzer et al. 
2007). To our knowledge, the current study is the first to describe the use of polyclonal NKp46-
specific antibodies for the detection of NK cells in formalin-fixed paraffin sections. A recent 
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publication however showed the use of another NKp46-specific antibody on the same type of 
sections to detect NK cell infiltrates in tumors (Guerriero et al. 2011).  
A relatively low infiltration of tumor centers with NKp46+ cells was observed. In contrast, some 
tumors contained large amounts of NKp46+ cells at the periphery. This highly unequal distribution of 
NK cells, although being an interesting finding, made it difficult to quantify NK cells infiltrates from 
immunohistological stainings. For this reason, and because of the relatively scarce evidence in the 
literature for the function and specificity of the polyclonal NKp46-antibodies, it was decided to 
quantify NK cell infiltrates by FACS. Importantly, the secondary lymphoid structures described above 
contained only few NKp46+ cells, thereby allowing to use FACS for the quantification of NK cell 
infiltrates (see 5.3). 
The trends observed for NK cell counts (defined as CD3- NK1.1+ cells among the total cell counts) 
were much more pronounced than those seen for T cells. Tumors treated with CXCL10-mucin-GPI 
contained on average 8.5 x more NK cells than untreated tumors. Also, application of CXCL10-mucin-
GPI was more effective than soluble CXCL10 at the same molar amount or even at 500-fold molar 
excess. The observation that CXCL10-mucin-GPI had a stronger effect on NK cell recruitment 
compared to T cell recruitment again mirrored the results of the in vitro experiments.  
NK cells present in tumors treated with CXCL10-mucin-GPI or high amounts of soluble CXCL10 
displayed an about 50% stronger surface staining for CXCR3 than NK cells recruited into untreated or 
sEGFP-GPI treated tumors (as assessed by the MFI values; data not shown). The signals on NK cells in 
tumors treated with low amounts of soluble CXCL10 (identical to CXCL10-mucin-GPI) ranged between 
the two extremes. This accumulation of strongly CXCR3-positive NK cells suggests that the cells were 
recruited via the CXCL10/CXCR3 axis. The degree of sensitivity of a given cell type towards a 
chemokine ligand also depends on the expression level of the receptor (D’Ambrosio et al. 2002). 
Thus, the recruited highly CXCR3-positive NK cells might constitute a strongly CXCL10-sensitive 
subset of NK cells that is consequently most effectively targeted by CXCL10. The time difference of 
four hours between the injection and the analysis might hereby be long enough for the NK cells to 
replenish surface CXCR3 that has been internalized upon recruitment (Meiser et al. 2008).  
A series of questions remain to be answered regarding the in vivo mechanism of action of CXCL10-
mucin-GPI. First, the evaluation of the potential therapeutic effect of CXCL10-mucin-GPI in terms of 
tumor growth is a central question. Here, also studies are planned using adoptive transfer of T or NK 
cells. Furthermore, in the current study we were not able to detect incorporated CXCL10-mucin-GPI 
proteins immunohistologically due to the low concentrations of purified proteins applied (data not 
shown). When higher amounts of purified proteins can be produced using the cell culture system 
described above and in 5.5, the detection of incorporated proteins in situ should become possible. 
This information would allow correlating the positions of leukocytes within the tumors to the 
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gradient of CXCL10-mucin-GPI. Thereby, the question if a stable CXCL10-mucin-GPI gradient can be 
used by recruited leukocytes for haptotaxis towards the tumor center may be answered, assessing 
another potentially important effect of CXCL10-mucin-GPI. 
In summary, the current study showed that CXCL10-mucin-GPI can be used to enhance recruitment 
of CXCR3+ leukocytes in vitro and strongly suggested that the positive effects hold true also in vivo in 
a tumor setting. Following this first proof of principle, the underlying concept of a chemokine head 
fused to the mucin domain of CX3CL1 and a GPI anchor signal sequence may be expanded into a 
broader family of reagents that allow targeted recruitment of cells into various tissues.  
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5 Addendum 
5.1 Purification and characterization of CXCL8-mucin-GPI 
The basic objective of this study was to establish the approach of a fusion protein consisting of a 
chemokine head, the mucin domain of CX3CL1 and a GPI anchor as a novel type of flexible reagents 
allowing the modification of various tissue micromilieus. Such reagents could have diverse 
applications ranging from tumor therapy to wound healing or ischemia reperfusion injuries. By 
utilizing different chemokine heads, the specificity of the respective fusion proteins could be 
redirected towards virtually any desired subset of cells, as long as the expression of the matching 
chemokine receptor is reasonably restricted to the desired cell type or types. As proof of concept, 
the CXCL10 fusion proteins were characterized in great detail as described in the last chapters. 
However, another set of fusion proteins was additionally generated, expressed and initially 
characterized that contained a human CXCL8 chemokine head at the N-terminus. The use of this 
chemokine should allow the recruitment of a subset of highly cytotoxic CD8+ T cells along with 
neutrophils into tumor tissues (see 1.4). The compositions of the various proteins were identical to 
the ones of the corresponding CXCL10 fusion proteins except for the chemokine head. The proteins 
were generated as described in 2.2.3.3, yielding a set of fusion proteins that paralleled the set 
depicted in Figure 9 (page 55), including constructs with and without the mucin domain and with and 
without the GPI anchor signal sequence.  
Essentially, the procedures which had been developed for the CXCL10 fusion proteins could also be 
applied for the CXCL8 proteins, including the use of the c-myc epitope tag for purification and 
detection purposes. A protocol for the solubilization of the proteins was developed using the assay 
described in 3.3. The results were comparable to those obtained for the CXCL10 proteins (data not 
shown), indicating that rather the general architecture of the proteins dictated the most efficient 
detergent than the single chemokine domains. Therefore, n-Dodecyl-β-D-maltoside could potentially 
be applied to solubilize all chemokine fusion proteins generated in the here described way, a finding 
which should facilitate broader application of this technique.  
As an example, Figure 28 shows the expression (A), purification (B) and incorporation (C) of CXCL8-
mucin-GPI. As depicted in panel A, CXCL8-mucin-GPI could readily be detected on the surface of 
transfected CHO cells. The same was true for cells transfected with CXCL8-GPI, while cells expressing 
the soluble CXCL8-Stop or CXCL8-mucin-Stop proteins could as expected not be stained (data not 
shown). These findings indicated that also the CXCL8 fusion proteins were correctly anchored to the 
cell membrane via their GPI anchor and not by nonspecific binding via the chemokine or the mucin 
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domains. As found also for the CXCL10 proteins, treatment with methotrexate could be used to 
eliminate cells with a low expression level (data not shown).  
 
 
Figure 28: CXCL10-mucin-GPI can be expressed, purified and incorporated into endothelial cells 
using the procedures established for CXCL10-mucin-GPI. A: CXCL8-mucin-GPI can be detected on 
the surface of transfected CHO cells. Stably transfected CHO cells were incubated with CXCL8-specific 
antibodies (blue line) or isotype-matched control antibodies (black line). FITC-conjugated secondary 
antibodies were used to detect bound antibodies and the fluorescence intensity was measured by 
FACS. B: Solubilized CXCL8-mucin-GPI can be purified by affinity chromatography. Cell extracts from 
transfected CHO cells were applied to an anti c-myc affinity resin. Following a washing step at high 
salt concentration, proteins were eluted using c-myc peptides. The UV absorption as a measure of 
protein content (blue line) and the conductivity as a measure of salt concentration (brown line) were 
continuously measured. The green line represents the percentage of washing buffer applied to the 
column. Chromatography fractions were subjected to western blotting using CXCL8-specific 
antibodies (insert). C: Purified CXCL8-mucin-GPI incorporates into the cell membranes of micro-
vascular endothelial cells. Microvascular endothelial cells (HMEC) were incubated with 0.36 nM of 
purified CXCL8-mucin-GPI or a buffer control, with both samples being diluted in medium at the 
same ratio. The cells were washed and incorporated proteins on the surface were detected by FACS 
analysis using anti c-myc primary and RPE-labeled secondary antibodies. The MFIs (geometric mean 
of isotype stained sample – geometric mean of anti c-myc stained sample) are given for each 
condition.  
 
Addendum   103 
Panel B shows a chromatogram obtained during the purification of CXCL8-mucin-GPI using the same 
affinity resin as the one used for the purification of the CXCL10 proteins. Additionally, a 
corresponding western blot of the chromatography fractions is shown. Western blots of the CXCL8 
proteins were performed using CXCL8-specific antibodies which were purified from culture 
supernatants of a hybridoma cell line. In the blots, CXCL8-mucin-GPI predominantly appeared in a 
dimeric form with an apparent molecular weight of about 120 kDa, while the monomeric form with 
50-60 kDa was less abundant. The difference between the apparent molecular weights of monomeric 
CXCL10-mucin-GPI (45-50 kDa) and CXCL8-mucin-GPI (50-60 kDa) and also the relative amounts of 
monomeric versus dimeric forms were most likely due to the fact that western blots for CXCL10 were 
performed under reducing conditions, while the antibody against CXCL8 required non-reducing 
conditions. The western blot depicted in panel B shows that the majority of specific proteins could be 
recovered in the elution fractions with relatively little loss in the flow through, indicating that the 
large amount of proteins that did not bind to the column and was removed in the flow through and 
the washing step (see chromatogram) contained mostly contaminating proteins.  
Panel C illustrates the ability of purified CXCL8-mucin-GPI proteins to incorporate into the cell 
membranes of endothelial cells. Microvascular endothelial cells were incubated with 0.36 nM CXCL8-
mucin-GPI or a buffer control, both diluted in medium at the same volumetric percentage. 
Subsequently, the cells were washed and the presence of CXCL8-mucin-GPI on the surface of the 
endothelial cells was tested by FACS staining using anti c-myc primary and RPE-labeled secondary 
antibodies. The histograms show that incorporated CXCL10-mucin-GPI could be detected on the cell 
surface. The same was found for CXCL8-GPI (data not shown).  
These experiments indicated that the principle outlined in this study could easily be expanded to 
constructs containing other chemokine domains than CXCL10, at least in terms of production of the 
proteins and incorporation of purified proteins into various cells. It will be an interesting question to 
be adressed in future studies whether recombinant proteins containing other chemokine heads are 
also bioactive.  
5.2 Murine and human CXCL10 have identical effects on murine CXCR3+ cells 
In order to assess the effects of human and murine CXCL10 on murine cells, calcium mobilization and 
receptor internalization assays were performed, analogous to those applied in 3.2 to verify the 
bioactivity of the recombinant proteins. A murine T cell line (kindly provided by F. Lehmann, 
Helmholtz Zentrum Munich) was used as target cells, which had been shown to be CXCR3-positive 
(data not shown) and was available in sufficiently high numbers for the experiments.  
For calcium mobilization assays, cells were loaded with the calcium-sensitive fluorescent dye Fluo-4 
as described in 2.2.5.2.1. Using a FACS machine, the fluorescence of the cells was measured over 
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time. After 30 sec, commercially available human or murine CXCL10 at final concentrations of 
1 µg/ml or a buffer control was added to the cells and the fluorescence was followed for an 
additional 3 min. Dead cells were identified by 7-AAD staining and excluded from the analysis.  
Analysis of CXCR3 internalization was performed as described in 2.2.5.1.4. Briefly, murine T cells 
were incubated with 660 ng/ml of human or murine CXCL10 or a buffer control for 30 min at 37°C. 
Subsequently, the cell surface level of CXCR3 in each sample was determined using APC-labeled, 
CXCR3-specific antibodies. FACS was used to determine fluorescence intensities, while dead cells 
were identified by PI staining and excluded from the analysis. The results were expressed as percent 
CXCR3 surface signal with the fluorescence intensity of the buffer control defined as 100%. Figure 29 
shows the results of both experiments.  
Panel A depicts the results of the calcium mobilization analyses with the fluorescence intensities of 
single cells as a measure of intracellular calcium levels plotted against the time. A pronounced 
transient fluorescence signal was observed after addition of either human or murine CXCL10 (orange 
and blue line, respectively). In the buffer control (black line), no fluorescence signal was observed as 
had been expected. The curves obtained in the samples with murine and human CXCL10 were 
virtually identical, both in terms of maximal signal strength and signal duration. Thus, CXCL10 from 
both species elicited identical responses in terms of calcium mobilization, which indicated that both 
chemokines were similarly effective at triggering the CXCR3 receptor.  
 
Figure 29: Human and murine CXCL10 elicit comparable levels of calcium mobilization and CXCR3 
internalization on murine cells. A: Calcium mobilization. Murine CXCR3-positive cells were loaded 
with a calcium-sensitive fluorescent dye. The fluorescence in the population was continuously 
monitored by FACS. After 30 sec (black arrow), 1 µg/ml (115 nM) human (orange line) or murine 
(blue line) CXCL10 or a buffer control (black line) were added to the samples and the fluorescence 
was monitored. B: CXCR3 internalization. Murine CXCR3+ T cells were incubated for 30 min with 
660 ng/ml (76 nM) of human or murine CXCL10 or a buffer control and the CXCR3 surface levels were 
subsequently determined by FACS analysis. The fluorescence intensity in the buffer control was set 
as 100% and the levels of the other samples related to it.  
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Panel B depicts the results of the analysis of CXCR3 internalization. Here, the CXCR3 surface levels 
were decreased to 19.6% after incubation with human CXCL10 and to 15.7% with murine CXCL10. 
According to our experience with similar experiments, the difference of 3.9% was within the 
experimental variation, although the experiment presented here was not repeated often enough to 
prove this assumption statistically.  
In summary, human CXCL10 was as effective as the murine pendant in triggering the murine CXCR3 
receptor as assessed by calcium mobilization and receptor internalization.  
5.3 Additional immunohistological findings 
In the immunohistological analysis of the subcutaneously implanted tumors (see 3.7) it was noted 
that at the margins of many tumors, secondary lymphatic organs had been resected together with 
the tumor. These organs clearly were not parts of the primary tumors. However, in order to analyze 
the influence of this finding on the analysis of infiltrates by FACS, immunohistological stainings were 
performed to detect CD3+ and NKp46+ cells. Figure 30 shows representative images of one of these 
structures.  
The staining showed that the described organs contained numerous CD3+ cells, as it would be 
expected for a secondary lymphatic organ. Thus, the presence of these organs in the resected tumors 
ruled out the possibility to analyze T cell infiltrates by FACS. In contrast, only very few NKp46+ cells 
were found to reside within the described organs, indicating that FACS analysis could still be used to 
characterize NK cell infiltration.  
 
Figure 30: Secondary lymphatic organs co-resected with some subcutaneous tumors contain large 
numbers of T cells, but very few NK cells. Tumors were implanted subcutaneously in C57/Bl6 mice 
using the 291 cell line. Following excision, tumors were fixed with formalin and tumor sections were 
stained for the presence of NKp46+ or CD3+ cells. While the structures contained numerous CD3+ cells 
(dark grey/ black staining), only very few NKp46+ cells were found. Both images were acquired using 
50 x magnification. 
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5.4 CXCL10-mucin-GPI on target cells does not enhance killing by NK cells 
For NK cells, it has been shown that the presence of CX3CL1 on target cell surfaces can enhance 
tumor cell lysis (Zhang et al. 2006; Zhang et al. 2007).  In addition, also CXCL10 has been shown to 
activate NK cells leading to higher amounts of granule exocytosis and enhanced target cell lysis (Taub 
et al. 1995; Taub et al. 1996). Therefore, it was hypothesized that the presence of CXCL10-mucin-GPI 
on target cells would also enhance NK cell mediated killing. This would represent an additional 
beneficial effect of the GPI-anchored protein in an adjuvant setting for tumor therapy, as treatment 
of the tumors with CXCL10-mucin-GPI might in this case not only enhance recruitment but also 
directly influence tumor cell clearance by recruited NK cells. Chromium release assays were 
conducted in order to test this hypothesis. In such assays, target cells are labeled with radioactive 
Chromium and subsequently incubated with effector cells. Cell-mediated lysis of the target cells 
results in release of Chromium into the medium, which can be quantified and expressed as 
percentage of target cell lysis.  
Human NK cells were isolated from peripheral blood as described in 2.2.5.5 and experiments were 
performed using both freshly isolated cells and such that had been activated by an overnight 
incubation with 500 U/ml recombinant IL-2. Two different target cell lines were used: K562, a human 
erythroleukemia line, and RCC26, a renal cell carcinoma line, which were both kindly provided by 
Prof. E. Noessner, Helmholtz Zentrum Munich. The cells were labeled with Na2
51CrO4 and 
subsequently incubated with 0.24 nM of purified CXCL10-mucin-GPI, 14 nM of commercially available 
CXCL10 or a buffer control. The commercially available CXCL10 was used at a higher concentration 
than CXCL10-mucin-GPI in order to detect even modest effects mediated by the soluble protein. All 
samples were diluted in medium and contained the same percentage of chromatography buffer. 
Following treatment, the target cells were incubated for 4 h with different amounts of NK cells and 
the radioactivity of the supernatants was measured. The maximal radioactivity of the labeled cells of 
one well was additionally determined (100% lysis) and readings in the other samples were referred 
to this value. Figure 31 summarizes the lysis efficiencies for the differently treated target cells at 
different effector to target (E:T) ratios.   
Freshly isolated NK cells were only able to lyse the K562 cell line, with lysis rates ranging from 60% to 
4%, depending on the respective E:T ratio. The lysis rates could in this case be influenced neither by 
incubating the target cells with CXCL10-mucin-GPI nor by treating them with commercially available 
CXCL10. Activated NK cells, in contrast, mediated lysis of both RCC26 and K562 cells with lysis rates 
ranging from 75% to 19% for K562 and from 68% to 11% for RCC26. A much higher E:T ratio was 
required to achieve efficient lysis of RCC26 cells indicating that the stimulus delivered by these cells 
to the NK cells was weaker than in the case of K562.  
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The lysis values for RCC26 cells treated with CXCL10-mucin-GPI did not differ substantially from that 
of cells incubated with commercially available CXCL10 or the buffer control, indicating that the 
presence of CXCL10-mucin-GPI on these cells did not enhance the activating stimulus delivered to the 
NK cells. In the case of the K562 cells, target cells that had been incubated with CXCL10-mucin-GPI 
displayed the lowest lysis values (62% to 19%), followed by cells treated with normal CXCL10 (66% to 
19%), while the highest values were found for the buffer control (75% to 28%). In summary, CXCL10-
mucin-GPI on the target cell could not enhance tumor cell lysis by NK cells, at least not at the 
concentrations tested. 
5.5 Adaptation of transfected CHO cells to large-scale suspension culture 
In the experiments described in the chapter 3, relatively low amounts of the GPI-anchored proteins 
were used. These low amounts may have prevented the detection of some physiologic effects of the 
proteins, for example in the recruitment of T cells (see 3.6.4). However, the production of 
significantly higher amounts of proteins would require much higher amounts of primary cell culture 
material, which could not be produced at reasonable cost and effort using adherent cells as 
described in this study. Therefore, a suspension cell culture system was established as a first step in 
the direction of producing higher protein amounts. This system should allow the production of much 
higher amounts of transfected CHO cells in relation to the volume of medium than an adherent 
 
Figure 31: CXCL10-mucin-GPI does not enhance tumor cell lysis by human NK cells. Chromium 
release assays were performed to investigate the effect of CXCL10-mucin-GPI on NK cell mediated 
tumor cell lysis. Target cells (K562 in A or RCC26 in B) were labeled with Na2
51CrO4 and subsequently 
incubated with CXCL10-mucin-GPI (0.24 nM) or commercially available CXCL10 (14 nM). Freshly 
isolated human NK cells (open symbols) or such that had been activated overnight using 500 U/ml 
IL-2 (filled symbols) were added at different effector to target (E:T) ratios and the release of 51Cr was 
used to quantify the percentage of target cell lysis using the maximal radioactivity of the respective 
target cells as reference. Symbols represent average values of duplicates +/- standard error of the 
mean (SEM).  
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system. Exponentially growing cells were transferred directly into CD CHO medium, a chemically 
defined serum free medium designed for growing CHO cells in suspension. The medium was 
exchanged every 3-4 days until the cells had adapted to the new medium. If clusters of cells formed 
during this time, the cells were singularized using Trypsin/EDTA. FACS analysis was used to ensure 
maintenance of transgene expression. A slight decrease of protein production could be seen upon 
transition into suspension growth, which could however be compensated by sorting the cells for high 
expression by FACS sorting (data not shown). Large numbers of cells were grown in 1 l spinner flasks. 
The flasks were inoculated with 1.4 x 105 cells/ml in a volume of 100 ml and continuously mixed at 
50-60 rpm. The medium in the flask was doubled every 3-4 days by addition of fresh medium and the 
numbers of cells were monitored every day. Figure 32 shows the growth characteristic of a 
representative suspension culture. 
The figure indicates that the CHO cells displayed robust growth in suspension culture with up to 1.5 x 
106 cells/ml. The cell counts usually reached a peak after 7-8 days (green line). At this time, the 
amount of cells that could be harvested was 4-5 x higher than if the cells had been grown in adherent 
culture using the same volume of medium (blue line; refers to 650 ml medium). Thus, the suspension 
culture system should represent a valuable tool for future studies, allowing the isolation of higher 
amounts of recombinant proteins from higher numbers of cells.   
5.6 The GPI anchor signal sequence from DAF does not enhance incorporation 
Different GPI-anchor signal sequences may differ in their efficiency to mediate GPI anchor 
attachment (Chen et al. 2001). If this transfer is inefficient, the proteins can exist as a mixture of 
transmembrane and GPI-anchored species. This has also been shown for the LFA-3 protein from 
 
Figure 32: CHO cells grown in suspension culture yield over 4 x more cells than an adherent culture 
at the same expense of medium. A suspension culture system was established in order to produce 
larger amounts of cells at reasonable costs. The green line indicates the total numbers of viable cells 
in the spinner flask, the red line the numbers of dead cells identified by trypan blue staining. The blue 
line indicates the amount of cells that could be obtained using the same total volume of medium 
(650 ml) in adherent culture.  
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which the GPI anchor signal sequence used in the present study was taken (Hollander 1992). For this 
reason, DNA constructs were generated as described in 2.2.3.1.2 and 2.2.3.2.2 in which the signal 
sequence from DAF was used instead of the one from LFA-3, the rests of the respective constructs 
remaining identical to the constructs with the LFA-3 anchor sequence. The proteins were expressed 
in CHO cells and detected on their cell surface by FACS staining (data not shown). Since cleavage by 
PI-PLC, which is normally used to test if a given protein is GPI-anchored, was hampered by various 
effects as discussed above and transmembrane-anchored protein species could not be discriminated 
from GPI-anchored ones by western blotting or other established methods, the efficiency of 
incorporation was chosen as functional readout for the degree of GPI anchorage. As only GPI-
anchored proteins have the ability to incorporate into cell membranes, the surface signal intensity 
after incorporation should correlate with the percentage of GPI-anchored proteins. To test this 
efficiency, CXCL10-mucin-DAFPI was exemplarily purified as described in 2.2.4.1.3 in the same way as 
and parallel to CXCL10-mucin-GPI (see 3.4). Specific concentrations of both proteins were obtained 
by ELISA and CHO cells were treated using 0.3 nM of both proteins. Subsequently, the cells were 
stained with anti c-myc primary and RPE-labeled secondary antibodies and fluorescence intensities 
were assessed by FACS. Figure 33 shows the results of the FACS staining. 
Both CXCL10-mucin-GPI and CXCL10-mucin-DAFPI incorporated with similar efficiency into the cell 
membranes of the CHO cells. The MFI was slightly lower for cells treated with CXCL10-mucin-DAFPI 
as compared to an identical concentration of CXCL10-mucin-GPI. Thus, it was concluded that the GPI 
anchor signal sequence from DAF was not more efficient in mediating GPI anchor attachment than 
the signal sequence from LFA-3.  
 
Figure 33: The GPI anchor signal sequence from DAF does not enhance incorporation compared to 
the signal sequence from LFA-3. In order to compare the reincorporation efficiencies of CXCL10-
mucin-GPI and CXCL10-mucin-DAFPI (a protein containing the GPI anchor signal sequence from DAF 
instead of the one from LFA-3), CHO cells were treated with identical concentrations (0.3 nM) of 
purified CXCL10-mucin-GPI, CXCL10-mucin-DAFPI or a buffer control and subsequently analyzed by 
FACS staining for the presence of the GPI-anchored proteins on the cell surface using anti c-myc 
primary and RPE-labeled secondary antibodies. Histograms are gated on viable cells based on 7-AAD 
exclusion. Blue lines indicate staining with c-myc specific antibodies, black lines indicate staining with 
isotype control antibodies. The MFIs are given for every sample.  
 
Addendum   110 
5.7 DNA sequences of the recombinant fusion proteins 
Start and stop codons in the respective constructs are underlined, available restriction sites are 
printed in bold.  
 
Restriction sites Genes or gene segments 
GAATTC: EcoRI  CXCL10 gene  
GTCGAC: SalI  CXCL8 gene 
GCTAGC: NheI  Double c-myc epitope tag 
TCTAGA: XbaI EGFP gene 
ACGCGT: MluI GPI signal sequence from DAF 
 GPI signal sequence from LFA-3 
Mucin domain from CX3CL1 
Secretion signal sequence from TIMP-1 
 
 
>CXCL10-GPI 
GAATTCCCAGTCTCAGCACCATGAATCAAACTGCCATTCTGATTTGCTGCCTTATCTTTCTGACTCTAAGTGGCA
TTCAAGGAGTACCTCTCTCTAGAACTGTACGCTGTACCTGCATCAGCATTAGTAATCAACCTGTTAATCCAAGGT
CTTTAGAAAAACTTGAAATTATTCCTGCAAGCCAATTTTGTCCACGTGTTGAGATCATTGCTACAATGAAAAAG
AAGGGTGAGAAGAGATGTCTGAATCCAGAATCGAAGGCCATCAAGAATTTACTGAAAGCAGTTAGCAAGGAA
AGGTCTAAAAGATCTCCTGCTAGAGAACAGAAGCTGATCAGCGAGGAGGACCTGGAGCAGAAGTTGATCAGC
GAGGAGGACCTGGCTAGAACAACCTGTATCCCAAGCAGCGGTCATTCAAGACACAGATATGCACTTATACCCA
TACCATTAGCAGTAATTACAACATGTATTGTGCTGTATATGAATGTATTATGAGTCGAC 
 
>CXCL10-mucin-GPI 
GAATTCCCAGTCTCAGCACCATGAATCAAACTGCCATTCTGATTTGCTGCCTTATCTTTCTGACTCTAAGTGGCA
TTCAAGGAGTACCTCTCTCTAGAACTGTACGCTGTACCTGCATCAGCATTAGTAATCAACCTGTTAATCCAAGGT
CTTTAGAAAAACTTGAAATTATTCCTGCAAGCCAATTTTGTCCACGTGTTGAGATCATTGCTACAATGAAAAAG
AAGGGTGAGAAGAGATGTCTGAATCCAGAATCGAAGGCCATCAAGAATTTACTGAAAGCAGTTAGCAAGGAA
AGGTCTAAAAGATCTCCTGCTAGAAATGGCGGCACCTTCGAGAAGCAGATCGGCGAGGTGAAGCCCAGGACC
ACCCCTGCCGCCGGGGGAATGGACGAGTCTGTGGTCCTGGAGCCCGAAGCCACAGGCGAAAGCAGTAGCCTG
GAGCCGACTCCTTCTTCCCAGGAAGCACAGAGGGCCCTGGGGACCTCCCCAGAGCTGCCGACGGGTGTGACT
GGTTCCTCAGGGACCAGGCTCCCCCCGACGCCAAAGGCTCAGGATGGAGGGCCTGTGGGCACGGAGCTTTTC
CGAGTGCCTCCCGTCTCCACTGCCGCCACGTGGCAGAGTTCTGCTCCCCACCAACCTGGGCCCAGCCTCTGGGC
TGAGGCAAAGACCTCTGAGGCCCCGTCCACCCAGGACCCCTCCACCCAGGCCTCCACTGCGTCCTCCCCAGCCC
CAGAGGAGAATGCTCCGTCTGAAGGCCAGCGTGTGTGGGGTCAGGGGCAGAGCCCCAGGCCAGAGAACTCT
CTGGAGCGGGAGGAGATGGGTCCCGTGCCAGCGCACACGGATGCCTTCCAGGACTGGGGGCCTGGCAGCAT
GGCCCACGTCTCTGTGGTCCCTGTCTCCTCAGAAGGGACCCCCAGCAGGGAGCCAGTGGCTTCAGGCAGCTGG
ACCCCTAAGGCTGAGGAACCCATCCATGCCACCATGGACCCCCAGAGGCTGGGCGTCCTTATCACTCCTGTCCC
TGACGCCCAGGCTGCCACCCGGAGGCAGGCTAGAGAACAGAAGCTGATCAGCGAGGAGGACCTGGAGCAGA
AGTTGATCAGCGAGGAGGACCTGGCTAGCACAACCTGTATCCCAAGCAGCGGTCATTCAAGACACAGATATGC
ACTTATACCCATACCATTAGCAGTAATTACAACATGTATTGTGCTGTATATGAATGTATTATGAGTCGAC 
 
>CXCL10-Stop 
GAATTCCCAGTCTCAGCACCATGAATCAAACTGCCATTCTGATTTGCTGCCTTATCTTTCTGACTCTAAGTGGCA
TTCAAGGAGTACCTCTCTCTAGAACTGTACGCTGTACCTGCATCAGCATTAGTAATCAACCTGTTAATCCAAGGT
CTTTAGAAAAACTTGAAATTATTCCTGCAAGCCAATTTTGTCCACGTGTTGAGATCATTGCTACAATGAAAAAG
AAGGGTGAGAAGAGATGTCTGAATCCAGAATCGAAGGCCATCAAGAATTTACTGAAAGCAGTTAGCAAGGAA
AGGTCTAAAAGATCTCCTGCTAGAGAACAGAAGCTGATCAGCGAGGAGGACCTGGAGCAGAAGTTGATCAGC
GAGGAGGACCTGTAGTCGAC 
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>CXCL10-mucin-Stop 
GAATTCCCAGTCTCAGCACCATGAATCAAACTGCCATTCTGATTTGCTGCCTTATCTTTCTGACTCTAAGTGGCA
TTCAAGGAGTACCTCTCTCTAGAACTGTACGCTGTACCTGCATCAGCATTAGTAATCAACCTGTTAATCCAAGGT
CTTTAGAAAAACTTGAAATTATTCCTGCAAGCCAATTTTGTCCACGTGTTGAGATCATTGCTACAATGAAAAAG
AAGGGTGAGAAGAGATGTCTGAATCCAGAATCGAAGGCCATCAAGAATTTACTGAAAGCAGTTAGCAAGGAA
AGGTCTAAAAGATCTCCTGCTAGAAATGGCGGCACCTTCGAGAAGCAGATCGGCGAGGTGAAGCCCAGGACC
ACCCCTGCCGCCGGGGGAATGGACGAGTCTGTGGTCCTGGAGCCCGAAGCCACAGGCGAAAGCAGTAGCCTG
GAGCCGACTCCTTCTTCCCAGGAAGCACAGAGGGCCCTGGGGACCTCCCCAGAGCTGCCGACGGGTGTGACT
GGTTCCTCAGGGACCAGGCTCCCCCCGACGCCAAAGGCTCAGGATGGAGGGCCTGTGGGCACGGAGCTTTTC
CGAGTGCCTCCCGTCTCCACTGCCGCCACGTGGCAGAGTTCTGCTCCCCACCAACCTGGGCCCAGCCTCTGGGC
TGAGGCAAAGACCTCTGAGGCCCCGTCCACCCAGGACCCCTCCACCCAGGCCTCCACTGCGTCCTCCCCAGCCC
CAGAGGAGAATGCTCCGTCTGAAGGCCAGCGTGTGTGGGGTCAGGGGCAGAGCCCCAGGCCAGAGAACTCT
CTGGAGCGGGAGGAGATGGGTCCCGTGCCAGCGCACACGGATGCCTTCCAGGACTGGGGGCCTGGCAGCAT
GGCCCACGTCTCTGTGGTCCCTGTCTCCTCAGAAGGGACCCCCAGCAGGGAGCCAGTGGCTTCAGGCAGCTGG
ACCCCTAAGGCTGAGGAACCCATCCATGCCACCATGGACCCCCAGAGGCTGGGCGTCCTTATCACTCCTGTCCC
TGACGCCCAGGCTGCCACCCGGAGGCAGGCTAGAGAACAGAAGCTGATCAGCGAGGAGGACCTGGAGCAGA
AGTTGATCAGCGAGGAGGACCTGTAGTCGAC 
 
>CXCL10-DAFPI 
GAATTCCCAGTCTCAGCACCATGAATCAAACTGCCATTCTGATTTGCTGCCTTATCTTTCTGACTCTAAGTGGCA
TTCAAGGAGTACCTCTCTCTAGAACTGTACGCTGTACCTGCATCAGCATTAGTAATCAACCTGTTAATCCAAGGT
CTTTAGAAAAACTTGAAATTATTCCTGCAAGCCAATTTTGTCCACGTGTTGAGATCATTGCTACAATGAAAAAG
AAGGGTGAGAAGAGATGTCTGAATCCAGAATCGAAGGCCATCAAGAATTTACTGAAAGCAGTTAGCAAGGAA
AGGTCTAAAAGATCTCCTGCTAGAGAACAGAAGCTGATCAGCGAGGAGGACCTGGAGCAGAAGTTGATCAGC
GAGGAGGACCTGGCTAGAGGAAGTGGAACCACTTCAGGTACTACCCGTCTTCTATCTGGGCACACGTGTTTCA
CGTTGACAGGTTTGCTTGGGACGCTAGTAACCATGGGCTTGCTGACTTAGGTCGAC 
 
>CXCL10-mucin-DAFPI 
GAATTCCCAGTCTCAGCACCATGAATCAAACTGCCATTCTGATTTGCTGCCTTATCTTTCTGACTCTAAGTGGCA
TTCAAGGAGTACCTCTCTCTAGAACTGTACGCTGTACCTGCATCAGCATTAGTAATCAACCTGTTAATCCAAGGT
CTTTAGAAAAACTTGAAATTATTCCTGCAAGCCAATTTTGTCCACGTGTTGAGATCATTGCTACAATGAAAAAG
AAGGGTGAGAAGAGATGTCTGAATCCAGAATCGAAGGCCATCAAGAATTTACTGAAAGCAGTTAGCAAGGAA
AGGTCTAAAAGATCTCCTGCTAGAAATGGCGGCACCTTCGAGAAGCAGATCGGCGAGGTGAAGCCCAGGACC
ACCCCTGCCGCCGGGGGAATGGACGAGTCTGTGGTCCTGGAGCCCGAAGCCACAGGCGAAAGCAGTAGCCTG
GAGCCGACTCCTTCTTCCCAGGAAGCACAGAGGGCCCTGGGGACCTCCCCAGAGCTGCCGACGGGTGTGACT
GGTTCCTCAGGGACCAGGCTCCCCCCGACGCCAAAGGCTCAGGATGGAGGGCCTGTGGGCACGGAGCTTTTC
CGAGTGCCTCCCGTCTCCACTGCCGCCACGTGGCAGAGTTCTGCTCCCCACCAACCTGGGCCCAGCCTCTGGGC
TGAGGCAAAGACCTCTGAGGCCCCGTCCACCCAGGACCCCTCCACCCAGGCCTCCACTGCGTCCTCCCCAGCCC
CAGAGGAGAATGCTCCGTCTGAAGGCCAGCGTGTGTGGGGTCAGGGGCAGAGCCCCAGGCCAGAGAACTCT
CTGGAGCGGGAGGAGATGGGTCCCGTGCCAGCGCACACGGATGCCTTCCAGGACTGGGGGCCTGGCAGCAT
GGCCCACGTCTCTGTGGTCCCTGTCTCCTCAGAAGGGACCCCCAGCAGGGAGCCAGTGGCTTCAGGCAGCTGG
ACCCCTAAGGCTGAGGAACCCATCCATGCCACCATGGACCCCCAGAGGCTGGGCGTCCTTATCACTCCTGTCCC
TGACGCCCAGGCTGCCACCCGGAGGCAGGCTAGAGAACAGAAGCTGATCAGCGAGGAGGACCTGGAGCAGA
AGTTGATCAGCGAGGAGGACCTGGCTAGAGGAAGTGGAACCACTTCAGGTACTACCCGTCTTCTATCTGGGCA
CACGTGTTTCACGTTGACAGGTTTGCTTGGGACGCTAGTAACCATGGGCTTGCTGACTTAGGTCGAC 
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>sEGFP-GPI 
GAATTCATGGCCCCCTTTGAGCCCCTGGCTTCTGGCATCCTGTTGTTGCTGTGGCTGATAGCCCCCACGCGTGC
CATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAA
ACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCA
TCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTC
AGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGC
GCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGG
TGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACA
ACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCG
CCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCC
CGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGAT
CACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTCTAGAG
AACAGAAGCTGATCAGCGAGGAGGACCTGGAGCAGAAGTTGATCAGCGAGGAGGACCTGGCTAGCACAACC
TGTATCCCAAGCAGCGGTCATTCAAGACACAGATATGCACTTATACCCATACCATTAGCAGTAATTACAACATG
TATTGTGCTGTATATGAATGTATTATGAGTCGAC 
 
>CXCL8-GPI 
GAATTGAAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGCTCTCTTGGCAGCCTTCCTG
ATTTCTGCAGCTCTGTGTGAAGGTGCAGTTTTGCCAAGGAGTGCTAAAGAACTTAGATGTCAGTGCATAAAGA
CATACTCCAAACCTTTCCACCCCAAATTTATCAAAGAACTGAGAGTGATTGAGAGTGGACCACACTGCGCCAAC
ACAGAAATTATTGTAAAGCTTTCTGATGGAAGAGAGCTCTGTCTGGACCCCAAGGAAAACTGGGTGCAGAGG
GTTGTGGAGAAGTTTTTGAAGAGGGCTGAGAATTCATCTAGAGAACAGAAGCTGATCAGCGAGGAGGACCTG
GAGCAGAAGTTGATCAGCGAGGAGGACCTGGCTAGCACAACCTGTATCCCAAGCAGCGGTCATTCAAGACAC
AGATATGCACTTATACCCATACCATTAGCAGTAATTACAACATGTATTGTGCTGTATATGAATGTATTATGAGTC
GAC 
 
>CXCL8-mucin-GPI 
GAATTGAAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGCTCTCTTGGCAGCCTTCCTG
ATTTCTGCAGCTCTGTGTGAAGGTGCAGTTTTGCCAAGGAGTGCTAAAGAACTTAGATGTCAGTGCATAAAGA
CATACTCCAAACCTTTCCACCCCAAATTTATCAAAGAACTGAGAGTGATTGAGAGTGGACCACACTGCGCCAAC
ACAGAAATTATTGTAAAGCTTTCTGATGGAAGAGAGCTCTGTCTGGACCCCAAGGAAAACTGGGTGCAGAGG
GTTGTGGAGAAGTTTTTGAAGAGGGCTGAGAATTCATCTAGAAATGGCGGCACCTTCGAGAAGCAGATCGGC
GAGGTGAAGCCCAGGACCACCCCTGCCGCCGGGGGAATGGACGAGTCTGTGGTCCTGGAGCCCGAAGCCAC
AGGCGAAAGCAGTAGCCTGGAGCCGACTCCTTCTTCCCAGGAAGCACAGAGGGCCCTGGGGACCTCCCCAGA
GCTGCCGACGGGTGTGACTGGTTCCTCAGGGACCAGGCTCCCCCCGACGCCAAAGGCTCAGGATGGAGGGCC
TGTGGGCACGGAGCTTTTCCGAGTGCCTCCCGTCTCCACTGCCGCCACGTGGCAGAGTTCTGCTCCCCACCAAC
CTGGGCCCAGCCTCTGGGCTGAGGCAAAGACCTCTGAGGCCCCGTCCACCCAGGACCCCTCCACCCAGGCCTC
CACTGCGTCCTCCCCAGCCCCAGAGGAGAATGCTCCGTCTGAAGGCCAGCGTGTGTGGGGTCAGGGGCAGAG
CCCCAGGCCAGAGAACTCTCTGGAGCGGGAGGAGATGGGTCCCGTGCCAGCGCACACGGATGCCTTCCAGGA
CTGGGGGCCTGGCAGCATGGCCCACGTCTCTGTGGTCCCTGTCTCCTCAGAAGGGACCCCCAGCAGGGAGCCA
GTGGCTTCAGGCAGCTGGACCCCTAAGGCTGAGGAACCCATCCATGCCACCATGGACCCCCAGAGGCTGGGC
GTCCTTATCACTCCTGTCCCTGACGCCCAGGCTGCCACCCGGAGGCAGGCTAGAGAACAGAAGCTGATCAGCG
AGGAGGACCTGGAGCAGAAGTTGATCAGCGAGGAGGACCTGGCTAGCACAACCTGTATCCCAAGCAGCGGTC
ATTCAAGACACAGATATGCACTTATACCCATACCATTAGCAGTAATTACAACATGTATTGTGCTGTATATGAAT
GTATTATGAGTCGAC 
 
>CXCL8-Stop 
GAATTGAAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGCTCTCTTGGCAGCCTTCCTG
ATTTCTGCAGCTCTGTGTGAAGGTGCAGTTTTGCCAAGGAGTGCTAAAGAACTTAGATGTCAGTGCATAAAGA
CATACTCCAAACCTTTCCACCCCAAATTTATCAAAGAACTGAGAGTGATTGAGAGTGGACCACACTGCGCCAAC
ACAGAAATTATTGTAAAGCTTTCTGATGGAAGAGAGCTCTGTCTGGACCCCAAGGAAAACTGGGTGCAGAGG
GTTGTGGAGAAGTTTTTGAAGAGGGCTGAGAATTCATCTAGAGAACAGAAGCTGATCAGCGAGGAGGACCTG
GAGCAGAAGTTGATCAGCGAGGAGGACCTGTAGTCGAC 
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>CXCL8-mucin-Stop 
GAATTGAAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGCTCTCTTGGCAGCCTTCCTG
ATTTCTGCAGCTCTGTGTGAAGGTGCAGTTTTGCCAAGGAGTGCTAAAGAACTTAGATGTCAGTGCATAAAGA
CATACTCCAAACCTTTCCACCCCAAATTTATCAAAGAACTGAGAGTGATTGAGAGTGGACCACACTGCGCCAAC
ACAGAAATTATTGTAAAGCTTTCTGATGGAAGAGAGCTCTGTCTGGACCCCAAGGAAAACTGGGTGCAGAGG
GTTGTGGAGAAGTTTTTGAAGAGGGCTGAGAATTCATCTAGAAATGGCGGCACCTTCGAGAAGCAGATCGGC
GAGGTGAAGCCCAGGACCACCCCTGCCGCCGGGGGAATGGACGAGTCTGTGGTCCTGGAGCCCGAAGCCAC
AGGCGAAAGCAGTAGCCTGGAGCCGACTCCTTCTTCCCAGGAAGCACAGAGGGCCCTGGGGACCTCCCCAGA
GCTGCCGACGGGTGTGACTGGTTCCTCAGGGACCAGGCTCCCCCCGACGCCAAAGGCTCAGGATGGAGGGCC
TGTGGGCACGGAGCTTTTCCGAGTGCCTCCCGTCTCCACTGCCGCCACGTGGCAGAGTTCTGCTCCCCACCAAC
CTGGGCCCAGCCTCTGGGCTGAGGCAAAGACCTCTGAGGCCCCGTCCACCCAGGACCCCTCCACCCAGGCCTC
CACTGCGTCCTCCCCAGCCCCAGAGGAGAATGCTCCGTCTGAAGGCCAGCGTGTGTGGGGTCAGGGGCAGAG
CCCCAGGCCAGAGAACTCTCTGGAGCGGGAGGAGATGGGTCCCGTGCCAGCGCACACGGATGCCTTCCAGGA
CTGGGGGCCTGGCAGCATGGCCCACGTCTCTGTGGTCCCTGTCTCCTCAGAAGGGACCCCCAGCAGGGAGCCA
GTGGCTTCAGGCAGCTGGACCCCTAAGGCTGAGGAACCCATCCATGCCACCATGGACCCCCAGAGGCTGGGC
GTCCTTATCACTCCTGTCCCTGACGCCCAGGCTGCCACCCGGAGGCAGGCTAGAGAACAGAAGCTGATCAGCG
AGGAGGACCTGGAGCAGAAGTTGATCAGCGAGGAGGACCTGTAGTCGAC 
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5.8 Abbreviations and symbols 
Symbols, numbers 
µCi micro-Curie 
µF microfarad 
µg microgram 
µl microliter 
µm micrometer 
µM micromolar 
µmol micromole 
2-ME 2-mercaptoethanol 
7-AAD 7-aminoactinomycin D 
A 
aa amino acid 
APC allophycocyanin 
APS ammoniumpersulfate 
B 
BCA bicinchonic acid 
bFGF basic fibroblast growth factor 
BiTE bispecific T cell engager 
bp basepairs 
BRIJ 35 trade name; tricosaethylene glycol 
ether 
BSA bovine serum albumin 
C 
C celsius 
C12E8 octaethylene glycol monododecyl 
ether 
CD cluster of differentiation 
CD CHO chemically defined CHO medium 
cDNA copy deoxyribonucleic acid 
CHO Chinese hamster ovary 
cm centimeter 
CpG cytosine-guanine 
CTLA-4 cytotoxic T lymphocyte associated 
antigen 4 
CV column volumes 
D 
DAF decay accelerating factor 
DC dendritic cell 
DDM n-Dodecyl-β-D-maltoside 
dFCS dialyzed fetal calf serum 
Dhfr dihydrofolate reductase 
DMEM Dulbecco´s modified eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonuleoside triphosphate 
dyn dynes 
E 
ECGM Endothelial cell growth medium 
ECGS Endothelial cell growth supplement 
ECL enhanced chemiluminsecence 
EDTA ethylenediaminetetraacetic acid 
EGFP enhanced green fluorescent protein 
EGFR epidermal growth factor receptor 
EGTA ethylene glycol tetraacetic acid 
ELISA enzyme linked immunosorbent assay 
EpCAM epithelial cell adhesion molecule 
ER endoplasmatic reticulum 
F 
FACS fluorescence activated cell scanning 
Fc fragment, crystallizable 
FCS fetal calf serum 
FDA food and drug administration 
FITC fluorescein isothiocyanate 
FPLC fast protein liquid chromatography 
FSC forward scatter 
fw forward 
G 
g gram 
GAG glycosaminoglycan 
GM-CSF granulocyte macrophage colony 
stimulating factor 
GPI glycosylphosphatidylinositol 
GPI-PLD glycosylphosphatidylinositol-specific 
phospholipase D 
H 
h hour 
H/E hematoxylin / eosin 
HAM-F12 Ham´s F12  
HBSS Hank´s balanced salt solution 
HDBEC human dermal microvascular 
endothelial cells from blood vessels 
HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
HMEC human microvascular endothelial cells 
HRP horseradish peroxidase 
HT hypoxanthine / thymidine 
I 
ICAM intercellular adhesion molecule 
IHC immunohistochemistry 
IF immunofluorescence microscopy 
IFN interferon 
Ig immunoglobulin 
IgGlow low IgG content 
IL interleukin 
K 
kDa kilo-Daltons 
L 
LB lysogeny broth 
LFA-3 lymphocyte function antigen 3 
M 
M molar 
mAU milli-absorption units 
MEM minimum essential medium 
MFI mean fluorescence intensity 
mg milligram 
MHC I major histocompatibility complex I 
min minutes 
ml milliliter 
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mm millimeter 
mM millimolar 
mmol millimole 
mRNA messenger ribonucleic acid 
mS milli-Siemens 
N 
NEAA non-essential amino acids 
ng nanogram 
NK natural killer 
nm nanometer 
nM nanomolar 
nmol nanomole 
NMR nuclear magnetic resonance 
NP40 nonidet P40 
O 
Octyl-
glucoside 
n-Octyl-β-D-glucopyranoside 
OD optical density 
P 
P/S penicillin / streptomycin 
PAGE polyacrylamide gelelectrophoresis 
PBMCs peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PFA paraformaldehyde 
pH potentia hydrogenia 
PIPES piperazine-N,N′-bis(2-ethanesulfonic 
acid) 
PI-PLC phosphatidylinositol-specific 
phospholipase C 
pM picomolar 
pmol picomole 
PVDF polyvinylidene fluoride 
R 
RCC renal cell carcinoma 
rh recombinant human 
RNA ribonucleic acid 
RPE R-Phycoerythrin 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute 
rProtA recombinant protein A 
rt room temperature 
rv reverse 
S 
s secreted 
SDS sodium dodecyl sulfate 
sec seconds 
SSC sideward scatter 
T 
TBE Tris/Borate/EDTA 
TBS Tris-buffered saline 
TBST Tris-buffered saline with Tween20 
TCR T cell receptor 
TEM transendothelial migration 
TEMED N,N,N',N'-tetramethyl-ethane-1,2-
diamine 
TGF-β transforming growth factor β 
Th T helper 
TIL tumor-infiltrating lymphocyte 
TIMP-1 tissue inhibitor of matrix 
metalloproteases 1 
TNF tumor necrosis factor 
Treg T regulatory 
Tris tris(hydroxymethyl)aminomethane 
Triton X-
100h 
Triton X-100, hydrogenated 
U 
U units 
UV ultraviolet 
V 
V volts 
v/v volume per volume 
VCAM vascular endothelial cell adhesion 
molecule 
VEGF vascular endothelial growth factor 
W 
w/v weight per volume 
WB western blotting 
WHO world health organization 
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